日本臨牀　65/増刊1　造血器腫瘍

出版社： 日本臨牀社
発行日： 2007-01-28
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 造血器腫瘍
電子書籍版： 2007-01-28 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

16,060 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

16,060 円(税込)

購入する

目次

  • 日本臨牀　65/増刊1　造血器腫瘍

    ―目次―

    特集　造血器腫瘍

    基礎編 　 　 　
    I． 疫学 　 　
    　1 日本の造血器腫瘍の疫学 　
    II． 総論 　 　
    　1 発癌機構 　 　
    　2 新しい分子標的薬 　
    　3 造血幹細胞制御と白血病 　
    　4 低分子分子標的薬による治療 　
    III． 病因・病態解析−最近の展開− 　 　
    　1 急性白血病 　
    　2 慢性白血病 　
    　3 悪性リンパ腫 　
    　4 多発性骨髄腫 　
    IV． 造血器腫瘍研究 　 　
    　1 白血病 　 　
    　2 悪性リンパ腫 　 　

    臨床編 　 　 　
    I． 分　　　類 　 　
    　1 FAB・REAL分類から包括的造血器腫瘍のWHO分類へ　
    　2 WHO血液腫瘍分類 　 　
    II． 診　断　法 　 　
    　1 診断法 　 　
    　2 診断と鑑別診断 　 　
    III． 治療法 　 　
    　1 化学療法 　 　
    　2 細胞免疫療法(各論) 　
    　3 分子標的療法 　 　
    　4 抗体療法 　 　
    　5 造血幹細胞移植 　 　
    　6 支持療法 　 　
    IV． 治療の実際 　 　
    　1 急性白血病 　 　
    　2 慢性骨髄性白血病 　 　
    　3 骨髄異形成症候群の治療　
    　4 悪性リンパ腫 　 　
    　5 慢性リンパ性白血病とNK細胞白血病・リンパ腫の治療　
    　6 成人T細胞白血病・リンパ腫の治療 　
    　7 多発性骨髄腫 　 　
    V． 新しい治療の展開 　 　
    　1 最新治療の展開 　 　
    VI． 予後 　 　
    　1 造血器腫瘍の予後予測：概論 　
    　2 各造血器腫瘍の予後予測 　 　
    VII． 特論 　 　
    　1 先天性疾患と小児白血病 　
    　2 乳児白血病の発症機序とその治療 　
    　3 小児白血病・治療の現況 　
    　4 高齢者白血病・治療の現況 　
    　5 成人T細胞白血病・リンパ腫の分子標的療法　
    　6 ATRAによる成人T細胞白血病・リンパ腫治療の可能性 　　
    　7 急性前骨髄球性白血病の亜砒酸療法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.5 掲載の参考文献
1) Nowell PC, Hungerford DA : A minute chromosome in human granulocytic leukemia. Science 132 : 1497, 1960.
 
2) Rowley JD : A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 : 290-293, 1973.
PubMed
3) Daley GQ, et al : Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 247 : 824-830, 1990.
 
4) Ohno R : Treatment of chronic myeloid leukemia with imatinib mesylate. Int J Clin Oncol 11 : 176-183, 2006.
PubMed
5) Ohno R, et al : Treatment of acute promyelocytic leukemia : strategy toward further increase of cure rate. Leukemia 17 : 1454-1463, 2003.
PubMed
6) Fisher RI, et al : Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 : 1002-1006, 1993.
PubMed
7) Coiffier B, et al : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346 : 235-242, 2002.
PubMed

基礎編

P.13 掲載の参考文献
1) GLOBOCAN 2002 : Cancer Incidence, Mortality and Prevalence Worldwide (ed by Ferlay F, et al), IARC Press, Lyon, 2002.
 
2) Cancer Incidence in Five Continetns, Vol VIII (ed by Parkin DM, et al), IARC Press, Lyon, 2002.
 
3) Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues (ed by Jaffe ES, et al), IARC Press, Lyon, 2004.
 
4) 国際疾病分類-腫瘍学, 第3版 (厚生労働省大臣官房統計情報部編), 厚生統計協会, 2003.
 
5) 大野ゆう子ほか : 日本のがん罹患の将来推計. がん統計白書-罹患/死亡/予後-(大島明ほか編), p201-217, 篠原出版新社, 2004.
 
P.22 掲載の参考文献
1) ロバート・A・ワインバーグ : がん研究レース 発癌の謎を解く, 岩波書店, 2003.
 
2) 黒木登志夫 : がん遺伝子の発見-がん解明の同時代史, 中央公論社, 1996.
 
3) Gilliland DG, Griffin JD : Role of FLT3 in leukemia. Curr Opin Hematol 9 : 274-281, 2002.
PubMed
4) Hess JL : MLL : a histone methyltransferase disrupted in leukemia. Trends Mol Med 10 : 500-507, 2004.
PubMed
5) Gotlib J, et al : The FIP1L1-PDGFRαfusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia : implications for diagnosis, classification, and management. Blood 103 : 2879-2891, 2004.
 
6) Yamada Y, et al : The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to indtlce murine hypereosinophilic syndrome (HES) /chronic eosinophilic leukemia (CEL)-like disease. Blood 107 : 4071-4079, 2006.
PubMed
7) Papenhausen PR, et al : Oncogene amplification in transforming myelodysplasia. Exp Mol Pathol 79 : 168-175, 2005.
PubMed
8) Tefferi A, Gilliland DG : The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders : status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 80 : 947-958, 2005.
PubMed
9) Walters DK, et al : Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10 : 65-75, 2006.
PubMed
10) Ding J, et al : Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103 : 4198-4200, 2004.
 
11) Kiyoi H, Naoe T : Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int J Hematol 83 : 301-308, 2006.
PubMed
12) Taketani T, et al : FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 103 : 1085-1088, 2004.
PubMed
13) Harada H, et al : High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103 : 2316-2324, 2004.
PubMed
P.33 掲載の参考文献
1) Honda H, et al : Identification of PU.1 and Sp1 as essential transcriptional factors for the promoter activity of mouse tec gene. Biochem Biophys Res Commun 234 : 376-381, 1997.
PubMed
2) Honda H, et al : Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl : a novel transgenic model for human Ph 1-positive leukemias. Blood 91 : 2067-2075, 1998.
 
3) Kuribara R, et al : Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 24 : 6172-6183, 2004.
PubMed
4) Honda H, et al : Acquired loss of p53 caused blastic transformation of p210bcr/abl-expressing hematopoietic cells : a transgenic study for blast crisis of human CML. Blood 95 : 1144-1150, 2000.
 
5) Yergeau DA, et al : Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 15 : 303-306, 1997.
PubMed
6) Higuchi M, et al : Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t (8 ; 21) acute myeloid leukemia. Cancer Cell 1 : 63-74, 2002.
 
7) Yuan Y, et al : AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 98 : 10398-10403, 2001.
PubMed
8) He LZ, et al : Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci USA 94 : 5302-5307, 1997.
PubMed
9) He LZ, et al : Two critical hits for promyelocytic leukemia. Mol Cell 6 : 1131-1141, 2000.
PubMed
10) Castilla LH, et al : Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 87 : 687-696, 1996.
PubMed
11) Kogan SC, et al : The PEBP2betaMYH11 fusion created by Inv (16) (p13 ; q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc Natl Acad Sci USA 95 : 11863-11868, 1998.
PubMed
12) Castilla LH, et al : The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic Ieukaemia. Nat Genet 23 : 144-146, 1999.
 
13) Dedera DA, et al : Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice. Cell 74 : 833-843, 1993.
PubMed
14) Honda H, et al : Expression of E2A-HLF chimeric protein induced T-cell apoptosis, B-cell maturation arrest, and development of acute lymphoblastic leukemia. Blood 93 : 2780-2790, 1999.
PubMed
15) McDonnell TJ, Korsmeyer SJ : Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t (14 ; 18). Nature 349 : 254-256, 1991.
 
16) Kelliher MA, et al : Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase II alpha. EMBO J 15 : 5160-5166, 1996.
 
17) Larson RC, et al : Protein dimerization between Lmo 2 (Rbtn2) and Tall alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J 15 : 1021-1027, 1996.
 
P.39 掲載の参考文献
1) Taki T, Taniwaki M : Chromosomal translocations in cancer and their relevance for therapy. Curr Opin Oncol 18 : 62-68, 2006.
PubMed
2) Ishkanian AS, et al : A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 36 (3) : 299-303, 2004.
PubMed
3) Ota A, et al : Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64 (9) : 3087-3095, 2004.
PubMed
4) He L, et al : A microRNA polycistron as a potential human oncogene. Nature 435 (7043) : 828-833, 2005.
PubMed
5) Mitelman F, et al : Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat Genet 36 (4) : 331-334, 2004.
PubMed
6) Streubel B, et al : T (14 ; 18) (q32 ; q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101 (6) : 2335-2339, 2003.
PubMed
7) 滝智彦ほか : t (12 ; 13) (p13 ; q14) を有するmyeloid/NK前駆細胞型急性白血病におけるTEL-TTL融合遺伝子の同定, 第64回日本癌学会学術総会, 2005.
 
8) Nakai H, et al : Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res 52 : 6588-6593, 1992.
PubMed
9) Nomura K, et al : An additional segment at 1p36 derived from der (18) t (14 ; 18) in patients with diffus e large B-cell lymphomas transformed from follicular lymphoma. Ann Hematol 84 (7) : 474-476, 2005.
 
10) Graux C, et al : Fusion of NUP214 to ABLI on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 36 (10) : 1084-1089, 2004.
 
11) Golub TR, et al : Molecular classification of cancer : class discovery and class prediction by gene expression monitoring. Science 286 : 531-537, 1999.
PubMed
12) Haferlach T, et al : AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. Genes Chromosom Cancer 43 : 113-127, 2005.
PubMed
13) Vey N, et al : Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene 23 : 9381-9391, 2004.
PubMed
14) Jaffe ES, et al (eds) : World Health Organization Classification of Tumors. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001.
 
15) Grimwade D, et al ; Medical Research Council Adult Leukemia Working Party : The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML) : analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98 : 1312-1320, 2001.
PubMed
16) Nakamura T, et al : Gastric low-grade B-cell MALT lymphoma : treatment, response, and genetic alteration. J Gastroenterol 38 : 921-929, 2003.
PubMed
17) 谷脇雅史ほか : 悪性リンパ腫の診断の実際-必要な検査とその読み方-. Medical Practice 20 : 1165-1169, 2003.
Medical*Online
18) Matsumoto Y, et al : Detection of t (14 ; 18) in follicular lymphoma by dual-color fluorescence in situ hybridization on paraffin-embedded tissue sections. Cancer Genet Cytogenet 150 (1) : 22-26, 2004.
PubMed
19) Nishida K, et al : The immunoglobulin heavy chain gene is frequently involved in chromosomal trasnlocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridlzation. Blood 90 : 526-534, 1997.
PubMed
20) Fonseca R, et al : Genetics and cytogenetics of multiple myeloma : a workshop report. Cancer Res 64 : 1546-1558, 2004.
PubMed
P.44 掲載の参考文献
1) Miyoshi H, et al : t (8 ; 21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 88 (23) : 10431-10434, 1991.
PubMed
2) Aikawa Y, et al : Roles of HIPK1 and HIPK2 in AML1-and p300-dependent transcription, hematopoiesis and blood vessel formation. EMBO J 25 (17) : 3955-3965, 2006.
PubMed
3) Leroy H, et al : CEBPA point mutations in hematological malignancies. Leukemia 19 (3) : 329-334, 2005.
 
4) Pabst T, et al : AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t (8 ; 21) myeloid leukemia. Nat Med 7 (4) : 444-451, 2001.
 
5) Wechsler J, et al : Acquired mutations in GATAl in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32 (1) : 148-152, 2002.
 
6) Xu G, et al : Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 102 (8) : 2960-2968, 2003.
PubMed
7) Shimizu R, et al : Leukemogenesis caused by incapacitated GATA-1 function. Mol Cell Biol 24 (24) : 10814-10825, 2004.
PubMed
8) Mueller BU, et al : Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 100 (3) : 998-1007, 2002.
PubMed
9) Lamandin C, et al : Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? Blood 100 (13) : 4680-4681, 2002.
PubMed
10) Dohner K, et al : Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia : a study of the AML Study Group Ulm (AMLSG ULM). Blood 102 (10) : 3850-3851, 2003.
 
11) Moreau-Gachelin F, et al : Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol Cell Biol 16 (5) : 2453-2463, 1996.
PubMed
12) Rekhtman N, et al : Direct interaction of hematopoietic transcription factors PU.1 and GATA-1 : functional antagonism in erythroid cells. Genes Dev 13 (11) : 1398-1411, 1999.
PubMed
13) Zhang P, et al : PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood 96 (8) : 2641-2648, 2000.
PubMed
14) Vangala RK, et al : The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t (8 ; 21) myeloid leukemia. Blood 101 (1) : 270-277, 2003.
 
15) Rosenbauer F, et al : Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 36 (6) : 624-630, 2004.
PubMed
16) Pearson M, et al : PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406 (6792) : 207-210, 2000.
PubMed
17) Fogal V, et al : Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19 (22) : 6185-6195, 2000.
 
18) Guo A, et al : The function of PML in p53-dependent apoptosis. Nat Cell Biol 2 (10) : 730-736, 2000.
PubMed
19) Nguyen LA, et al : Physical and functional link of the leukemia-associated factors AMLI and PML. Blood 105 (1) : 292-300, 2005.
 
20) Yokoyama A, et al : The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123 (2) : 207-218, 2005.
PubMed
21) Katsumoto T, et al : MOZ is essential for maintenance of hematopoietic stem cells. Genes Dev 20 (10) : 1321-1330, 2006.
PubMed
22) Thomas T, et al : Monocytic leukemia zinc finger protein is essential for the development of longterm reconstituting hematopoietic stem cells. Genes Dev 20 (9) : 1175-1186, 2006.
PubMed
23) Kitabayashi I, et al : Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J 20 (24) : 7184-7196, 2001.
PubMed
P.51 掲載の参考文献
1) International Human Genome Sequencing Consortium : Finishing the euchromatic sequence of the human genome. Nature 431 : 931-945, 2004.
 
2) Kimura S, et al : NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106 : 3948-3954, 2005.
PubMed
3) 木村晋也, 前川平 : イマチニブ以後の白血病に対する分子標的療法薬. Annual Review 2006 血液 (高久文麿編), p99-113, 中外医薬社, 2006.
 
4) 木村晋也 : 分子標的薬剤の考え方. BIO Clinica 19 : 61-67, 2004.
 
5) Cersosimo RJ : Gefitinib : an adverse effects profile. Expert Opin Drug Saf 5 : 469-479, 2006.
PubMed
6) Nagar B, et al : Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD 173955 and imatinib (STI-571). Cancer Res 62 : 4236-4243, 2002.
PubMed
7) Hochhaus A, La Rosee P : Imatinib therapy in chronic myelogenous leukemia : strategies to avoid and overcome resistance. Leukemia 18 : 1321-1331, 2004.
PubMed
8) Michor F, et al : Dynamics of chronic myeloid leukaemia. Nature 435 : 1267-1270, 2005.
PubMed
9) Komarova NL, Wodarz D : Drug resistance in cancer : Principles of emergence and prevention. Proc Natl Acad Sci USA 102 : 9714-9719, 2005.
PubMed
10) Kimura S, Maekawa T : Stem cell transplantation for Ph+ leukemias in the imatinib and post-imatinib eras. In : Bone Marrow Transplantation : New Research, p 1-38, Nova Publisher, New York, 2006.
 
P.58 掲載の参考文献
1) Goodell MA, et al : Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183 : 1797-1806, 1996.
PubMed
2) Ito K, et al : Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 431 : 997-1002, 2004.
PubMed
3) Zhang J, et al : Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425 : 836-841, 2003.
PubMed
4) Calvi LM, et al : Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425 : 841-846, 2003.
PubMed
5) Arai F, et al : Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118 : 149-161, 2004.
PubMed
6) Suda T, et al : Hematopoietic stem cells and their niche. Trends Immunol 26 : 426-433, 2005.
PubMed
7) Kiel MJ, et al : SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121 : 1109-1121, 2005.
PubMed
8) Wong S, Witte ON : Modeling Philadelphia chromosome positive leukemias. Oncogene 20 : 5644-5659, 2001.
PubMed
9) Huntly BJ, et al : MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6 : 587-596, 2004.
 
10) Bhatia M. et al : Purification of primitive human hematopoietic cells capable of repopulating immunedeficient mice. Proc Natl Acad Sci USA 94 : 5320-5325, 1997.
PubMed
11) Bonnet D, Dick JE : Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 : 730-737, 1997.
PubMed
12) Miyamoto T, et al : AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8 ; 21 chromosomal translocation. Proc Natl Acad Sci USA 97 : 7521-7526, 2000.
PubMed
13) Cozzio A, et al : Similar MLL-associated leukemias arising from self-renewing stem cells and shortlived myeloid progenitors. Genes Dev 17 : 3029-3035, 2003.
PubMed
14) Yilmaz OH, et al : Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 : 475-482, 2006.
PubMed
15) Clarke MF, Fuller M : Stem cells and cancer : two faces of eve. Cell 124 : 1111-1115, 2006.
PubMed
P.66 掲載の参考文献
1) O'Brien SG, et al : Imatinib compared with interferon and low-dose cytrabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 : 994-1004, 2003.
 
2) Tallman MS, et al : Drug therapy for acute myeloid leukemia. Blood 106 : 1154-1163, 2005.
PubMed
3) Kottaridis P, et al : The presence of FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and responses to the first cycle of chemotherapy : analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 : 1752-1759, 2001.
 
4) Stirewalt DL, Radich JP : The role of FLT3 in hematopoiesis and leukemia. Nat Rev Cancer 3 : 650-665, 2003.
 
5) Reuter CW, et al : Targeting the RAS signaling pathway : a rational, mechanism-based treatment in hematological malignancies. Blood 96 : 1655-1669, 2000.
PubMed
6) Kurzrock R, et al : Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22 : 1287-1292, 2004.
PubMed
7) Gottlicher M, et al : Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20 : 6969-6978, 2001.
PubMed
8) Wijermans P, et al : Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome : a multicenter phase II study in elderly patients. J Clin Oncol 18 : 956-962, 2000.
PubMed
9) Fiedler W, et al : A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102 : 2763-2767, 2003.
PubMed
10) Marcucci G, et al : Phase 1 and pharmacokinetic study of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101 : 425-432, 2003.
PubMed
11) Adams J. Development of proteasome inhibitor PS-341. Oncologist 7 : 9-16, 2002.
PubMed
12) Richardson PG, et al : A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 : 2609-2617, 2003.
PubMed
13) Richardson PG, et al : Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 : 2487-2498, 2005.
 
14) Richardson PG, et al : Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100 : 3063-3067, 2002.
PubMed
15) List A, et al : Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 : 549-557, 2005.
PubMed
P.74 掲載の参考文献
1) de The H, et al : The t (15 ; 17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347 : 558-561, 1990.
 
2) Savage DG, Antman KH : Imatinib mesylate-a new oral targeted therapy. N Engl J Med 346 : 683-693, 2002.
PubMed
3) Yanada M, et al : High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24 : 460-466, 2006.
 
4) Bullinger L, et al : Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350 : 1605-1616, 2004.
PubMed
5) Valk PJ, et al : Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350 : 1617-1628, 2004.
PubMed
6) Lapidot T, et al : A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 : 645-648, 1994.
PubMed
7) Matsunaga T, et al : Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9 : 1158-1165, 2003.
PubMed
8) Rombouts EJ, et al : Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 104 : 550-557, 2004.
PubMed
9) Wechsler J, et al : Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32 : 148-152, 2002.
PubMed
10) Tartaglia M, et al : Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34 : 148-150, 2003.
PubMed
11) Kralovics R, et al : Again-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 : 1779-1790, 2005.
PubMed
12) Weng AP, et al : Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306 : 269-271, 2004.
 
13) Falini B, et al : Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352 : 254-266, 2005.
PubMed
14) Suzuki T, et al : Clinical characteristics and prognostic implications of NPM l mutations in acute myeloid leukemia. Blood 106 : 2854-2861, 2005.
 
P.79 掲載の参考文献
1) Deutsch E, et al : BCR-ABL downregurates the DNA repair protein DNA-PKCS. Blood 97 : 2084-2090, 2001.
PubMed
2) Ma Y, et al : Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in non-homologous end joining and V (D) J recombination. Cell 108 : 781-794, 2002.
 
3) Skorski T : BCR-ABL regulates response to DNA damage : the role in resistance to genotoxic treatment and in genomic instability. Oncogene 21 : 8591-8604, 2002.
PubMed
4) Druker BJ : Log-term benefit of imatinib for patients newly diagnosed with chronic myeloid leukemia in chronic phase : The 5-year update from IRIS study. 2006 ASCO Annual Meeting : June 2-6, 2006.
 
5) Calabretta B, Perrotti D : The biology of CML blastic crisis. Blood lO3 : 4010-4022, 2004.
 
P.84 掲載の参考文献
1) Epstein MA, et al : Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet i : 702-703, 1964.
PubMed
2) Poiesz BJ, et al : Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T cell lymphoma. Proc Natl Acad Sci USA 77 : 7415-7419, 1980.
PubMed
3) Weiss LM, et al : Detection of Epstein-Barr viral genome in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 302 : 502-506, 1989.
 
4) Fukayama M, et al : Epstein-Barr virus in pyothorax-assoicated pleural lymphoma. Am J pathol 143 : 1044-1049, 1993.
 
5) Nagai H, et al : Genetic alteration of p53 in some patients with adult T-cell leukemia. Jpn J Cancer Res 82 : 1421-1427, 1991.
PubMed
6) Hasegawa H, et al : Thymus-derived leukemia-lymphoma in mice transgnic for the Tax gene of human T-lymphotropic virus type I. Nat Med 12 : 466-472, 2006.
 
7) Misiani R, et al : Hepatitis C infection in patients with essential mixed cryogloburinemia. Ann Intern Med 117 : 573-577, 1992.
PubMed
8) Zuckerman E, et al : The effect of antiviral therapy on t (14 ; 18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 97 : 1555-1559, 2001.
 
9) Vallisa D, et al : Association between hepatitis C and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course. Am J Med 106 : 556-560, 1999.
PubMed
10) Cesarman E, et al : Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332 : 1186-1189, 1995.
PubMed
11) Wotherspoon AC, et al : Regression of primaly low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342 : 575-577, 1993.
 
12) Parsonnet J, et al : Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330 : 1267-1271, 1994.
PubMed
13) Hofbauer GF, et al : Multilesional primary cutaneous diffuse large B-cell lymphoma responsive to antibiotic treatment. Dermatology 203 : 168-170, 2001.
PubMed
14) Lecuit M, et al : Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 350 : 239-248, 2004.
PubMed
15) Ferreri AJM, et al : Evidence for an association between Chlamidia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 96 : 586-594, 2004.
 
16) Loren AW, et al : Post-transplant lymphoproliferative disorder : a review. Bone Marrow Transplant 31 : 145-155, 2003.
PubMed
17) Oyama T, et al : Senile EBV+ B-cell lymphoproliferative disorders. A clinico-pathologic study of 22 patients. Am J Surg Pathol 27 : 16-26, 2003.
 
18) Rosenwald A, et al : The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 : 1937-1947, 2002.
PubMed
19) Jane N, et al : Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP : a prospective correlative study. Blood 107 : 4207-4213, 2006.
 
P.92 掲載の参考文献
1) Kawano M, et al : Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 332 : 83-85, 1988.
PubMed
2) Ishikawa H, et al : Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood 99 : 2172-2178, 2002.
PubMed
3) Zhan F, et al : Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined signhicance, and normal bone marrow plasma cells. Blood 99 : 1745-1757, 2002.
PubMed
4) Ishikawa H, et al : Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules. Int J Hematol 78 : 95-105, 2003.
PubMed
5) Huang N, et al : Heterogeneous expression of a novel MPC-1 antigen on myeloma cells : possible involvement of MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells. Blood 82 : 3721-3729, 1993.
PubMed
6) Otsuyama K, et al : An increase in MPC-1-and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis : the revised phenotypic classification monoclonal marrow plasmacytosis (MOMP-2005). Int J Hematol 83 : 39-43, 2006.
PubMed
7) Liu S, et al : DHEA can inhibit the proliferation of myeloma cells and the IL-6 production of bone marrow mononuclear cells from the myeloma patients. Cancer Res 65 : 2269-2276, 2005.
PubMed
8) Li F-J, et al : A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma. Blood 105 : 3295-3302, 2005.
 
9) Liu S, et al : Increased susceptibility to apoptosis in CD45 (+) myeloma cells accompanied by the increased expression of VDAC1. Oncogene 19 : 419-429, 2006.
 
10) Ma Z, et al : Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood 105 : 3312-3318, 2004.
PubMed
P.99 掲載の参考文献
1) Greaves MF, et al : Leukemia in twins : lessons in natural history. Blood 102 : 2321-2333, 2003.
PubMed
2) Greaves M : Biology of leukemia : a overview. In : Leukemia, 7th ed (ed by Henderson ES, et al), p8-18, Saunders, Philadelphia, 2002.
 
3) Liu Y, et al : BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 91 : 8910-8914, 1994.
PubMed
4) Matsuoka M, Jeang KT : Human T-cell leukemia virus type I at age 25 : aprogress report. Cancer Res 65 : 4467-4470, 2005.
PubMed
5) Matsuoka M : Human T-cell leukemia virus type 1 (HTLV-1) infection and the onset of adult T-cell leukemia (ATL). Retrovirology 2 : 27, 2005.
PubMed
6) Grassmann R, et al : Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 24 : 5976-5985, 2005.
PubMed
7) Ballgham CR : Human T-lymphotropic virus type 1 (HTLV-1) : persistence and immune control. Int J Hematol 78 : 297-303, 2003.
 
8) Satou Y, et al : HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA 103 : 720-725, 2006.
PubMed
9) Mitani K : Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene 23 : 4263-4269, 2004.
PubMed
10) Nanri T, et al : Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t (8 ; 21) (q22 ; q22). Leukemia 19 : 1361-1366, 2005.
 
11) Pikarsky E, et al : NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 : 461-466, 2004.
PubMed
12) Hoshida Y, et al : Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 91 : 869-875, 2001.
PubMed
13) Tamaki H, Matsuoka M : Donor-derived T-cell leukemia after bone marrow transplantation. N Engl J Med 354 : 1758-1759, 2006.
PubMed
14) Harashima N, et al : Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res 64 : 391-399, 2004.
PubMed
15) Bocchia M, et al : Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87 : 3587-3592, 1996.
PubMed
P.104 掲載の参考文献
1) Mrozek K, et al : Cytogenetics in acute leukemia. Blood Rev 18 : 115-136, 2004.
PubMed
2) Frohling S, et al : Genetics of myeloid malignancies : pathogenetic and clinical implications. J Clin Oncol 23 : 6285-6295, 2005.
PubMed
P.108 掲載の参考文献
1) Kottaridis PD, et al : Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia : implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 100 : 2393-2398, 2002.
PubMed
2) Gambacorti-Passerini CB, et al : Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4 : 75-85, 2003.
PubMed
3) Ramiro AR, et al : Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 440 : 105-109, 2006.
PubMed
4) Kolomietz E, et al : The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosom Cancer 35 : 97-112, 2002.
PubMed
5) Broeker PL, et al : Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia : correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 87 : 1912-1922, 1996.
PubMed
6) Nakada S, et al : Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations. J Clin Invest 116 : 80-89, 2006.
PubMed
7) Slupianek A, et al : BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 8 : 795-806, 2001.
PubMed
8) Difilippantonio MJ, et al : DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 404 : 510-514, 2000.
PubMed
9) Riballo E, et al : Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr Biol 9 : 699-702, 1999.
 
10) Gaymes TJ, et al : Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res 62 : 2791-2797, 2002.
PubMed
11) Aten JA, et al : Dynamics of DNA double-strand breaks revealed by clustering of damaged chromosome domains. Science 303 : 92-95, 2004.
PubMed
12) Roix JJ, et al : Spatial proximity of translocation-prone gene loci in human lymphomas. Nat Genet 34 : 287-291, 2003.
PubMed
13) Kuroda M, et al : Alteration of chromosome positioning during adipocyte differentiation. J Cell Sci 117 : 5897-5903, 2004.
PubMed
14) Lisby M, et al : Colocalization of multiple DNA double-strand breaks at a single Rad52 repair centre. Nat Cell Biol 5 : 572-577, 2003.
 
15) Farmer H, et al : Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 : 917-921, 2005.
PubMed
P.112 掲載の参考文献
1) Golub TR, et al : Molecular classification of cancer : class discovery and class prediction by gene expression monitoring. Science 286 : 531-537, 1999.
PubMed
2) Armstrong SA, et al : MLL translocations specify a distinct gene expression profile that distinguishes aunique leukemia. Nat Genet 30 : 41-47, 2002.
 
3) Yeoh EJ, et al : Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1 : 133-143, 2002.
PubMed
4) Yagi T, et al : Identification of a gene expression signature associated with pediatric AML prognosis. Blood 102 : 1849-1856, 2003.
PubMed
5) Ross ME, et al : Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104 : 3679-3687, 2004.
PubMed
6) Valk RI, et al : Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350 : 1617-1628, 2004.
 
7) Bullinger L, et al : Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350 : 1605-1616, 2004.
PubMed
8) Tsutsumi S, et al : Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. Cancer Res 63 : 4882-4887, 2003.
PubMed
9) Ohno R, Nakamura Y : Prediction of response to imatinib by cDNA microarray analysis. Semin Hematol 40 (2 Suppl 2) : 42-49, 2003.
 
10) Armstrong SA, et al : FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 103 : 3544-3546, 2004.
PubMed
11) Taketani T, et al : FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangement and pediatric ALL with hyperdiploidy. Blood 103 : 1085-1088, 2004.
PubMed
12) Nanri T, et al : Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t (8 ; 21) (q22 ; q22). Leukemia 19 : 1361-1366, 2005.
 
13) Shimada A, et al : KIT mutation, and not FLT3 internal tandem duplication, is strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t (8 ; 21) : a study of the Japanese Childhood AML Cooperative Study Group. Blood 107 : 1806-1809, 2006.
 
14) Schnittger S, et al : KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107 : 1791-1799, 2006.
PubMed
15) Cairoli R, et al : Prognostic impact of c-KIT mutations in core binding factor leukemias : an Italian retrospective study. Blood 107 : 3463-3468, 2006.
PubMed
P.117 掲載の参考文献
1) Hacein-Bey-Abina S, et al : LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 : 415-419, 2003.
PubMed
2) Coffin JM, et al : Varmus, Retroviruses, Cold Spring Harbor Laboratory Press, New York, 1997.
 
3) Suzuki T, et al : New genes involved in cancer identified by retroviral tagging. Nat Genet 32 : 166, 2002.
PubMed
4) Schroeder ARW, et al : HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110 : 521, 2002.
 
5) Wu X, et al : Transcription start regions in the human genome are favored targets for MLV integration. Science 300 : 1749, 2003.
PubMed
6) Tsuruyama T, et al : Constitutive activation of Stat5a by retrovirus integration in early pre-B lymphomas of SL/Kh strain mice. Proc Natl Acad Sci USA 99 : 8253, 2002.
PubMed
7) Takemoto S, et al : Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA 94 : 13897-13902, 1997.
PubMed
8) Yoshikawa Y, et al : Ascorbic acid induces a marked conformational change in long duplex DNA. Eur J Biochem 270 : 3101, 2003.
PubMed
9) Yoshinaga T, Fujiwara T : Different roles of bases within the integration signal sequence of human immunodeficiency virus type 1 in vitro. J Virol 69 : 3233, 1995.
PubMed
10) Hiai H, et al : Pre-B lymphomas in SL/Kh mice : a multifactorial disease model. Cancer Sci 94 : E47, 2003.
 
P.122 掲載の参考文献
1) Yokota S, et al : Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11 : 1605-1609, 1997.
 
2) Kiyoi H, et al : Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21 : 2555-2563, 2002.
PubMed
3) Armstrong SA, et al : Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3 : 173-183, 2003.
PubMed
4) Goldman JM, Melo JV : Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 349 : 1451-1464, 2003.
PubMed
5) Donato NJ, et al : BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 : 690-698, 2003.
PubMed
6) Gotlib J, et al : The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia : implications for diagnosis, classification, and management. Blood 103 : 2879-2891, 2004.
PubMed
7) Kosmider O, et al : Kit-activating mutations cooperate with Spi-1/PU.1. overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell 8 : 467-478, 2005.
PubMed
8) Cairoli R, et al : Prognostic impact of c-KIT mutations in core binding factor leukemias : an Italian retrospective study. Blood 107 : 3463-3468, 2006.
PubMed
9) Tartaglia M, et al : Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34 : 148-150, 2003.
PubMed
10) Wiestner A : More ZAP for chronic lymphocytic leukemia (CLL). Blood 105 : 1839-1840, 2005.
PubMed
11) Janssen JW, et al : RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci USA 84 : 9228-9232, 1987.
PubMed
12) Milella M, et al : Beyond single pathway inhibition : MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 11 : 2779-2795, 2005.
PubMed
13) Zebisch A, et al : Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res 66 : 3401-3408, 2006.
PubMed
14) Liu TC, et al : Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol 63 : 170-175, 2000.
PubMed
15) Weng AP, et al : Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306 : 269-271, 2004.
 
P.127 掲載の参考文献
1) Karin M, Greten FR : NF-κB : Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5 : 749-759, 2005.
 
2) Hayden MS, Ghosh S : Signaling to NF-κB. Genes Dev 18 : 2195-2224, 2004.
 
3) Chen ZJ : Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol 7 : 758-768, 2005.
 
4) Karin M, et al : NF-κB in cancer : from innocent bystander to major culprit. Nat Rev Cancer 2 : 301-310, 2002.
 
5) Yamaoka S, et al : Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell 93 : 1231-1240, 1998.
 
6) Senftleben U, et al : Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293 : 1495-1499, 2001.
PubMed
7) Xiao G, et al : NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 7 : 401-409, 2001.
PubMed
8) Hironaka N, et al : Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells. Neoplasia 6 : 266-278, 2004.
PubMed
9) Nonaka M, et al : Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts. Oncogene 24 : 3976-3986, 2005.
PubMed
10) Nakanishi C, Toi M : Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5 : 297-309, 2005.
 
11) Tanaka A, et al : A novel NF-κB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105 : 2324-2331, 2005.
 
P.134 掲載の参考文献
1) Nakao M, et al : Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10 (12) : 1911-1918, 1996.
PubMed
2) Schnittger S, et al : KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107 (5) : 1791-1799, 2006.
PubMed
3) Taketani T, et al : FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 103 (3) : 1085-1088, 2004.
PubMed
4) Druker BJ, et al : Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (14) : 1031-1037, 2001.
PubMed
5) Cools J, et al : A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (13) : 1201-1214, 2003.
PubMed
6) Joensuu H, et al : Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 (14) : 1052-1056, 2001.
 
7) Karp JE, et al : Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias : a phase 1 clinical-laboratory correlative trial. Blood 97 (11) : 3361-3369, 2001.
PubMed
8) Kuroda J, et al : The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 102 (6) : 2229-2235, 2003.
PubMed
9) Jenuwein T, Allis CD : Translating the histone code. Science 293 (5532) : 1074-1080, 2001.
PubMed
10) Tallman MS, et al : Acute promyelocytic leukemia : evolving therapeutic strategies. Blood 99 (3) : 759-767, 2002.
PubMed
11) Miyoshi H, et al : The t (8 ; 21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 12 (7) : 2715-2721, 1993.
 
12) Look AT : Oncogenic transcription factors in the human acute leukemias. Science 278 (5340) : 1059-1064, 1997.
PubMed
13) Wechsler J, et al : Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32 (1) : 148-152, 2002.
PubMed
14) Shimizu R, et al : Leukemogenesis caused by incapacitated GATA-1 function. Mol Cell Biol 24 (24) : 10814-10825, 2004.
PubMed
15) Pabst T, et al : Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27 (3) : 263-270, 2001.
PubMed
16) Mueller BU, et al : Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 100 (3) : 998-1007, 2002.
PubMed
17) Rosenbauer F, et al : Acute myeloid leukemia induced by graded reduction of a lineage-spechic transcription factor, PU.1. Nat Genet 36 (6) : 624-630, 2004.
PubMed
18) Heidenreich O, et al : AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t (8 ; 21)-positive leukemic cells. Blood 101 (8) : 3157-3163, 2003.
PubMed
19) Yokoyama A, et al : The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123 (2) : 207-218, 2005.
PubMed
P.140 掲載の参考文献
1) Lange B : The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 110 : 512-524, 2000.
PubMed
2) Zipursky A, et al : Leukemia in Down syndrome. A review. Pediatr Hematol Oncol 9 : 139-149, 1992.
PubMed
3) Yamamoto M, et al : Upstream and downstream of erythroid transcription factor GATA-1. Genes Cells 2 : 107-115, 1997.
PubMed
4) Wechsler J, et al : Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32 : 148-152, 2002.
PubMed
5) Xu G, et al : Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down's syndrome. Blood 102 : 2960-2968, 2003.
PubMed
6) Shimada A, et al : Fetal origin of the GATA-1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down's syndrome. Blood 103 : 366, 2004.
 
7) Li Z, et al : Development of stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 37 : 613-619, 2005.
 
8) Rainis L, et al : The proto-oncogene ERG in megakaryoblastic leukemias. Cancer Res 65 : 7596-7602, 2005.
 
9) Elagib KE, et al : RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic dfierentiation. Blood 101 : 4333-4341, 2003.
PubMed
10) Xu G, et al : Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome. Leukemia 20 : 1002-1008, 2006.
PubMed
11) Oyake T, et al : Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site. Mol Cell Biol 16 : 6083-6095, 1996.
PubMed
12) Toki T, et al : Transgenic expression of Bach1 transcription factor results in megakaryocytic impairment. Blood 105 : 3100-3108, 2005.
PubMed
13) Bourquin JP, et al : Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci USA 103 : 3339-3344, 2006.
PubMed
14) Harigae H, et al : The GATA-1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down's syndrome. Blood 103 : 3242-3243, 2004.
 
15) Ahmed M, et al : Natural history of GATA1 mutations in Down syndrome. Blood 103 : 2480-2489, 2004.
PubMed
P.145 掲載の参考文献
1) Jaffe ES, et al (ed) : World Health Organization Classification of Tumors : Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001.
 
2) Seto M : Genetic and epigenetic factors involved in B-cell lymphomagenesis. Cancer Sci 95 : 704-710, 2004.
 
3) Akagi T, et al : A novel gene, MALT1 at 18q21, is involved in t (11 ; 18) (q21 ; q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18 : 5785-5794, 1999.
 
4) Motegi M, et al : API2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products. Am J Pathol 156 : 807-812, 2000.
PubMed
5) Avet-Loiseau H, et al : High incidence of translocations t (11 ; 14) (q13 ; q32) and t (4 ; 14) (p16 ; q32) in patients with plasma cell malignancies. Cancer Res 58 : 5640-5645, 1998.
 
6) Streubel B, et al : T (14 ; 18) (q32 ; q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101 : 2335-2339, 2003.
PubMed
7) Willis TG, et al : Bcl10 is involved in t (1 ; 14) (p22 ; q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96 : 35-45, 1999.
 
8) Graninger WB, et al : Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 80 : 1512-1515, 1987.
 
9) Liu Y-J, et al : Germinal centers in T-cell-dependent antibody responses. Immunol Today 13 : 17-21, 1992.
 
10) Bakhshi A, et al : Mechanism of the t (14 ; 18) chromosomal translocation : structural analysis of both derivative 14 and 18 reciprocal partners. Proc Natl Acad Sci USA 84 : 2396-2400, 1987.
 
11) Tsujimoto Y, et al : The reciprocal partners of both the t (14 ; 18) and the t (11 ; 14) translocations involved in B-cell neoplasms are rearranged by the same mechanism. Oncogene 2 : 347-351, 1988.
 
12) Yoshida S, et al : Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas : 5'-RACE and LA-PCR analyses of biopsy samples. Oncogene 18 : 7994-7999, 1999.
 
13) Lucas PC, et al : Bcl10 and MALT1, independent targets of chromosomal translocation in MALT lymphoma, cooperate in a novel NF-kappa B signaling pathway. J Biol Chem 276 : 19012-19019, 2001.
 
14) Nakagawa M, et al : Molecular pathogenesis of MALT Iymphoma : two signaling pathways underlying the antiapoptotic effect of API2-MALT1 fusion protein. Leukemia 20 : 929-936, 2006.
 
P.150 掲載の参考文献
1) Kuppers R : Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5 : 251-262, 2005.
PubMed
2) Hoglund M, et al : Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 39 : 195-204, 2004.
PubMed
3) Dave SS, et al : Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351 : 2159-2169, 2004.
PubMed
4) Barista I, et al : Mantle-cell lymphoma. Lancet Oncol 2 : 141-148, 2001.
PubMed
5) Farinha P, Gascoyne RD : Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 23 : 6370-6378, 2005.
PubMed
6) Uren AG, et al : Identification of paracaspases and metacaspases : two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 6 : 961-967, 2000.
 
7) Sanchez-Izquierdo D, et al : MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood 101 : 4539-4546, 2003.
 
8) Ohno H : Pathogenetic role of BCL6 translocation in B-cell non-Hodgkin's lymphoma. Histol Histopathol 19 : 637-650, 2004.
 
9) Cattoretti G, et al : Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7 : 445-455, 2005.
 
10) Alizadeh AA, et al : Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 : 503-511, 2000.
PubMed
11) Monti S, et al : Molecular profiling of diffuse Iarge B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105 : 1851-1861, 2005.
PubMed
12) Stein H, et al : CD30+ anaplastic large cell lymphoma : a review of its histopathologic, genetic, and clinical features. Blood 96 : 3681-3695, 2000.
PubMed
13) Horie R, et al : The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-κB activation in anaplastic large cell lymphoma. Cancer Cell 5 : 353-364, 2004.
 
14) Kuppers R, et al : Identification of Hodgkin and Reed-Stemberg cell-specific genes by gene expression profiling. J Clin Invest 111 : 529-537, 2003.
 
15) Rosenwald A, et al : Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198 : 851-862, 2003.
PubMed
P.160 掲載の参考文献
1) Fearon ER, et al : A genetic model for colorectal tumorigenesis. Cell 61 (5) : 759-767, 1990.
PubMed
2) Lengauer C, et al : Genetic instabilities in human cancers. Nature 396 (6712) : 643-649, 1998.
PubMed
3) Perucho M : Cancer of the microsatellite mutator phenotype. Biol Chem 377 (11) : 675-684, 1996.
PubMed
4) Perucho M : Microsatellite instability : the mutator that mutates the other mutator. Nat Med 2 (6) : 630-631, 1996.
PubMed
5) de Jong D : Molecular pathogenesis of follicular lymphoma : a cross talk of genetic and immunologic factors. J Clin Oncol 23 (26) : 6358-6363, 2005.
PubMed
6) Boxer LM, et al : Translocations involving c-myc and c-myc function. Oncogene 20 (40) : 5595-5610, 2001.
 
7) Campo E, et al : Mantle-cell lymphoma. Semin Hematol 36 (2) : 115-127, 1999.
PubMed
8) Levine EG, Bloornfield CD : Cytogenetics of non-Hodgkin's lymphoma. J Natl Cancer Inst Monogr (10) : 7-12, 1990.
 
9) Mrozek K, et al : Cytogenetics of indolent lymphomas. Semin Oncol 20 (5 Suppl 5) : 47-57, 1993.
 
10) Chaganti RSK, et al : Recurring chromosomal abnormalities in non-Hodgkin's lymphoma : biologic and clinical significance. Semin Hematol 37 (4) : 396-411, 2000.
 
11) Whang-Peng J, et al : Sequential analysis of 43 patients with non-Hodgkin's lymphoma : clinical correlations with cytogenetic, histologic, immunophenotyping, and molecular studies. Blood 85 (1) : 203-216, 1995.
PubMed
12) Bernstein R : Cytogenetics of chronic myelogenous leukemia. Semin Hematol 25 (1) : 20-34, 1988.
PubMed
13) Mitelman F : The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 11 (Suppl 1) : 11-15, 1993.
 
14) Huettner CS, et al : Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24 (1) : 57-60, 2000.
PubMed
15) Preudhomme C, et al : The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. Br J Haematol 98 (3) : 502-511, 1997.
PubMed
16) Krug U, et al : Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21 (21) : 3475-3495, 2002.
PubMed
17) Neri A, et al : Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA 85 (23) : 9268-9272, 1988.
PubMed
18) Hamatani K, et al : Increased expression of ras genes in non-Hodgkin's lymphomas is not associated with oncogenic activation of those genes by point mutation. Jpn J Cancer Res 80 (8) : 706-710, 1989.
 
19) Ahuja HG, et al : The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 75 (8) : 1684-1690, 1990.
PubMed
20) Cesarman E, et al : Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood 80 (12) : 3205-3216, 1992.
PubMed
21) Ballerini P, et al : Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 81 (1) : 166-176, 1993.
PubMed
22) Knowles DM, et al : Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85 (2) : 552-565, 1995.
PubMed
23) Trumper L, et al : N-ras genes are not mutated in Hodgkin and Reed-Sternberg cells : results from single cell polymerase chain-reaction examinations. Leukemia 10 (4) : 727-730, 1996.
 
24) Clark HM, et al : Mutadon of the ras genes is a rare genetic event in the histologic transformation of follicular lymphoma. Leukemia 10 (5) : 844-847, 1996.
PubMed
25) Nedergaard T, et al : A one-step DGGE scanning method for detection of mutations in the K-, N-, and H-ras oncogenes : mutations at codons 12, 13 and 61 are rare in B-cell non-Hodgkin's lymphoma. Int J Cancer 71 (3) : 364-369, 1997.
 
26) Takakuwa T, et al : Microsatellite instability and k-ras, p53 mutations in thyroid lymphoma. Jpn J Cancer Res 91 (3) : 280-286, 2000.
 
27) Hoshida Y, et al : Gene mutations in lymphoproliferative disorders of T and NK/T cell phenotypes developing in renal transplant patients. Lab Invest 82 (3) : 257-264, 2002.
PubMed
28) Hiyama T, et al : p53 expression, K-ras gene mutation and microsatellite instability in gastric B-cell lymphomas. J Gastroenterol Hepatol 18 (9) : 1047-1053, 2003.
PubMed
29) Lichter P, et al : Comparative genomic hybridization : uses and limitations. Semin Hematol 37 (4) : 348-357, 2000.
PubMed
30) Gebhart E : Genomic imbalances in human leukemia and lymphoma detected by comparative genomic hybridization (Review). Int J Oncol 27 (3) : 593-606, 2005.
PubMed
31) Ionov Y, et al : Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363 (6429) : 558-561, 1993.
PubMed
32) Thibodeau SN, et al : Microsatellite instability in cancer of the proximal colon. Science 260 (5109) : 816-819, 1993.
PubMed
33) Aaltonen LA, et al : Clues to the pathogenesis of familial colorectal cancer. Science 260 (5109) : 812-816, 1993.
 
34) Peltomaki P, et al : Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 53 (24) : 5853-5855, 1993.
PubMed
35) Fishel R, et al : The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75 (5) : 1027-1038, 1993.
PubMed
36) Leach FS, et al : Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75 (6) : 1215-1225, 1993.
PubMed
37) Arzimanoglou II, et al : Microsatellite instability in human solid tumors. Cancer 82 (10) : 1808-1820, 1998.
PubMed
38) Maehara Y, et al : The instability within : problems in current analyses of microsatellite instability. Mutat Res 461 (4) : 249-263, 2001.
PubMed
39) Boland CR, et al : A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition : development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (22) : 5248-5257, 1998.
PubMed
40) Oda S, et al : Precise assessment of microsatellite instability using high resolution fluorescent microsatellite analysis. Nucleic Acids Res 25 (17) : 3415-3420, 1997.
PubMed
41) Oki E, et al : Mutated gene-specific phenotypes of dinucleotide repeat instability in human colorec-tal carcinoma cell lines deficient in DNA mismatch repair. Oncogene 18 (12) : 2143-2147, 1999.
 
42) Ikeda Y, et al : Features of microsatellite instability in colorectal cancer : comparison between colon and rectum. Oncology 61 (2) : 168-174, 2001.
PubMed
43) Oda S, et al : Two modes of microsatellite instability in human cancer : differential connection of defective DNA mismatch repair to dinucleotide repeat instability. Nucleic Acids Res 33 (5) : 1628-1636, 2005.
PubMed
44) Peng H, et al : Replication error phenotype and p53 gene mutation in lymphomas of mucosa-associated lymphoid tissue. Am J Pathol 148 (2) : 643-648, 1996.
PubMed
45) Chong JM, et al : Microsatellite instability and loss of heterozygosity in gastric lymphoma. Lab Invest 77 (6) : 639-645, 1997.
PubMed
46) Xu WS, et al : No evidence of replication error phenotype in primary gastric lymphoma of mucosa-associated lymphoid tissue. Int J Cancer 76 (5) : 635-638, 1998.
PubMed
47) Takakuwa T, et al : No evidence of replication error phenotype in nasal NK/T cell lymphoma. Int J Cancer 84 (6) : 623, 1999.
PubMed
48) Hoeve MA, et al : Frequent allelic imbalance but infrequent microsatellite instability in gastric lymphoma. Leukemia 13 (11) : 1804-1811, 1999.
PubMed
49) Furlan D, et al : Microsatelhte instability in gastiric MALT lymphomas and other associated neoplasms. Ann Oncol 10 (7) : 783-788, 1999.
 
50) Starostik P, et al : Genetic aberrations common in gastric high-grade large B-cell lymphoma. Blood 95 (4) : 1180-1187, 2000.
 
51) Starostik P, et al : The role of microsatellite instability in gastric low-and high-grade lymphoma development. Am J Pathol 157 (4) : 1129-1136, 2000.
PubMed
52) Scarisbrick JJ, et al : Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN. Blood 95 (9) : 2937-2942, 2000.
PubMed
53) Skacel M, et al : Diffuse large B-cell lymphoma of the stomach : assessment of microsatellite instability, allelic imbalance, and trisomy of chromosomes 3, 12, and 18. Diagn Mol Pathol 11 (2) : 75-82, 2002.
PubMed
54) Scarisbrick JJ, et al : Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 121 (4) : 894-901, 2003.
PubMed
55) Baumgartner AK, et al : High frequency of genetic aberrations in enteropathy-type T-cell lymphoma. Lab Invest 83 (10) : 1509-1516, 2003.
PubMed
56) Jordanova ES, et al : Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system. Int J Cancer 103 (3) : 393-398, 2003.
PubMed
57) Rubben A, et al : Multilineage progression of genetically unstable tumor subclones in cutaneous T-cell lymphoma. Exp Dermatol 13 (8) : 472-483, 2004.
PubMed
58) Niv E, et al : Microsatellite instability in gastric MALT lymphoma. Mod Pathol 17 (11) : 1407-1413, 2004.
PubMed
59) Mark Z, et al : Instability of dinucleotide repeats in Hodgkin's disease. Am J Hematol 57 (2) : 148-152, 1998.
PubMed
60) Re D, et al : Proficient mismatch repair protein expression in Hodgkin and Reed Stemberg cells. Int J Cancer 97 (2) : 205-210, 2002.
 
61) Robledo M, et al : Genetic instability of microsatellites in hematological neoplasms. Leukemia 9 (6) : 960-964, 1995.
PubMed
62) Randerson J, et al : Microsatellite instability in follicle centre cell lymphoma. Br J Haematol 93 (1) : 160-162, 1996.
PubMed
63) Gamberi B, et al : Microsatellite instability is rare in B-cell non-Hodgkin's lymphomas. Blood 89 (3) : 975-979, 1997.
 
64) Nagy M, et al : Genetic instability is associated with histological transformation of follicle center lymphoma. Leukemia 14 (12) : 2142-2148, 2000.
PubMed
65) Bedi GC, et al : Microsatellite instability in primary neoplasms from HIV+ patients. Nat Med 1 (1) : 65-68, 1995.
PubMed
66) Volpe G, et al : Analysis of microsatellite instability in chronic lymphoproliferative disorders. Ann Hematol 72 (2) : 67-71, 1996.
PubMed
67) Larson RS, et al : Microsatellite instability in natural killer cell-like T-cell lymphomas in immunocompromised and immunocompetent individuals. Blood 89 (3) : 1114-1115, 1997.
PubMed
68) Fulop Z, et al : Microsatellite instability and hMLH I promoter hypermethylation in Richter'stransformation of chronic lymphocytic Ieukemia. Leukemia 17 (2) : 411-415, 2003.
 
69) Branch P, et al : Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362 (6421) : 652-654, 1993.
 
70) Ribic CM, et al : Tumor microsatellite-instability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N Engl J Med 349 (3) : 247-257, 2003.
PubMed
71) Pasqualucci L, et al : Molecular pathogenesis of non-Hodgkin's lymphoma : the role of Bcl-6. Leuk Lymphoma 44 (Suppl 3) : S5-12, 2003.
 
72) Duyster J, et al : Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20 (40) : 5623-5637, 2001.
PubMed
73) Gartenhaus R, et al : Mutator phenotype in a subset of chronic lymphocytic leukemia. Blood 87 (1) : 38-41, 1996.
 
74) Larson RS, et al : Microsatellite analysis of posttransplant lymphoproliferative disorders : determination of donor/recipient origin and identification of putative lymphomagenic mechanism. Cancer Res 56 (19) : 4378-4381, 1996.
 
75) De Vita S, et al : Rarity of microsatellite genomic instability in B-cell non-Hodgkin's lymphomas in hepatitis C virus-infected patients. Br J Haematol 97 (2) : 463-465, 1997.
 
76) Sol Mateo M, et al : Analysis of the frequency of microsatellite instability and p53 gene mutation in splenic marginal zone and MALT lymphomas. Mol Pathol 51 (5) : 262-267, 1998.
PubMed
77) Indraccolo S, et al : Mutator phenotype in human hematopoietic neoplasms and its association with deletions disabling DNA repair genes and bcl-2 rearrangements. Blood 94 (7) : 2424-2432, 1999.
PubMed
78) Hodges KB, et al : Rarity of genomic instability in pathogenesis of systemic anaplastic large cell lymphoma (ALCL) in immunocompetent patients. Hum Pathol 30 (2) : 173-177, 1999.
PubMed
79) Sanz-Vaque L, et al : Microsatellite instability analysis in typical and progressed mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Haematologica 86 (2) : 181-186, 2001.
 
80) Duval A, et al : The mutator pathway is a feature of immunodeficiency-related lymphomas. Proc Natl Acad Sci USA 101 (14) : 5002-5007, 2004.
PubMed
P.167 掲載の参考文献
1) ISCN (2005) : An International System for Human Cytogenetic Nomenclature (ed by Shaffer LG, Tommerup N), S. Karger, Basel, 2005.
 
2) The Association of Genetic Technologists : The AGT Cytogenetics Laboratory Manual, 3rd ed (ed by Barch MJ, et al), Lippincott-Raven, Philadelphia, 1997.
 
3) Therman E : Human Chromosome, 2nd ed, Springer-Verlag, New York, 1980.
 
4) 古庄敏行ほか編 : 臨床染色体診断法, 金原出版, 1996.
 
5) 阿部達生ほか : 腫瘍染色体アトラス, 南江堂, 1986.
 
6) Heim S, Mitelman F : Cancer Cytogenetics, 2nd ed, Wiley-Liss, New York, 1995.
 
7) 阿部達生編著 : 造血器腫瘍アトラス-形態, 免疫, 染色体と遺伝子, 改訂第3版, 日本医事新報社, 2000.
 
8) 三浦偉久男 : 染色体異常-検査の方法と読み方-. 悪性リンパ腫 病理と臨床-ALTSGの研究から-, p29-60, 先端医学社, 2005.
 
9) 谷脇雅史ほか編 : 血液腫瘍-MIC-M診断から治療まで-, 先端医学社, 2005.
 
10) 横田昇平ほか編 : 分子生物学, 細胞遺伝学, 細胞免疫学に基づく血液・固形腫瘍診断マニュアル, フジメディカル出版, 2002.
 
P.171 掲載の参考文献
1) Harris NL, et al : A revised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Study Group [see comments]. Blood 84 : 1361-1392, 1994.
 
2) Weber T, et al : Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol 10 : 73-84, 2000.
 
3) Kuratsu J, et al : Trends in the incidence of primary intracranial tumors in Kumamoto, Japan. Int J Clin Oncol 6 : 183-191, 2001.
PubMed
4) Eby NL, et al : Increasing incidence of primary brain lymphoma in the US. Cancer 62 : 2461-2465, 1988.
PubMed
5) Nakamura M, et al : Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 63 : 737-741, 2003.
PubMed
6) Nakamura M, et al : Frequent alterations of the p14ARF and p16INK4a genes in primary central nervous system lymphomas. Cancer Res 61 : 6335-6339, 2001.
PubMed
7) Nakamura M, et al : Histopathology, pathogenesis and molecular genetics in primary central nervous system lymphomas. Histol Histopathol 19 : 211-219, 2004.
 
8) Puthalakath H, Strasser A : Keeping killers on a tight leash : transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 9 : 505-512, 2002.
PubMed
9) Herman JG, et al : Methylation-specific PCR : a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 : 9821-9826, 1996.
PubMed
10) Nakamura M, et al : Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G : C→A : T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22 : 1715-1719, 2001.
 
11) Imaizumi K, et al : Molecular cloning of a novel polypeptide, DP5, induced during programmed neuronal death. J Biol Chem 272 : 18842-18848, 1997.
 
12) Obata T, et al : Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clin Cancer Res 9 : 6410-6418, 2003.
PubMed
13) Nakamura M, et al : Frequent HRK inactivation associated with low apoptotic index in secondary glioblastomas. Acta Neuropathol (Berl) 110 : 402-410, 2005.
PubMed
14) Toyota M, et al : Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA 97 : 710-715, 2000.
 
15) Abrey LE, et al : Treatment for primary CNS lymphoma : the next step. J Clin Oncol 18 : 3144-3150, 2000.
PubMed
P.177 掲載の参考文献
1) Torlakovic E, et al : The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections : a novel pan pre-B and B-cell marker. Am J Surg Pathol 26 : 1343-1350, 2002.
 
2) Asano N, et al : Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 29 : 1284-1293, 2005.
PubMed
3) Yatabe Y, et al : A clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 95 : 2253-2261, 2000.
 
4) Nakamura S, et al : Anaplastic large cell lymphoma : a distinct molecular pathologic entity, a reappraisal with special reference to p80NPM/ALK expression. Am J Surg Pathol 21 : 1420-1432, 1997.
 
5) Oyama T, et al : Senile EBV+ B-cell lymphoproliferative disorders : a clinicopathologic study of 22 patients. Am J Surg Pathol 27 : 16-26, 2003.
PubMed
6) Suzuki R, et al : Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96 : 2993-3000, 2000.
PubMed
7) Tsuchiya T, et al : Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified : comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 103 : 236-241, 2004.
PubMed
8) Ishida T, et al : The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res 10 : 7529-7539, 2004.
 
9) Hans CP, et al : Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 : 275-282, 2004.
PubMed
10) Ohshima K, et al : CD10 and Bcl10 expression in diffuse large B-cell lymphoma : CD10 is a marker of improved prognosis. Histopathology 39 : 156-162, 2001.
PubMed
11) Alizadeh AA, et al : Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 : 503-511, 2000.
PubMed
12) Rosenwald A, et al : The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 346 : 1937-1947, 2002.
PubMed
13) Roberts RA, et al : Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 108 : 311-318, 2006.
 
14) Farinha P, et al : Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106 : 2169-2174, 2005.
PubMed
15) Yang Z-Z, et al : Intratumoral CD4+ CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107 : 3639-3646, 2006.
 
P.181 掲載の参考文献
1) Akagi T, et al : A novel gene, MALT1 at 18q21, is involved in t (11 ; 18) (q21 ; q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18 : 5785-5794, 1999.
 
2) Lucas PC, et al : Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J Biol Chem 276 : 19012-19019, 2001.
 
3) Streubel B, et al : T (3 ; 14) (p14.1 ; q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 19 : 652-658, 2005.
 
4) Inagaki H, et al : Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 28 : 1560-1567, 2004.
PubMed
5) Ye H, et al : Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication. GUT 55 : 137-139, 2006.
PubMed
6) Ruskone-Fourmestraux A, et al : Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. GUT 48 : 297-303, 2001.
PubMed
7) Nakamura S, et al : Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. GUT 48 : 454-460, 2001.
PubMed
8) Kaneko Y, et al : Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas. GUT 52 : 641-646, 2003.
PubMed
9) Barth TF, et al : Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. Genes Chromosomes Cancer 31 : 316-325, 2001.
 
10) Starostik P, et al : Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 99 (1) : 3-9, 2002.
 
11) Takada S, et al : Involvement of the chromosomal translocation t (11 ; 18) in some mucosa-associated lymphoid tissue lymphomas and diffuse large B-cell lymphomas of the ocular adnexa : evidence from multiplex reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization on using formalin-fixed, paraffin-embedded specimens. Mod Pathol 16 : 445-452, 2003.
 
12) Streubel B, et al : Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 18 : 1722-1726, 2004.
PubMed
13) Ferreri AJ, et al : Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 96 : 586-594, 2004.
PubMed
14) Daibata M, et al : Absence of Chlamydia psittaci in ocular adnexal lymphoma from Japanese patients. Br J Haematol 132 : 651-652, 2006.
PubMed
15) Rosado MF, et al : Ocular adnexal lymphoma : a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood 107 : 467-472, 2006.
PubMed
16) Chanudet E, et al : Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J pathol 209 : 344-351, 2006.
PubMed
17) Sakugawa ST, et al : API2-MALT1 fusion gene in colorectal lymphoma. Mod Pathol 16 : 1232-1241, 2003.
PubMed
P.188 掲載の参考文献
1) Karnan S, et al : Analysis of chromosomal imbalances in de novo CD5-positive diffuse large B-cell lymphoma detected by comparative genomic hybridization. Genes Chromosome Cancer 39 : 77-81, 2004.
PubMed
2) Zhang X, et al : Comparison of genetic aberrations in CD10+ diffused large B-cell lymphoma and follicular lymphoma by comparative genomic hybridization and tissue-fluorescence in situ hybridization. Cancer Sci 95 : 809-814, 2004.
 
3) Pinkel D, et al : High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20 : 207-211, 1998.
PubMed
4) Ota A, et al : Identification and characterization of a novel gene, C130rf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64 : 3087-3095, 2004.
PubMed
5) Tagawa H, et al : Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma : comparison between CD5-positive and CD5-negative cases. Cancer Res 64 : 5948-5955, 2004.
PubMed
6) Ishkanian AS, et al : A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 36 : 299-303, 2004.
PubMed
7) Tagawa H, et al : Genome-wide array-based CGH for mantle cell lymphoma : Identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24 : 1348-1358, 2005.
PubMed
8) Tagawa H, et al : Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 106 : 1770-1777, 2005.
PubMed
9) Oshiro A, et al : Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 107 : 4500-4507, 2006.
PubMed
10) Seto M, et al : Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t (11 ; 14) (q13 ; q32) translocation. Oncogene 7 : 1401-1406, 1992.
 
11) Yatabe Y, et al : Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma (MCL) : a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negativc MCL-like B-cell lymphoma. Blood 95 : 2253-2261, 2000.
 
12) Hofmann WK, et al : Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 98 : 787-794, 2001.
PubMed
13) Alizadeh AA, et al : Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 : 503-511, 2000.
PubMed
14) Rosenwald A, et al : The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 : 1937-1947, 2002.
PubMed
15) Kameoka Y, et al : Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma. Oncogene 23 : 9148-9154, 2004.
 
16) Kasugai Y, et al : Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma. Clin Cancer Res 11 : 8265-8272, 2005.
PubMed
17) Fukuhara N, et al : Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma. Cancer Sci 97 : 499-504, 2006.
PubMed
18) Tagawa H, Seto M : A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia 19 : 2013-2016, 2005.
 
P.192 掲載の参考文献
1) Ott G, et al : Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma : 2 types of follicular lymphoma grade 3. Blood 99 (10) : 3806-3812, 2002.
PubMed
2) Bosga-Bouwer AG, et al : Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t (14 ; 18), 3q27, or other translocations : t (14 ; 18) and 3q27 are mutually exclusive. Blood 101 (3) : 1149-1153, 2003.
PubMed
3) Katzenberger T, et al : Cytogenetic alteration affecting BCL6 are predominantly found in follicular lymphoma grade 3B with a diffuse large B-cell component. Am J Pathol 165 (2) : 481-490, 2004.
 
4) Jardin F, et al : Follicular lymphoma without t (14 ; 18) and with BCL-6 rearrangement : a lymphoma subtype with distinct pathological, molecular and clinical characteristics. Leukemia 16 : 2309-2317, 2002.
PubMed
5) Horsman DE, et al : Follicular lymphoma lacking the t (14 ; 18) (q32 ; q21) : identification of two disease subtypes. Br J Haematol 120 : 424-433, 2003.
 
6) 中峯寛和, 吉野正 : 低悪性度B細胞リンパ腫. 悪性リンパ腫・臨床と病理-ALTSGの研究から- (成人リンパ腫治療研究会編), p75-77, 先端医学社, 2005.
 
7) Sekiguchi N : Follicular lymphoma subgrouping by fluorescence in situ hybridization analysis. Cancer Sci 96 : 77-82, 2005.
PubMed
8) 竹内賢吾 : 濾胞性リンパ腫. 最新・悪性リンパ腫アトラス (菊池昌弘, 森茂郎編), p 141-153, 文光堂, 2004.
 
9) Rosenwald A, et al : The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (25) : 1937-1947, 2002.
PubMed
10) Bohen SP, et al : Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci USA 100 : 1926-1930, 2003.
PubMed
11) Cartron G, et al : Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99 (3) : 754-758, 2002.
 
12) Bjorck E, et al : High expression of cyclin B1 predicts a favorable outocome in patients with follicular lymphoma. Blood 105 (7) : 2908-2915, 2005.
 
13) Dave SS, et al : Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351 (21) : 2159-2169, 2004.
PubMed
P.197 掲載の参考文献
1) Sheibani K, et al : Monocytoid B-cell lymphoma : a novel B-cell neoplasm. Am J Pathol 124 : 310-318, 1986.
 
2) Cousar JB, et al : Report of an ususal lymphoma arising from parafollicular B-lymphocytes (PBLs) or so-called "monocytoid" lymphocytes. Am J Clin Pathol 87 : 121-128, 1987.
PubMed
3) Wotherspoon AC, et al : Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338 : 1175-1176, 1991.
PubMed
4) Nathwani BN, et al : Marginal zone B-cell lymphoma : A clinical comparison of nodal and mucosa-associated lymphoid tissue types. J Clin Oncol 17 : 2486-2492, 1999.
PubMed
5) Thieblemont C, et al : Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior : analysis of 108 patients. J Clin Oncol 15 : 1624-1630, 1997.
PubMed
6) Jenkins C, et al : Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol 841907-913, 2000.
 
7) White WL, et al : Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid type. Ophthalmology 102 : 1994-2006, 1995.
PubMed
8) Tanimoto K, et al : Primary ocular adnexal MALT lymphoma : Long-term follow-up study of 114 patients. Proc ASCO : 445s, 2006.
 
9) Ferreri AJ, et al : Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 96 : 586-594, 2004.
PubMed
10) Ferreri AJ, et al : Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 23 : 5067-5073, 2005.
PubMed
11) Yakushijin Y, et al : Absence of chlamydial infection in Japanese patients with orbital adnexal MALT lymphoma. Int J Hematol 2006. (in press)
 
12) Gninberger B, et al : 'Blind' antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Annal Oncol 17 : 484-487, 2006.
 
13) Knowles DM, et al : Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbita, conjunctiva, and eyelids) : A prospective multiparametric analysis of 108 cases during 1977 to 1987. Hum Pathol 21 : 959-973, 1990.
PubMed
14) Meijer A, et al : Genomic relatedness of Chlamydia isolated determined by amplified fragment length polymorphism analysis. J Bacteriol 181 : 4469-4475, 1999.
PubMed
15) Madico G, et al : Touchdown enzyme time release-PCR for detection and identification of C. trachomatis, C. pneumoniae, C. psittaci using the 16S and 16S-23S spacer rRNA genes. J Clin Microbiol 38 : 1085-1093, 2000.
PubMed
P.201 掲載の参考文献
1) Horie R, et al : Hodgkin's lymphoma and CD30 signal transduction. Int J Hematol 77 : 37-47, 1993.
 
2) Thomas RK, et al : Part I : Hodgkin's lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 5 : 11-18, 2004.
PubMed
3) Skinnider BF, Mak TW : The role of cytokines in classical Hodgkin lymphoma. Blood 99 : 4283-4297, 2002.
PubMed
4) Bargou RC, et al : Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100 : 2961-2969, 1997.
 
5) Hinz M, et al : Nuclear factor kappaB-dependent gene expression profiling of Hodgkin'sdisease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 196 : 605-617, 2002.
 
6) Ben-Neriah Y, Schmitz ML : Of mice and men. EMBO Rep 5 : 668-673, 2004.
PubMed
7) Nonaka M, et al : Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts. Oncogene 24 : 3976-3986, 2005.
PubMed
8) Coope HJ, et al : CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 21 : 5375-5385, 2002.
PubMed
9) Muller JR, Siebenlist U : Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways. J Biol Chem 278 : 12006-12012, 2003.
PubMed
10) Horie R, et al : Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21 : 2493-2503, 2002.
PubMed
11) Re D, et al : From Hodgkin disease to Hodgkin lymphoma : biologic insights and therapeutic potential. Blood 105 : 4553-4560, 2005.
PubMed
12) Saito N, et al : Two carboxyl-terminal activation regions of Epstein-Barr virus latent membrane protein 1 activate NF-kappaB through distinct signaling pathways in fibroblast cell lines. J Biol Chem 278 : 46565-46575, 2003.
 
P.213 掲載の参考文献
1) Iida S, Ueda R : Multistep tumorigenesis of multiple myeloma : Its molecular delineation. Int J Hematol 77 : 207-212, 2003.
PubMed
2) Kuehl WM, Bergsagel PL : Multiple myeloma : Evolving genetic events and host interactions. Nat Rev Cancer 2 : 177-192, 2002.
 
3) Fonseca R, et al : Genetics and cytogenetics of multiple myeloma : A workshop report. Cancer Res 64 : 1546-1558, 2004.
PubMed
4) Kyle RA, et al : A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346 (8) : 564-569, 2002.
PubMed
5) Kyle RA, Rajkumar SV : Monoclonal gammopathies of undetermined significance : a review. Immunol Rev 194 : 112-139, 2003.
PubMed
6) Taniwaki M, et al : Detection of 14q32 translocations in B-cell malignancies by in situ hybridization with yeast artificial chromosome clones containing the human IgH gene locus. Blood 83 : 2962-2969, 1994.
 
7) Bergsagel PL, Kuehl WM : Chromosome translocations in multiple myeloma. Oncogene 20 : 5611-5622, 2001.
PubMed
8) Chesi M, et al : Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88 : 674-681, 1996.
PubMed
9) Shaughnessy J Jr, et al : Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98 : 217-223, 2001.
PubMed
10) Chesi M, et al : Frequent translocation t (4 ; 14) (p16.3 ; q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16 : 260-264, 1997.
PubMed
11) Santra M, et al : A subset of multiple myeloma harboring the t (4 ; 14) (p16 ; q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101 (6) : 2374-2376, 2003.
 
12) Chesi M, et al : Dysreguiation of MMSET is tumorigenic in-vivo. Blood (ASH Annual Meeting Abstracts) 104 : 74, 2004.
 
13) Trudel S, et al : CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t (4 ; 14) multiple myeloma. Blood 105 (7) : 2941-2948, 2005.
PubMed
14) Chesi M, et al : Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91 : 4457-4463, 1998.
 
15) Hurt EM, et al : Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5 : 191-199, 2004.
PubMed
16) Hanamura I, et al : Ectopic expression of MAFB gene in human myeloma cells carrying (14 ; 20) (q32 ; q11) chromosomal translocations. Jpn J Cancer Res 92 : 638-644, 2001.
PubMed
17) Suzuki A, et al : ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma : ARK5 as a new molecular deterrninant of malignant multiple myeloma. Oncogene 24 (46) : 6936-6944, 2005.
PubMed
18) Suzuki A, et al : ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol 24 (8) : 3526-3535, 2004.
PubMed
19) Zhan F, et al : The molecular classification of multiple myeloma. Blood 108 : 2020-2028, 2006.
PubMed
20) Iida S, et al : Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 17 : 226-230, 1997.
PubMed
21) Alizadeh AA, et al : Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 : 503-511, 2000.
PubMed
22) Hatzivassiliou G, et al : IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 14 : 277-289, 2001.
 
23) Hanamura I, et al : Identification of three novel chromosomal translocation partners involving the immunoglobulin loci in newly diagnosed myeloma and human myeloma cell lines. Blood (ASH Annual Meeting Abstracts) 106 : 1552, 2005.
 
24) Gabrea A, et al : Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell 3 : 119-123, 1999.
 
25) Hayami Y, et al : Inactivation of the E3/LAPTm5 gene by chromosomal rearrangement and DNA methylation in human multiple myeloma. Leukemia 17 : 1650-1657, 2003.
PubMed
26) Bergsagel P, et al : Cyclin D dysregulation : an early and unifying pathogenic event in multiple myeloma. Blood 106 : 296-303, 2005.
PubMed
27) Agnelli L, et al : Molecular classification of multiple myeloma : A distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 23 : 7296-7306, 2005.
PubMed
28) Hanamura I, et al : Prognostic value of Cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia 20 (7) : 1288-1290, 2006.
PubMed
29) Lossos IS, et al : Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350 (18) : 1828-1837, 2004.
 
30) Kato M, et al : Lack of ku80 alteration in multiple myeloma. Jpn J Cancer Res 93 : 359-362, 2002.
PubMed
31) Hanamura I, et al : Frequent gain of chromosome band 1q21 in plasma cell dyscrasias detected by fluorescence in situ hybridization : incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108 : 1724-1732, 2006.
PubMed
32) Inoue J, et al : Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 165 (1) : 71-81, 2004.
PubMed
33) Carrasco R, et al : Comprehensive genome-wide profile of regional gains and losses in multiple myeloma using array-CGH : The 1q21 amplification and potential role of the BCL-9 gene in multiple myeloma pathogenesis. Blood (ASH Annual Meeting Abstracts) 104 : 785, 2004.
 
34) Zhan F, et al : Elevated expression of CKS1B at 1q21 is highly crrelated with short survival in myeloma. Blood (ASH Annual Meeting Abstracts) 104 : 77, 2004.
 
35) Rasmussen T, et al : Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 105 (1) : 317-323, 2005.
 
36) Billadeau D, et al : Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res 55 : 3640-3646, 1995.
PubMed
37) Hoang B, et al : Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood 107 (11) : 4484-4490, 2006.
PubMed
38) Chang H, et al : p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105 : 358-360, 2005.
PubMed
39) Uchida T, et al : Hypermethylation of p161NK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia 15 : 157-165, 2001.
 
40) Chang H, et al : Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res 30 (3) : 262-265, 2006.
PubMed
P.218 掲載の参考文献
1) Harada H, et al : Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81 : 2658-2663, 1993.
PubMed
2) Mahmoud MS, et al : Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood 92 : 3887-3897, 1998.
PubMed
3) Li FJ, et al : A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma. Blood 105 : 3295-3302, 2005.
 
4) Kawano MM, et al : Transdifferentiation of human myeloma cells and their dedifferentiation by IL-6. Blood 106 (Suppl 1) : 951a, 2005.
 
5) Zhan F, et al : Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99 : 1745-1757, 2002.
PubMed
6) Zhan F, et al : Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101 : 1128-1140, 2003.
 
7) Shaughnessy J Jr, et al : High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96 : 1505-1511, 2000.
 
8) Fonseca R, et al : Genetics and cytogentics of multiple myeloma : A workshop report. Cancer Res 64 : 1546-1558, 2004.
 
9) Nishida K, et al : The immunoglobulin heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90 : 526-534, 1997.
PubMed
10) Chesi M, et al : Frequent translocation t (4 ; 14) (p16.3 ; q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16 : 260-264, 1997.
PubMed
11) Iida S, et al : Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 17 : 226-230, 1997.
PubMed
12) Honjo T, et al : AID : how does it aid antibody diversity? Immunity 20 : 659-668, 2004.
PubMed
13) Nutt SL, et al : Commitment to the B-lymphoid lineage depends on the transcription factor Pax-5. Nature 401 : 556-562, 1999.
 
14) Busslinger M : Transcriptional control of early B cell development. Ann Rev Immunol 22 : 55-79, 2004.
 
15) Mahmoud MS, et al : Altered expression of Pax-5 gene in human myeloma cells. Blood 87 : 4311-4315, 1996.
PubMed
P.224 掲載の参考文献
1) Yasui H, et al : Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 132 : 385-397, 2006.
PubMed
2) Hideshima T, et al : Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 23 : 6345-6350, 2005.
PubMed
3) Mitsiades CS, et al : Transcriptional signature of histone deacetylase inhibition in multiple myeloma : biological and clinical implications. Proc Natl Acad Sci USA 101 : 540-545, 2004.
PubMed
4) Maiso P, et al : The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66 : 5781-5789, 2006.
PubMed
5) Abe M, et al : Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100 : 2195-2202, 2002.
PubMed
6) Tian E, et al : The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in muldple myeloma. N Engl J Med 349 : 2483-2494, 2003.
PubMed
7) Oshima T, et al : Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106 : 3160-3165, 2005.
PubMed
8) Body JJ, et al : A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12 : 1221-1228, 2006.
 
9) Singhal S, et al : Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 : 1565-1571, 1999.
PubMed
10) Rajkumar SV, et al : Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 : 4050-4053, 2005.
PubMed
11) Schey SA, et al : Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22 : 3269-3276, 2004.
PubMed
12) Hideshima T, Anderson KC : Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2 : 927-937, 2002.
PubMed
13) Richardson PG, et al : Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 : 2487-2498, 2005.
 
14) Chauhan D, et al : A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8 : 407-419, 2005.
 
15) Badros AZ, et al : Phase II study of G3139, a BcL2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 23 : 4089-4099, 2005.
PubMed
16) Yan H, et al : Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 66 : 2305-2313, 2006.
PubMed
17) Lin B, et al : The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 62 : 5019-5026, 2002.
PubMed
18) Navas TA, et al : Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X (L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 20 : 1017-1027, 2006.
PubMed
19) Amit-Vazina M, et al : Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 93 : 70-80, 2005.
PubMed
20) Hussein MA, et al : Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 125 : 470-476, 2004.
PubMed
21) Mitsiades CS, et al : Antimyeloma activity of heat shock protein-90 inhibition. Blood 107 : 1092-1100, 2006.
PubMed
22) Trudel S, et al : CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t (4 ; 14) multiple myeloma. Blood 105 : 2941-2948, 2005.
PubMed
23) Raje N, et al : Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106 : 1042-1047, 2005.
PubMed
24) Hideshima T, et al : Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102 : 8567-8572, 2005.
PubMed
25) Hideshima T, et al : Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107 : 4053-4062, 2006.
PubMed
P.230 掲載の参考文献
1) Takeuchi T, et al : Skeletrophin, a novel ubiquitin ligase to the intracellular region of Jagged-2, is aberrantly expressed in multiple myeloma. Am J Pathol 166 : 1817-1826, 2005.
 
2) Itoh M, et al : Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta. Dev Cell 4 : 67-82, 2003.
PubMed
3) 竹内保, 大朏祐治 : 多発性骨髄腫 (およびB細胞性腫瘍) におけるNotchの関与. 医学のあゆみ 217 : 1097-1100, 2006.
Medical*Online
4) Hori K, et al : Drosophila deltex mediates suppressor of Hairless-independent and late-endosomal activation of Notch signaling. Development 131 : 5527-5537, 2004.
PubMed
5) Wilkin MB, et al : Regulation of notch endosomal sorting and signaling by Drosophila Nedd4 family proteins. Curr Biol 14 : 2237-2244, 2004.
PubMed
6) Qiu L, et al : Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase. J Biol Chem 275 : 35734-35737, 2000.
PubMed
7) Sakata T, et al : Drosophila Nedd4 regulates endocytosis of notch and suppresses its ligand-independent activation. Curr Biol 14 : 2228-2236, 2004.
PubMed
8) Pavlopoulos E, et al : neuralized Encodes a peripheral membrane protein involved in delta signaling and endocytosis. Dev Cell 1 : 807-816, 2001.
PubMed
9) Koo BK, et al : Mind bomb 1 is essential for generating functional Notch ligands to activate Notch. Development 132 : 3459-3470, 2005.
PubMed
10) Jundt F, et al : Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 103 : 3511-3515, 2004.
PubMed
11) Houde C, et al : Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 104 : 3697-3704, 2004.
PubMed
12) Takeuchi T, et al : A ubiquitin ligase, skeletrophin, is a negative regulator of melanoma invasion. Oncogene 25 : 7059-7069, 2006.
PubMed
13) Chauhan D, et al : Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 4 : 686-692, 2005.
PubMed

臨床編

P.240 掲載の参考文献
1) Bennett JM, et al : Proposals for the classification of acute leukaemias (FAB Cooperative Group). Br J Haematol 33 : 451-458, 1976.
PubMed
2) Bennett JM, et al : Proposals for the classhication of the myelodysplastic syndromes. Br J Haematol 51 : 189-199, 1982.
PubMed
3) Bennett JM, et al : Proposed revised criteria for the classification of acute leukaemia : A report from the French-American-British Cooperative Group. Ann Intern Med 103 : 620-625, 1985.
PubMed
4) Bennett JM, et al : Proposals for the classification of chronic (mature) Band T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 42 : 567-584, 1989.
 
5) Bennett JM, et al : The chronic myeloid leukaemias : guidelmes for distinguishing chronic granulocytic leukaemia, atypical chronic granulocytic leukaemia, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87 : 746-754, 1994.
PubMed
6) Harris NL, et al : A revised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Group. Blood 84 : 1361-1392, 1994.
PubMed
7) World Health Orgnanization Classification of Tumors. Pathology and Genetics : Tumors of Haematopoietic and Lymphoid Tissues (ed by Jaffe WS, et al), IARC Press, Lyon, 2001.
 
8) List A, et al : Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 : 549-557, 2005.
PubMed
9) Ozeki K, et al : Biologic and chnical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 103 : 1901-1908, 2004.
 
10) Tiacci E, et al : Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352 : 254-266, 2005.
PubMed
11) Baxter EJ, et al : Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 : 1054-1061, 2005.
PubMed
P.243 掲載の参考文献
1) Bennett JM, et al : Proposals for the classification of acute leukaemias. Br J Haematol 33 : 451-458, 1976.
PubMed
2) Bennett JM, et al : Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103 : 620-629, 1985.
PubMed
3) Bennett JM, et al : Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Ann Intern Med 103 : 460-462, 1985.
PubMed
4) Bennett JM, et al : Proposal for the recognition minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 78 : 325-329, 1991.
 
5) Harris NL, et al : World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues : report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 : 3835-3849, 1999.
PubMed
6) Brunning RD, et al : Acute myeloid leukaemias. In : Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues (ed by Jaffe ES, et al), p 75-107, IARC Press, Lyon, 2001.
 
7) Vardiman JW, et al : The World Health Organization (WHO) classification of the niyeloid neoplasms. Blood 100 : 2292-2302, 2002.
PubMed
8) Bennett JM, et al : A variant form of hypergranular promyelocytic leukaemia (M3). Ann Intern Med 92 : 261-262, 1980.
 
9) Kuriyama K, et al : Morphological diagnoses of the Japan Adult Leukemia Study Group Acute Myeloid Leukemia Protocols : Central Review. Int J Hematol 73 : 93-99, 2001.
 
10) Brito-Babapulle F, et al : Clinical and laboratory features of de novo acute myeloid leukaeniia with trilineage myelodysplasia. Br J Haematol 66 : 445-450, 1987.
PubMed
11) 栗山一孝 : AMLのWHO分類-その有用性と課題-. 臨床血液 45 : 6-14, 2004.
 
12) Garand R, et al : Minimally differentiated erythroleukaemia (AML M6 'variant') : a rare subset of AML distinct from AML M6. Br J Haematol 90 : 868-875, 1995.
PubMed
13) 栗山一孝 : 急性骨髄性白血病の分類と現状. 日検血会誌 3 : 285-294, 2002.
 
14) Tallman MS, et al : Acute megakaryocytic leukemia : the Eastern Cooperative Oncology Group expenence. Blood 96 : 2405-2411, 2000.
 
15) Oki Y, et al : Adult acute megakaryocytic leukemia : an analysis of 37 patients treated at M. D. Anderson Cancer Center. Blood 107 : 880-884, 2006.
 
P.248 掲載の参考文献
1) Brunning RD, et al : Precursor B lymphoblastic leukaemia/lymphoma. In : World Health Organization Classification of Tumours. Pathology and genetics, tumor of haematopoeitic and lymphoid tissues (ed by Jaffe WS, et al), p 111-114, IARC Press, Lyon, 2001.
 
2) Brunning RD, et al : Precursor T lymphoblastic leukaemia/lymphoma. In : World Health Organization Classification of Tumours. Pathology and genetics, tumor of haematopoeitic and lymphoid tissues (ed by Jaffe WS, et al), p 115-117, IARC Press, Lyon, 2001.
 
3) Diebold J, et al : Burkitt lymphoma. In : World Health Organization Classhication of Tumours. Pathology and genetics, tumor of haematopoeitic and lymphoid tissues (ed by Jaffe WS, et al), p 181-184, LARC Press, Lyon, 2001.
 
4) Poi CH, Evans WE : Acute lymphoblastic leukemia. N Engl J Med 339 : 605-615, 1998.
 
5) Yanada M, et al ; Japan Adult Leukemia Study Group : High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24 : 460-466, 2006.
 
6) Lin P, et al : Precursor B-cell lymphoblastic lymphoma : a predominantly extra nodal tumor with low propensity for leukemic involvement. Am J Surg Pathol 24 : 1480-1490, 2000.
 
7) Thomas DA, et al : Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106 : 1569-1580, 2006.
PubMed
P.253 掲載の参考文献
1) Damsheck W : Some speculation on the myeloproliferative syndromes. Blood 6 : 372-375, 1951.
 
2) Vardiman JW, et al : Chronic myeloproliferative disordes : Introduction. In : Tumors of Hematopoietic and Lymphoid Tissues (ed by Jaffe E, et al), p 17-19, IARC Press, Lyon, 2001.
 
3) Cools J, et al : A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 368 : 1201-1214, 2003.
 
4) Baxter EJ, et al : Acquired mutation of the tyrosine kmase JAK2 in human myeloproliferative disorders. Lancet 365 : 1054-1061, 2005.
 
5) James C, et al : Aunique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434 : 1144-1148, 2005.
 
6) Levine RL, et al : Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplkasia with myelofibrosis. Cancer Cells 7 : 387-397, 2005.
 
7) Kralovics R, et al : A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 : 1779-1790, 2005.
PubMed
8) Bennett JM, et al : The chronic myeloid leukaemias : guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87 : 746-754, 1994.
PubMed
9) Bain B, et al : Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In : Tumors of Hematopoietic and Lymphoid Tissues (ed by Jaffe E, et al), p 29-31, IARC Press, Lyon, 2001.
 
10) Gotlib J, et al : The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia : implications for diagnosis, classification, and management. Blood 103 : 2879-2891, 2004.
 
11) Ohyashiki K, et al : The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 19 : 2359-2360, 2005.
 
P.257 掲載の参考文献
1) 待井隆志 : 慢性リンパ性白血病 (CLL) と類縁疾患の分類. 血液フロンティア 14 : 9-16, 2004.
 
2) Benett JM, et al : Proposals for the classification of chronic (mature) Band T lymphoid leukaemias. J Clin Pathol 42 : 567-584, 1989.
 
3) Jaffe ES, et al : Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In : WHO Classification of Tumours, IARC Press, Lyon, 2001.
 
4) Harris NL et al : World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues : report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 : 3835-3849, 1999.
PubMed
5) 森茂郎ほか : 新WHO分類による白血病・リンパ系腫瘍の病態学, 中外医学社, 2004.
 
P.263 掲載の参考文献
1) Bennett JM, et al : Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 51 : 189-199, 1982.
PubMed
2) Jaffe ES, et al : World Health Organization Classification of Tumours : Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissue, IARC Press, Lyon, 2001.
 
3) Bellamy WT, et al : Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97 : 1427-1434, 2001.
PubMed
4) Greenberg P, et al : International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 : 2079-2088, 1997.
PubMed
5) Vardiman JW, et al : The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 : 2292-2302, 2002.
PubMed
6) Greenberg P, et al : Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol 18 : 3447-3452, 2000.
 
7) Nosslinger T, et al : Myelodysplastic syndromes, from French-American-British to World Health Organization : comparison of classifications on 431 unselected patients from a single institution. Blood 98 : 2935-2941, 2001.
PubMed
8) Bennett JM, et al : Myelodysplastic syndromes : from French-American-British to World Health Organization : a commentary. Blood 99 : 3074-3075, 2002.
PubMed
9) Cermak J, et al : A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q-syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk Res 27 : 221-229, 2003.
PubMed
10) Breccia M, et al : Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes. Leuk Res 30 : 178-182, 2006.
PubMed
11) Malcovati L, et al : Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria : a basis for clinical decision making. J Clin Oncol 23 : 7594-7603, 2005.
PubMed
12) Germing U, et al : Refractory anaemia with excess of blasts (RAEB) : analysis of reclassification according to the WHO proposals. Br J Haematol 132 : 162-167, 2005.
 
13) Matsuda A, et al : Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 106 : 2633-2640, 2005.
PubMed
P.267 掲載の参考文献
1) Stein H, et al : Hodgkin lymphoma. In : World Health Organization Classification of Tumours, Pathology&Genetics, Tumours of Haematopoietic and Lymphoid Tissue (ed by Jaffe ES, et al), p237-253, IARC Press, Lyon, 2001.
 
2) 新津望, 岡本昌隆 : 活動状況・各種統計.悪性リンパ腫・病理と臨床-ALTSGの研究から-(平野正美編), p14-28, 先端医学社, 2005.
 
3) Marafioti T, et al : Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 337 : 453-458, 1997.
PubMed
4) Kuppers R, et al : Cellular origin of human B-cell lymphomas. N Engl J Med 341 : 1520-1529, 1999.
 
5) Poppema S : Immunobiology and pathophysiology of Hodgikin lymphomas. Hematology Am Soc Hematol Educ Program 231-238, 2005.
 
6) Stein H, et al : Down-regulation of BOB.1/OBE1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 97 : 496-510, 2001.
 
7) Carbone A, et al : Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 97 : 744-751, 2001.
PubMed
8) Foss HD, et al : Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 94 : 3108-3113, 1999.
 
9) 田丸淳一 : Hodgkinリンパ腫 (平野正美編), p 198-207, 先端医学社, 2005.
 
10) Colby TV, et al : Hodgkin's diseases : a clinicopathologic study of 659 cases. Cancer 49 : 1848-1858, 1982.
 
11) Diehl V, et al : Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease : Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 17 : 776-783, 1999.
PubMed
12) Tirelli U, et al : Hodgkin's disease and human immunodeficiency virus infection : clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 13 : 1758-1767, 1995.
 
13) 岡本昌隆 : Hodgkinリンパ腫 (平野正美編), p 208-221, 先端医学社, 2005.
 
14) Ohshima K, et al : Clonal HTLV-I-infected CD4+ T-lymphocytes and non-clonal non-HTLV-I-infected giant cells in incipient ATLL with Hodgkin-like histologic features. Int J Cancer 72 : 592-598, 1997.
PubMed
15) Wellmann A, et al : Detection of differentially expressed genes in lymphomas using cDNA arrays : identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 96 : 398-404, 2000.
PubMed
P.273 掲載の参考文献
1) World Health Organization classfication of tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (ed by Jaffe ES, et al), IARC Press, Lyon, 2001.
 
2) The World Health Organization classification of malignant lymphomas in Japan : Incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 50 : 696-702, 2000.
 
P.279 掲載の参考文献
1) World Heath Organization : Plasma cell neoplasma. In : World Heath Organization Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues (ed by Jaffe ES, et al), p 142-156, IARC Press, Lyon, 2001.
 
2) Durie BGM : Staging and kinetics of multiple myeloma. Semin Oncol 13 : 300-309, 1986.
 
3) 日本骨髄腫研究会 : 多発性骨髄腫の診療指針第1版, p35-49, 文光堂, 2004.
 
4) Salmon SE, Cassady JR : Plasma cell neoplasms. In : Cancer, Principles and Practice of Oncology (ed by DeVita VT, et al), p 1854, JB Lippincott, Philadelphia, 1988.
 
5) Tsuchiya J, et al : Ten-year survival and prognostic factors in multiple myeloma. Br J Haematol 87 : 832-834, 1994.
PubMed
6) Durie BGM : Cellular and molecular genetic features of myeloma and related disorders. Hematol Oncol Clin North Am 6 : 463-477, 1992.
 
7) Barlogie B, et al : Plasma cell myeloma-new biological insights and advances in therapy. Blood 73 : 865-879, 1989.
PubMed
8) Bourantas K : Nonsecretory multiple myeloma. Eur J Haematol 56 : 109-111, 1996.
PubMed
9) Garcia-Sanz R, et al : Primary plasma cell leukemia : clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 93 : 1032-1037, 1999.
PubMed
10) Kyle RA : "Benign" monoclonal gammopathy-after 20 to 35 years of follow-up. Mayo Clin Proc 68 : 26-36, 1993.
PubMed
11) Kyle RA, Bayrd ED : Multiple myeloma : variant forms. In : The Monoclonal Gammopathies, Multiple Myeloma and Related Plasma Cell Diseases (ed by Thomas CC), p 141-145, Springfield, London, 1976.
 
12) Dimopoulos MA, et al : Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96 : 2037-2044, 2000.
PubMed
13) Aleiou C, et al : Extramedullary plasmacytoma : tumor occurrence and therapeutic concepts. Cancer 85 : 2305-2314, 1999.
 
14) The International Myeloma Workmg Group : Criteria for the classhication of monoclonal gammopathies, multiple myeloma and related disorders : a report of the International Myeloma Wbrking Group. Br J Haematol 121 : 749-757, 2003.
PubMed
P.287 掲載の参考文献
1) Bennett JM, et al : Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103 : 626-629, 1985.
 
2) Jaffe E, et al (ed) : Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001.
 
3) Bennett JM, et al : Proposal for the recognition minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol 78 : 325-329, 1991.
 
4) Bennett JM, et al : Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Ann Intern Med 103 : 460-462, 1985.
PubMed
5) 三浦偉久男 : 染色体異常-検査の方法と読み方-. 悪性リンパ腫 : 臨床と病理-ALTSGの研究から-(平野正美監修, 成人リンパ腫治療研究会 (ALTSG) 編集), p 29-60, 先端医学社, 2004.
 
P.292 掲載の参考文献
1) 金井泉, 金井正光 (編) : 血液検査.臨床検査法提要 (改訂第31版), p264-323, 金原出版, 1998.
 
P.297 掲載の参考文献
1) 米山彰子 : フローサイトメトリー. スタンダード検査血液学 (日本検査血液学会編), p158-165, 医歯薬出版, 2003.
 
2) Thomas ML : The leukocyte common antigen family. Annu Rev Immunol 7 : 339-369, 1989.
PubMed
3) Miyazaki T, et al : CD45 gating for flow cytometric analysis of acute leukemia. Rinsho Ketsueki 37 : 214-220, 1996.
PubMed
4) Inaba T, et al : CD45 negative acute leukemia in adulthood. Eur J Haematol 64 : 64-67, 2000.
PubMed
5) Hata H, et al : Interleukin-6 gene expression in multiple myeloma : a characteristic of immature tumor cells. Blood 81 : 3357-3364, 1993.
PubMed
6) 日本臨床検査標準協議会, 血液検査標準化検討委員会, フローサイトメトリーワーキンググループ : フローサイトメトリーによる造血器腫瘍表面抗原検査に関するガイドライン (JCCLS H2-P V1.0).日本臨床検査標準協議会雑誌 18 : 69-107, 2003.
 
7) Harada H, et al : Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81 : 2658-2663, 1993.
PubMed
8) Huang N, et al : Heterogeneous expression of a novel MPC-1 antigen on myeloma cells : possible involvement of MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells. Blood 82 : 3721-3729, 1993.
PubMed
9) Sahara N, et al : Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 117 : 882-885, 2002.
PubMed
10) Sahara N, et al : Role for interleukin-6 and insulin-like growth factor-I via PI3-K/Akt pathway in the proliferation of CD56-and CD56+ multiple myeloma cells. Exp Hematol 34 : 736-744, 2006.
PubMed
11) Takeshita A, et al : Efficacy of gemtuzumab ozogamicin on ATRA-and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 19 : 1306-1311, 2005.
 
12) Bennett JM : World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72 : 131-133, 2000.
PubMed
P.303 掲載の参考文献
1) Chilosi M, et al : Increased levels of soluble interleukin-2 receptor in non-Hodgkin's lymphomas. Relationship with clinical, histologic, and phenotypic features. Am J Clin Pathol 92 : 186-191, 1989.
PubMed
2) Wagner DK, et al : Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas : correlation with survival. J Clin Oncol 5 : 1262-1274, 1987.
PubMed
3) Harrington DS, et al : Soluble interleukin 2 receptors in patients with malignant lymphoma. Arch Pathol Lab Med 112 : 597-601, 1988.
PubMed
4) Pui CH, et al : High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood 70 : 624-628, 1987.
 
5) Yasuda N, et al : Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 71 : 1021-1026, 1988.
PubMed
6) Marcon L, et al : Elevated serum levels of soluble Tac peptide in adult T-cell leukemia : correlation with clinical status during chemotherapy. Ann Intern Med 109 : 274-279, 1988.
PubMed
7) Inoue K, et al : WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84 : 3071-3079, 1994.
 
8) Katzmann JA, et al : Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains : relative sensitivity for detection of monoclonal light chains. Clin Chem 48 : 1437-1444, 2002.
PubMed
9) Bradwell AR, et al : Serum test for assessment of patients with Bence Jones myeloma. Lancet 361 : 489-491, 2003.
PubMed
10) Drayson M, et al : Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97 : 2900-2902, 2001.
PubMed
P.307 掲載の参考文献
1) Gertz MA, et al : Clinical implications of t (11 ; 14) (q13 ; q32), t (4 ; 14) (p16.3 ; q32), and-17p13 in myeloma patients treated with high-dose therapy. Blood 106 : 2837-2840, 2005.
PubMed
2) van Dongen JJ, Wolvers-Tettero IL : Analysis of immunoglobulin and T cell receptor genes. Part I : Basic and technical aspects. Clin Chim Acta 198 : 1-91, 1991.
 
3) van Dongen JJ, et al : Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations : report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17 : 2257-2317, 2003.
 
4) Pallisgaard N, et al : Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 92 : 574-588, 1998.
PubMed
5) Hughes TP, et al : Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 : 1423-1432, 2003.
 
6) Baccarani M, et al : Evolving concepts in the management of chronic myeloid leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 : 1809-1820, 2006.
 
7) Willemse MJ, et al : Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 99 : 4386-4393, 2002.
PubMed
8) Bruggemann M, et al : Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107 : 1116-1123, 2006.
PubMed
9) Rambaldi A, et al : Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 99 : 856-862, 2002.
PubMed
P.315 掲載の参考文献
1) Ghanem N, et al : Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol 16 : 1005-1014, 2006.
 
2) Wang K, et al : Bone scintigraphy in common tumors with osteolytic components. Clin Nucl Med 30 : 655-671, 2005.
PubMed
3) Bredella MA, et al : Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 184 : 1199-1204, 2005.
PubMed
4) Alexandrakis MG, et al : Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBI scintigraphy and other biochemical markers of disease activity. Hematol Oncol 21 : 17-24, 2003.
PubMed
5) Alper E, et al : 99mTc-MIBI scintigraphy in untreated stage III multiple myeloma : comparison with X-ray skeletal survey and bone scintigraphy. Nucl Med Commun 24 : 537-542, 2003.
PubMed
6) Mileshkin L, et al : A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol 72 : 32-37, 2004.
PubMed
7) Jerusalem G, et al : Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 85 : 613-618, 2000.
PubMed
8) Spaepen K, et al : Early restaging positron emission tomography with (18) F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13 : 1356-1363, 2002.
PubMed
9) Takagi S, et al : Magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes or leukemia. Blood 86 : 316-322, 1995.
 
P.325 掲載の参考文献
1) Harris NL, et al : World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues : report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 : 3835-3849, 1999.
PubMed
2) 古沢新平 : 好中球の量的異常. 血液病学 (三輪史朗ほか編), p824-829, 文光堂, 1995.
 
3) Batista DA, et al : BCR/ABL rearrangement in two cases of Philadelphia chromosome negative chronic myeloid leukemia : deletion on the derivative chromosome 9 may or not be present. Cancer Genet Cytogenet 163 : 164-167, 2005.
PubMed
4) Johnston JB : Chronic lymphocytic leukemia. In : Wintrobe's Clinical Hematology (ed by Greer JP, et al), p 2429-2464, Lippincott & Wilkins, Philadelphia, 2004.
 
5) Ravandi F, O'Brien S : Chronic lymphoid leukemias other than chronic lymphocytic leukemia : diagnosis and treatment. Mayo Clin Proc 80 : 1660-1674, 2005.
PubMed
6) Wiestner A, et al : ZAP-70 expression identfies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101 : 4944-4951, 2003.
 
P.330 掲載の参考文献
1) 通山薫 : 「白血病 : 診断と治療の進歩」エビデンスに基づく標準的治療法 4) 骨髄異形成症候群. 日内会誌 92 : 992-998, 2003.
 
2) 小峰光博ほか : 不応性貧血 (骨髄異形成症候群) 診療の参照ガイド. 臨床血液 47 : 47-68, 2006.
 
3) Greenberg P, et al : International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 : 2079-2088, 1997.
PubMed
4) Brunning RD, et al : Myelodysplastic syndromes. In : World Health Organization classification of Tumours : Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (ed by Jaffe ES, et al), P 61-73, IA.RC Press, Lyon, 2001.
 
5) Bennett JM, et al : Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 : 189-199, 1982.
PubMed
6) Bennett JM, Komrokji RS : The myelodysplastic syndromes : diagnosis, molecular biology and risk assessment. Hematology 10 (Suppl 1) : 258-269, 2005.
 
7) 小川誠司 : 骨髄異形成症候群における遺伝子異常. 臨床血液 46 : 389-402, 2005.
 
8) Cherian S, Bagg A : The genetics of the myelodysplastic syndromes : classical cytogenetics and recent molecular insights. Hematology 11 : 1-13, 2006.
PubMed
9) Miyazato A, et al : Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 98 : 422-427, 2001.
PubMed
10) Chen G, et al : Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 104 : 4210-4218, 2004.
PubMed
11) Cermak J, et al : The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory ane-mia may reflect a multistep pathogenesis of myelodysplasia. Leuk Res 29 : 371-379, 2005.
PubMed
12) Briggs C, et al : Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol 126 : 93-99, 2004.
PubMed
P.334 掲載の参考文献
1) Dameshek W : Some speculations on the myeloproliferative syndromes. Blood 6 : 372-375, 1951.
PubMed
2) Vardiman JW, et al : Chronic myeloproliferative diseases : introduction. In : World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues (ed by Jaffe ES, et al), p 17-19, LARC Press, Lyon, 2001.
 
3) Pierre R, et al : Polycythaemia vera. In : World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues (ed by Jaffe ES, et al), p 32-34, IARC Press, Lyon, 2001.
 
4) Thiele J, et al : Chronic idiopathic myelonbrosis. In : World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues (ed by Jaffe ES, et al), P 35-38, IARC Press, Lyon, 2001.
 
5) Imbert M, et al : Essential thrombocythaemia. In : World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues (ed by Jaffe ES, et al), P 39-41, IARC Press, Lyon, 2001.
 
6) Kaushansky K : On the molecular origins of the chronic myeloproliferative disorders : it all make sense. Blood 105 : 4187-4190, 2005.
PubMed
7) Skoda R, et al : Chronic myeloproliferative disorders-introduction. Semin Hematol 42 : 181-183, 2005.
PubMed
8) Tefferi A, Spivak JL : Polycythemia vera : scientific advances and current practice. Semin Hematol 42 : 206-220, 2005.
PubMed
9) Thiele J, et al : Bone marrow histopathology in myeloproliferative disorders-current diagnostic approach. Semin Hematol 42 : 184-195, 2005.
PubMed
10) Barosi G : Myelofibrosis with myeloid metaplasia : diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17 : 2954-2970, 1999.
PubMed
11) Okamura T, et al : Primary chronic myelofibrosis : clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 73 : 194-198, 2001.
PubMed
12) Reilly JT : Idiopathic myelofibrosis : pathogenesis to treatment. Hematol Oncol 24 : 56-63, 2006.
PubMed
13) Thiele J, et al : European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90 : 1128-1132, 2005.
PubMed
14) Thiele J, et al : Clinicopathological diagnosis and differentiatial criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 33 : 207-218, 1999.
 
15) Barosi G, et al : The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 104 : 730-737, 1999.
PubMed
P.340 掲載の参考文献
1) Jaffe ES, et al (eds) : Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, IARC Press, Lyon, 2001.
 
2) Lister TA, et al : Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease : Cotswolds meeting. J Clin Oncol 7 : 1630-1636, 1989.
PubMed
3) Rohatiner A, et al : Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 5 : 397-400, 1994.
PubMed
4) Hasenclever D, et al : A prognostic score for advanced Hodgkin's disease. N Engl J Med 339 : 1506-1514, 1998.
PubMed
5) Apredictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lynlphoma Prognostic Factors Project. N Engl J Med 329 : 987-994, 1993.
 
6) Solal-C61igny P, et al : Follicular lymphoma international prognostic index. Blood 104 : 1258-1265, 2004.
PubMed
7) Gascoyne RD, et al : Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90 : 244-251, 1997.
PubMed
8) Yamaguchi M, et al : De novo CD5+ diffuse large B-cell lymphoma : a clinicopathologic study of 109 patients. Blood 99 : 815-821, 2002.
PubMed
9) Lossos IS, et al : Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 98 : 945-951, 2001.
PubMed
10) Sakane-Ishikawa E, et al : Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma : a study of the Osaka Lymphoma Study Group. J Clin Oncol 23 : 8012-8017, 2005.
 
11) Alizadeh AA, et al : Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 : 503-511, 2000.
PubMed
12) Rosenwald A, et al : The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 : 1937-1947, 2002.
PubMed
13) Dave SS, et al : Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351 : 2159-2169, 2004.
PubMed
P.345 掲載の参考文献
1) Pangalis GA, et al : Clinical approach to lymphadenopathy. Semin Oncol 20 (6) : 570-582, 1993.
PubMed
2) Vassilakopoulos TP, Pangalis GA : Application of a prediction rule to select which patients presenting with lymphadenopathy should undergo a lymph node biopsy. Medicine 79 (5) : 338-347, 2000.
PubMed
3) Williamson HA : Lymphadenopathy in a family practice : A descriptive study of 249 cases. J Fam Pract 20 (5) : 449-452, 1985.
 
4) van den Brekel MW, Castelijns JA : Imaging of lymph nodes in the neck. Semin Roentgenol 35 (1) : 42-53, 2000.
PubMed
5) Ying M, et al : Cervical lympadenopathy : sonographic differentiation between tubeculous nodes and nodal metastases from non-head and neck carcinomas. J Clin Ultrasound 26 (8) : 383-389, 1998.
 
6) Slap GB, et al : When to perform biopsy of enlarged peripheral lymph nodes in young patients. JAMA 252 (10) : 1321-1326, 1984.
PubMed
7) Saltzstein SL : The fate of patients with nondiagnostic lymph node biopsies. CA Cancer J Clin 16 (3) : 115-116, 1966.
PubMed
8) Sinclair S, et al : Biopsy of enlarged, superficial lymph nodes. JAMA 228 (5) : 602-603, 1974.
PubMed
P.349 掲載の参考文献
1) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders : a report of the International Myeloma Working Group. Br J Haematol 121 : 749-757, 2003.
 
2) Dispenzieri A, Kyle RA : Multiple myeloma : clinical features and indications for therapy. Best Pract Res Clin Haematol 18 : 553-568, 2005.
PubMed
3) Alexiou C, et al : Extramedullary plasmacytoma : tumor occurrence and therapeutic concepts. Cancer 85 : 2305-2314, 1999.
 
4) Noel P, Kyle RA : Plasma cell leukemia : an evaluation of response to therapy. Am J Med 83 : 1062-1068, 1987.
PubMed
5) Kyle RA : POEMS syndrome. Clin Lymphoma 4 : 186, 2003.
PubMed
6) Mead GP, et al : Serum free light chains for monitoring multiple myeloma. Br J Haematol 126 : 348-354, 2004.
PubMed
7) Kang SY, et al : Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Ann Hematol 84 : 588-593, 2005.
PubMed
8) Greipp PR, et al : Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates : Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 91 : 2501-2507, 1998.
 
P.354 掲載の参考文献
1) 多発性骨髄腫の診療指針 (日本骨髄腫研究会編), 文光堂, 2004.
 
2) 名倉英一 : 多発性骨髄腫の疫学. 多発性骨髄腫up-to-date (河野道生ほか編), p 57-63, メディカルレビュー社, 2006.
 
3) Shimizu K, et al : Management of patients with multiple myeloma in Japan : data of 1,383 patients from 16 hospitals and l treatment group. Leuk Lymphoma 45 : 2465-2469, 2004.
 
4) UK myeloma forum. British Committee for Standards in Haematology : Diagnosis and management of multiple myeloma. Br J Haemetol 115 : 522-540, 2001.
PubMed
5) Durie BGM, et al : Myeloma management guidelines : a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4 : 379-398, 2003.
PubMed
6) 朝長万左男ほか : 抗がん剤適正使用のガイドライン. 造血器腫瘍. Int J Clin Oncol 10 : 1-14, 2005.
 
7) The lnternational Myeloma Workmg Group : Criteria for the classhication of monoclonal gammopathies, multiple myeloma and related disorders : a report of the International Myeloma Working Group. Br J Haematol 121 : 749-757, 2003.
 
8) Durie BGM, Salmon SE : A clnical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36 : 842-854, 1975.
 
9) Greipp RP, et al : International staging system for multiple myeloma. J Clin Oncol 23 : 3412-3420, 2005.
 
10) Jacobson JL, et al : A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 122 : 441-450, 2003.
 
11) Blade J, et al : Criteria for evaluating disease response and progression in patients multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 102 : 1115-1123, 1998.
PubMed
12) Cavo M, et al : Superiority of thalidomide and dexamethazone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 : 35-39, 2005.
 
13) Attal M, et al : Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 : 2495-2502, 2003.
PubMed
14) Stewart A, et al : Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 23 : 6339-6344, 2005.
PubMed
15) http://www.jmsg.jp
 
P.359 掲載の参考文献
1) Blade J, et al : Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 102 : 1115-1123, 1998.
PubMed
2) The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders : a report of the International Myeloma Working Group. Br J Haematol 121 : 749-757, 2003.
 
3) Bradwell AR, et al : Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47 : 673-680, 2001.
PubMed
4) Rajkumar SV, et al : Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106 : 812-817, 2005.
PubMed
5) Bradwell AR, et al : Free light chain kinetics and disease management. In : Serum Free Light Chain Analysis, 3rd ed (ed by Bradwell AR, et al), p 115-126, The Binding Site, Birmingham, 2005.
 
6) 名倉英一, 藤井浩 : 臨床所見. 多発性骨髄腫の診療指針第1版 (日本骨髄腫研究会編), p2-6, 文光堂, 2004.
 
7) Abildgaard N, et al : Comparison of five biochemical markers of bone resorption in multiple myeloma : elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 120 : 235-242, 2003.
PubMed
8) Berenson JR, et al : American Society of Oncology clinical practice guidelines : the role of bisphosphonates in multiple myeloma. J Clin Oncol 20 : 3719-3736, 2002.
PubMed
9) Shimazaki C, et al : High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma : possible role of bortezomib on osteoblast differentiation. Leukemia 19 : 1102-1103, 2005.
 
10) Pelliniemi TT, et al : Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 85 : 765-771, 1995.
PubMed
11) Bataille R, et al : C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80 : 733-737, 1992.
PubMed
12) Pulkki K, et al : Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group. Br J Haematol 92 : 370-374, 1996.
PubMed
13) Schutt P, et al : Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma : serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival. Ann Hematol 84 : 594-600, 2005.
PubMed
14) Brown RD, et al : Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma : results from the MRC (UK) V trial. Br J Haematol 84 : 238-241, 1993.
 
15) Hatta Y, et al : WT1 expression level and clinical factors in multiple myeloma. J Exp Clin Cancer Res 24 : 595-599, 2005.
PubMed
P.368 掲載の参考文献
1) Busque L, et al : Clonal evolution in acute myeloid leukemia. Blood 82 : 337-342, 1993.
PubMed
2) Skipper HE, et al : Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35 : 1-111, 1964.
PubMed
3) Schabel FM Jr, Simpson-Herren L : Some variables in experimental tumor systems which complicate interpretation of data from in vivo kinetic and pharmacologic studies with anticancer drugs. Antibiot Chemother 23 : 113-127, 1978.
PubMed
4) Goldie JH, Coldman AJ : A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63 : 1727-1733, 1979.
PubMed
5) Endicott JA, Ling V : The biochemistry of P-glycoprotein mediated multidrug resistance. Ann Rev Biochem 58 : 137-171, 1989.
PubMed
6) Levin L Hryniuk WM : Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5 : 756, 1987.
PubMed
7) Frei E III, Antman KH : Principles of dose, schedule, and combination chemotherapy. In : Cancer Medicine, 5th ed (ed by Bast RC, et al), p 556-568, BC Decker, New York, 2000.
 
8) 上田孝典 : 化学療法. 三輪血液病学, 第3版 (浅野茂隆ほか編), p609-638, 文光堂, 2005.
 
9) Robatiner M, Lister TA : Acute myelogenous leukemia. In : Leukemia, 7th ed (ed by Henderson ES, et al), p 485-517, WB Saunders, Philadelphia, 2002.
 
10) Gandhi V, et al : Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52 : 897-903, 1992.
PubMed
11) Ossenkoppele GJ, et al : The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 103 : 2908-2913, 2004.
 
12) 上田孝典 : 抗悪性腫瘍薬の薬理学, 殺細胞効果の分類と作用機序, 代謝拮抗薬. 臨床腫瘍学, 第3版, p233-243, 癌と化学療法社, 2003.
 
13) Feugier P, et al : Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma : a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23 : 4117-4126, 2005.
 
14) Mounier N, et al : Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101 : 4279-4284, 2003.
 
P.373 掲載の参考文献
1) 上田孝典 : 造血器腫瘍における薬剤の使い方-合理的投与法と展望- (上田孝典編), p17-24, 医薬ジャーナル社, 1998.
 
2) 上田孝典 : 第2部臨床総論 III治療総論 B化学療法. 三輪血液病学, 第3版 (浅野茂隆ほか編), p609-638, 文光堂, 2005.
 
3) Kaufman DC, Chabner BA : Clinical strategies for cancer treatment : the role of drugs. In : Cancer Chemotherapy and Biotherapy, 3rd ed (ed by Chabner BA, Longo DL), p 1-16, Lippincott-Raven, Philadelphia, 2001.
 
4) Gilewski TA, Norton L : Chemotherapy : Cytokinetics. In : Cancer Medicine 7 (ed by Kufe DW, et al), p 570-589, American Association for Cancer Research, Philadelphia, 2006.
 
5) Skipper HE, et al : Experimental evaluation of potential anticancer agents XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35 : 1-111, 1964.
PubMed
6) Goldie JH, Coldman AI : Application of theoretical models to chemotherapy protocol design, Cancer Treat Rep 70 : 127-131, 1986.
 
7) Fisher RI, et al : Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 : 1002-1006, 1993.
PubMed
8) Canellos GP, et al : Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 : 1478-1484, 1992.
 
9) Levin L, Hryniuk W : The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin Oncol 14 (4 Suppl 4) : 12-19, 1987.
 
10) Laird AK : Dynamics of growth in tumors and in normal organisms. Natl Cancer Inst Monogr 30 : 15-28, 1969.
PubMed
11) Pfreundschuh M, et al : High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas : results of the NHL-B1 trial of the DSHNHL. Blood 104 : 626-633, 2004.
 
12) Pfreundschuh M, et al : High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas : results of the NHL-B2 trial of the DSHNHL. Blood 104 : 634-641, 2004.
 
13) Tew KD, et al : Alkylating agents. In : Cancer Chemotherapy and Biotherapy, 3rd ed (ed by Chabner BA, Longo DL), p 373-414, Lippincott-Raven, Philadelphia, 2001.
 
14) 山内高弘, 上田孝典 : 第4章 急性白血病の管理・治療 : 急性白血病に使用される薬物. 新しい治療と診断のABC, 血液, 急性白血病 (大野竜三編), p 84-94, 最新医学社, 2006.
 
15) 山内高弘, 上田孝典 : 急性骨髄性白血病のM2. 血液疾患ハンドブック, 上巻 (吉田弥太郎編), p 122-131, 医薬ジャーナル社, 2005.
 
16) Messmann RA, Allegra CJ : Antifolates. In : Cancer Chemotherapy and Biotherapy, 3rd ed (ed by Chabner BA, Longo DL), p 139-184, Lippincott-Raven, Philadelphia, 2001.
 
17) Koller CA, et al : The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. heukemia 11 : 2039-2044, 1997.
 
18) Batchelor T, et al : Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy : a report of NABTT 96-07. J Clin Oncol 21 : 1044-1049, 2003.
PubMed
19) Batchelor T, Loeffler JS : Primary CNS lymphoma. J Clin Oncol 24 : 1281-1288, 2006.
PubMed
P.378 掲載の参考文献
1) Germann UA : Molecular analysis of the multidrug transporter. In : Multidrug Resistance in Cancer (ed by Clynes M), p 33-62, Kluwer Academic, The Netherland, 1993.
 
2) Del Poeta G, et al : Clinical relevance of p-glycoprotein expression in de novo acute myeloid leukemia. Blood 87 : 1997-2004, 1996.
PubMed
3) Campos L, et al : Clinical significance of multidrug resistance p-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79 : 473-476, 1992.
PubMed
4) Sander V, et al : The role of MDR-1 in refractory lymphoma. Leuk Lymphoma 28 : 23-31, 1997.
 
5) Yuen AR, Sikic BI : Multidrug resistance in lymphomas. J Clin Oncol 12 : 2453-2459, 1994.
PubMed
6) Miller TP, et al : P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9 : 17-24, 1991.
PubMed
7) Grogan TM, et al : P-glycoprotein expression in human plasma cell myeloma : Correlation with prior chemotherapy. Blood 81 : 490-495, 1993.
PubMed
8) Wang YH, et al : Recovery of drug sensitivity by MS-209, a new multidrug resistance-reversing agent, on acute myelogeneous leukaemic blasts and K562 cells resistance to adriamycin cell line. Eur J Haematol 58 : 186-194, 1997.
PubMed
9) List AF, et al : Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia : aSouthwest Oncology Group study. Blood 98 : 3212-3220, 2001.
 
10) Wattel E, et al : Quinine improves the resuIts of intensive chemotherapy in myelodysplastic syndromes expressing P-glycoprotein : results of a randomized study. Br J Haematol 102 : 1015-1024, 1998.
 
11) Solary E, et al : Quinine as a multidrug resistance inhibitor : a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 102 : 1202-1210, 2003.
PubMed
12) Baer MR, et al : Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia : Cancer and Leukemia Group B Study 9720. Blood 100 : 1224-1232, 2002.
 
13) Wilson WH, et al : Controlled trial of dexverapami1, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13 : 1995-2004, 1995.
PubMed
14) Sonneveld P, et al : Cyclosporin A combined with vincristine, doxorubicine and dexamethasone (VAD) compared with VAD alone in patients with adavanced refractory multiple myeloma : an EORTC-HOVON randomized phase III study (06914). Br J Haematol 115 : 895-902, 2001.
 
15) Dalton WS, et al : A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group Study. Cancer 75 : 815-820, 1995.
 
P.383 掲載の参考文献
1) 有吉寛 : 厚生省 (現厚生労働省) 委託事業における「抗がん剤適正使用のガイドライン」 (案) の開示に際して. 癌と化学療法 29 : 969-977, 2002.
 
2) 坂巻壽ほか : 抗がん剤適正使用のガイドラインー造血器腫瘍. Int J Clin Oncol 10 (Supp1) : 1-14, 2005.
 
3) 関野秀人ほか : 混合診療問題・未承認薬問題が治験制度にもたらすインパクト. 臨床評価 32 : 149-212, 2005.
 
4) 中西茂昭 : 国民の皆様へ-混合診療について考えてください. 日本歯科技工士会声明文, 2005.
 
5) 佐々木常雄ほか : G-CSF適正使用のガイドライン. Int J Clin Oncol 6 (Suppl) : 1-24, 2001.
 
6) 池川康夫ほか : 多発性骨髄腫に対するサリドマイドの適正使用ガイドライン. 臨床血液 46 : 22-67, 2005.
 
P.389 掲載の参考文献
1) Jeha S : Tumor lysis syndrome. Semin Hematol 38 : 4-8, 2001.
PubMed
2) 「輸血療法の実施に関する指針」 (改訂版) 及び「血液製剤の使用指針」. 厚生労働省医薬食品局通知薬食発第0906002号, 平成17年9月6日.
 
3) Ewer MS : Cardiac complications. In : Cancer Medicine, 6th ed, p 2525, BC Becker, Hamilton, 2003.
 
4) Blakley BW, et al : Strategy for prevention of toxicity caused by platinum-based chemotherapy : review and summary of the annual meeting of the blood-brain barrier disruption program, Gleneden beach, Oregon, March 10, 2001. Laryngoscope 112 : 1997-2001, 2002.
PubMed
5) Kintzel PE, Dorr RT : Anticancer dnlg renal toxicity and elimination : dosing guideline for altered renal function. Cancer Treat Rev 21 : 33-64, 1995.
 
6) King PD, Perry MC : Hepatotoxicity of chemotherapy. Oncologist 6 : 162-176, 2001.
PubMed
7) Foucher P, et al : Drugs that may injure the respiratory system. Eur Respir J 10 : 265-279, 1997.
PubMed
8) Drake MJ, et al : Drug-induced bladder and urinary disorders. Incidence, prevention and management. Drug Saf 19 : 45-55, 1998.
 
9) Keime-Guilbert F, et al : Neurological complications of radiotherapy and chemotherapy. J Neurol 245 : 695-708, 1998.
 
10) Falcone T, et al : Ovarian function preservation in the cancer patient. Fertil Steril 81 : 243-257, 2004.
PubMed
11) Howell SJ, Shalet SM : Spermatogenesis after cancer treatment : damage and recovery. J Nat Cancer Inst Monogr 34 : 12-17, 2005.
 
12) Schneider SM, Distelhorst CW : Chemotherapy-induced emergencies. Semin Oncol 6 : 572-578, 1989.
PubMed
13) 佐々木純, 加藤淳 : 抗癌剤の血管外漏出. Medicina 38 : 1516-1519, 2001.
 
14) Goolsby TV, Lombarrdo FA : Extravasation of chemotherapeutic agents : prevention and treatment. Semin Oncol 33 : 139-143, 2006.
 
15) 佐々木純 : 化学療法の毒性とその対策. 臨床医 12 : 2214-2216, 2004.
 
P.394 掲載の参考文献
1) Molldrem JJ, et al : Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6 : 1018-1023, 2000.
PubMed
2) Molldrem JJ, et al : Peptide vaccination with PRI elicits active T cell immunity that induces cytogenetic remission in acute myelogenous leukemia. Blood 100 : 6a, 2002.
 
3) Ohminami H, et al : HLA class I restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WTI peptide. Blood 95 : 286-293, 2000.
 
4) Mailander V, et al : Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WTI peptide in the absence of hematological or renal toxicity. Leukemia 18 : 165-166, 2004.
PubMed
5) Oka Y, et al : Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 78 : 56-61, 2003.
PubMed
6) Oka Y, et al : Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101 : 13885-13890, 2004.
PubMed
7) Roddie H, et al : Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol 133 : 152-157, 2006.
PubMed
8) Pinilla-Ibarz J, et al : Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95 : 1781-1787, 2000.
PubMed
9) Cathcart K, et al : A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103 : 1037-1042, 2004.
PubMed
10) Bocchia M, et al : Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease : amulticentre observational trial. Lancet 365 : 657-662, 2005.
PubMed
11) Ossenkoppele GJ, et al : Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 17 : 1424-1426, 2003.
PubMed
12) Hsu FJ, et al : Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89 : 3129-3135, 1997.
PubMed
13) Bendandi M, et al : Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5 : 1171-1177, 1999.
PubMed
14) Titzer S, et al : Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells : immunological and clinical aspects. Br J Haematol 108 : 805-816, 2000.
PubMed
15) Rasmussen T, et al : Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 101 : 4607-4610, 2003.
PubMed
16) Coscia M, et al : Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 18 : 139-145, 2004.
PubMed
17) Timmerman JM, et al : Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma : clinical and immune responses in 35 patients. Blood 99 : 1517-1526, 2002.
PubMed
P.398 掲載の参考文献
1) Yokota S, et al : Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11 : 1605-1609, 1997.
 
2) Cools J, et al : A tyrosine kinase created by fusion of the PDGFRα and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 : 1201-1214, 2003.
 
3) Goldman JM, Melo JV : Chronic myeloid leukemia : advances in biology and new approaches to treatment. N Engl J Med 349 : 1451-1464, 2003.
PubMed
4) Kralovics R, Skoda RC : Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev 19 : 1-13, 2005.
 
5) Rowinsky EK, et al : Ras protein farnesyltransferase : A strategic target for anticancer therapeutic development. J Clin Oncol 17 : 3631-3652, 1999.
PubMed
6) Karin M, Greten FR : NF-κB : linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5 : 749-759, 2005.
 
P.403 掲載の参考文献
1) Kantarjian H, et al : High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103 : 2873-2878, 2004.
PubMed
2) Hughes TP, et al : Maintenance of imatinib dose intensity in the first six months of therapy for newly diagnosed patients with CML is predictive of molecular response, independent of the ability to increase dose at a later point. Blood 106 : 51a, 2005.
 
3) Angstreich GR, et al : Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol 130 : 373-381, 2005.
PubMed
4) Rosti G, et al : Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 88 : 256-259, 2003.
PubMed
5) Gardembas M, et al : Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 102 : 4298-4305, 2003.
PubMed
6) Cortes J, et al : A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (Pts) with chronic myeloid leukemia (CML) in chronic (CP) phase who failed IM therapy. Blood 104 : 1011a, 2004.
 
7) Cortes J, et al : A phase I study of lonafarnib (SCH66336) in combination with imatinib for patients (Pts) with chronic myeloid leukemia (CML) after failure to imatinib. Blood 102 : 909a, 2003.
 
8) Kuroda J, et al : The third-generation bisphosphonate Zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 102 : 2229-2235, 2003.
PubMed
9) Segawa H, et al : Zoledronate synergizes with imatinib mesylate to inhibit Ph+ primary leukaemic cell growth. Br J Haematol 130 : 558-560, 2005.
PubMed
10) Shah NP, et al : Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 : 399-401, 2004.
PubMed
11) Talpaz M, et al : Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 : 2531-2541, 2006.
PubMed
12) Weisberg D, et al : Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 : 129-141, 2005.
 
13) Kantarjian H, et al : Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 : 2542-2551, 2006.
 
14) Kimura S, et al : NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106 : 3948-3954, 2005.
PubMed
15) Naito H, et al : In Vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. beuk Res 30 : 1443-1446, 2006.
 
16) Yokota A, et al : Anti-tumor activity of a novel Bcr-Abl/Lyn dual inhibitor, NS-187, in murine CNS Ph+ leukemia models. Blood 106 : 148a, 2005.
 
P.406 掲載の参考文献
1) Kantarjian H, et al : Hematologic and cytogenetic responses to imanitib mesylate in chronic myelogenous leukemia. N Engl J Med 346 : 645-652, 2003.
 
2) 岡本真一郎 : グリベック治療とG-CSF. 血液・免疫・腫瘍 8 : 70-72, 2003.
 
3) Marin D, et al : Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Hematologica 88 : 227-229, 2003.
 
4) Druker BJ, et al : Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 : 1031-1037, 2001.
PubMed
5) Janes C, et al : Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 17 : 978-979, 2003.
 
6) Ohyashiki K, et al : Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 16 : 2160-2161, 2002.
PubMed
7) Ebnoether M, et al : Cerebral oedema as a possible complication of treatment with imatinib. Lancet 359 : 1751-1752, 2002.
PubMed
8) Hsiao LT, et al : Stevens-Johnson syndrome after treatment with STI571 : acase report. Br J Haematol 117 : 620-622, 2002.
 
9) Schwarz M, et al : Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 69 : 254-256, 2002.
PubMed
10) Konstantopoulos K, et al : Pityriasis rosea associated with imatinib. Dermatology 205 : 172-173, 2002.
PubMed
11) Berman E, et al : Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354 : 2006-2013, 2006.
PubMed
12) Gambacorti-Passerini C, et al : Gynaecomastia in men with chronic myelod leukaemia after imatinib. Lancet 361 : 1954-1956, 2003.
 
13) Kitiyakara C, et al : Renal failure associated with a specific inhibitor of bcr-abl tyrosine kinase, STI 571.Nephrol Dial Transplant 17 : 685-687, 2002.
PubMed
14) Isshiki I, et al : Interstitial pneumonitis during imatinib therapy. Br J Haematol 125 : 420, 2004.
PubMed
15) Bergeron A, et al : Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol 20 : 4271-4272, 2002.
PubMed
P.414 掲載の参考文献
1) Freeman SD, et al : Characterization of CD33 as a new member of the sialoadesin family of cellular interaction molecules. Blood 85 : 2005-2012, 1995.
PubMed
2) Hamann PR, et al : Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem 13 : 47-58, 2002.
 
3) Larson RA, et al : Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104 : 1442-1452, 2005.
PubMed
4) 吉場史朗ほか : 急性骨髄性白血病 (AML) に対するCMA676の有効性と安全性の評価-第2相臨床試験の報告. 臨床血液 46 : 733, Abstr WS2-2, 2005.
 
5) Linenberger ML : CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia : progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19 : 176-182, 2005.
 
6) Linenberger ML, et al : Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98 : 988-994, 2001.
PubMed
7) Naito K, et al : Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab ozogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 14 : 1436-1443, 2000.
 
8) Matsui H, et al : Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34 positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 16 : 813-819, 2002.
PubMed
9) Tsimberidou A, et al : Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 97 : 1481-1487, 2003.
PubMed
10) Estey EH, et al : Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome : comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 99 : 4343-4349, 2002.
 
11) Alvarado Y, et al : Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 51 : 87-90, 2003.
PubMed
12) Cortes J, et al : Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmaco150 : 497-500, 2002.
PubMed
13) Amadori S, et al : Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia : a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 89 : 950-956, 2004.
PubMed
14) Kell WJ, et al : A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consohdation in younger patients with acute myeloid leukemia. Blood 102 : 4277-4283, 2003.
PubMed
15) Stone RM, et al : A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients (pts) with refractory or relapsed acute myeloid leukemia (AML) : CALGB 19902. Blood 104 : 249a Abstr#893, 2004.
 
16) Tallman MS : New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology (Am Soc Hematol Educ Program) : 143-150, 2005.
PubMed
17) Takeshita A, et al : Efficacy of gemtuzumab ozogamicin on ATRA-and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 19 : 1306-1311, 2005.
 
18) Lo-Coco F, et al : Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104 : 1995-1999, 2004.
PubMed
19) Takeshita A, et al : Two patients with ATRA-resistant acute promyelocytic leukemia (APL) treated successfully with single agent of gemtuzumab ozogamicin. Int J Hematol 82 : 445-448, 2005.
PubMed
P.423 掲載の参考文献
1) Smith MR : Rituximab (monoclonal anti-CD20 antibody) : mechanisms of action and resistance. Oncogene 22 : 7359, 2002.
 
2) Grillo-bopez N : Rituximab : an insider's histrical perspective. Semin Oncol 2 : 9, 2000.
 
3) Reff ME, et al : Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD 20. Blood 83 : 435, 1994.
 
4) Terui Y, et al : Identification of CD20 mutations in malignant lymphoma : can they be predictors of response to rituximab? Abstract ASH in Atlanta, 2005.
 
5) Terui Y, et al : Point mutation of C-terminal region of CD20 molecule predicts rituximab-induced complement-dependent cytotoxicity and clinical response to rituximab in non-Hodgkin's lymphorna. Abstract ASCO in Atlanta, 2006.
 
6) Berinstein NL, et al : Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-gradc or follicular non-Hodgkin's lymphoma. Ann Oncol 9 : 995, 1998.
PubMed
7) Piro LD. et al : Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10 : 655, 1999.
 
8) Harjunpaa A, et al : Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 42 : 731, 2001.
PubMed
9) McLaughlin P, et al : Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma : half of patients respond to a four-dose treatment program. J Clin Oncol 8 : 2825, 1998.
 
10) Davis TA, et al : Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma : safety and efficacy of re-treatment. J Clin Oncol 17 : 3135, 2000.
 
11) Deans JP, et al : Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol 15 : 4494, 1993.
 
12) Pedersen IM, et al : The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99 : 1314, 2002.
 
13) Hofmeis ter JK, et al : Clustered CD20 induced apoptosis : src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 26 : 133, 2000.
 
14) Byrd JC, et al : The mechanism fo tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia : evidence of caspase activation and apoptosis induction. Blood 99 : 1038, 2002.
 
15) Charles J, Forester PAJ (ed) : Wintrobe'sClinical Hematology, vol 1, Chapter 44, P 1191, Williams & Winkins, Baltimore, 2003.
 
16) Czuczman MS, et al : Clearing of cells bearing the bcl-2 [t (14 ; 18) ] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 12 : 109, 2001.
PubMed
17) Terui Y, et al : Blockade of CD55 overcomes resistance to rituximab therapy. Abstract ASH in SanGiego, 2004.
 
18) Cartron G, et al : Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 : 754, 2002.
PubMed
P.428 掲載の参考文献
1) 森島泰雄 (編) : GVHD予防・治療マニュアル, 南江堂, 2005.
 
2) JSHCT : 造血幹細胞移植の適応ガイドライン. http://wwwjshct.com
 
3) Ljungman P, et al : Allogeneic and autologous transplantation for hematological disease, solid tumours and immune disorders : definition and current practice in Europe. Bone Marrow Transplant 37 : 439-449, 2006.
PubMed
P.432 掲載の参考文献
1) 日本造血細胞移植学会 平成16年度全国調査報告書, 日本造血細胞移植学会全国データ集計事務局, 2005.
 
2) Imamura M, et al : Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan. Int J Hematol 83 : 164-178, 2006.
PubMed
3) Zittoun RA, et al : Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332 : 217-223, 1995.
 
4) Burnett AK, et al : Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission : results of MRC AML10 trial. Lancet 351 : 700-708, 1998.
 
5) Philip T, et al : Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 : 1540-1545, 1995.
PubMed
6) Vose J : High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non Hodgkin's lymphoma. Ann Oncol 9 (Suppl 1) : S1-S3, 1998.
 
7) Shipp MA, et al : International conference on high-dose therapy in aggressive non-Hodgkin's lymphomas ; report of the jury. J Clin Oncol 17 : 423-429, 1999.
 
8) Kusumi E, et al : Reduced-intensity hematopoieitc stem-cell transplantation for malignant lymphoma : a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 36 : 205-213, 2005.
 
9) Barlogie B, et al : Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89 : 789-793, 1997.
PubMed
10) Bensinger W, et al : Allogeneic hematopoieitc cell transplantation for multiple myeloma. Semin Hematol 38 : 243-249, 2001.
 
11) Maloney DG, et al : Allografting with non-myeloablative conditioning following cytoreductive autografting for the treatment of patients with multiple myeloma. Blood 102 : 3447-3454, 2003.
 
P.437 掲載の参考文献
1) Sullivan KM, et al : Graf-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320 : 828-834, 1989.
 
2) Cullis JO, et al : Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 79 : 1379-1381, 1992.
PubMed
3) Dazzi F, et al : Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96 : 2712-2716, 2000.
PubMed
4) Porter DL, et al : Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 17 : 1234, 1999.
PubMed
5) Slavin S. et al : Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 : 756-763, 1998.
PubMed
6) Khouri IF, et al : Transplant-lite : induction of graft-versus-malignancy using fiudarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16 : 2817-2824, 1998.
PubMed
7) Childs R, et al : Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation : full donor T-cell chimerism precedes alloimmune responses. Blood 94 : 3234-3241, 1999.
PubMed
8) Giralt S, et al : Melphalan and purine analog-containing preparative regimens : reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 : 631-637, 2001.
PubMed
9) McSweeney PA, et al : Hematopoietic cell transplantation in older patients with hematologic malignancies : replacing high-dose cytotoxic therapy with graft-versus-tUmor effects. Blood 97 : 3390-3400, 2001.
PubMed
10) Giralt S : Non-myeloablative Stem Cell Transplaritation (NST), p 139-148, Darwin Scientific Publishing, Abington, Oxfordshire, United Kingdom, 2000.
 
11) Shimoni A, et al : Allogeneic transplantation with non-myeloablative or reduced intensity conditioning : the intensity of the conditioning regimen is related to outcome in patients with active disease but not in those in remission at the time of transplantation. Blood 96 (Suppl 1) : abstr 852, 2000.
 
12) Mohty M, et al : The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia : a donor vs no donor comparison. Leukemia 19 : 916-920, 2005.
 
13) Arnold R, et al : Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 16 : 2423-2428, 2002.
 
14) Hamaki T, et al : Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia : a retrospective study of 33 patients. Bone Marrow Transplant 35 : 549-556, 2005.
PubMed
15) Or R, et al : Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101 : 441-445, 2003.
PubMed
16) Crawley C, et al : Outcomes of reduced-intensity transplantation for chronic myeloid leukemia : an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106 : 2969-2976, 2005.
PubMed
17) Khouri IF, et al : Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma : low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98 : 3595-3599, 2001.
PubMed
18) Robinson SP, et al : Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation : an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 : 4310-4316, 2002.
 
19) Kusumi E, et al : Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma : a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 36 : 205-213, 2005.
PubMed
20) Khouri IF, et al : Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21 : 4407-4412, 2003.
PubMed
21) Maris MB, et al : Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 : 3535-3542, 2004.
PubMed
22) Maloney DG, et al : Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 : 3447-3454, 2003.
PubMed
23) Garban F, et al : Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 : 3474-3480, 2006.
PubMed
P.443 掲載の参考文献
1) Gluckman E, et al : Hematopoietic reconstitution in a patient with Fanconr s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321 : 1174-1178, 1989.
 
2) Laughlin MJ, et al : Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344 : 1815-1822, 2001.
PubMed
3) https://wwwj-cord.gr.jp/ja/wnew/isyokuseiseki2005.pdf
 
4) Cornetta K, et al : Umbilical cord blood transplantation in adults : results of the prospective Cord Blood Transplantation (COBLT). Biol Blood Marrow Transplant 11 : 149-160, 2005.
PubMed
5) Laughlin MJ, et al : Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 : 2265-2275, 2004.
 
6) Rocha V, et al : Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351 : 2276-2285, 2004.
 
7) Barker JN, et al : Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow : results of a matched-pair analysis. Blood 97 : 2957-2961, 2001.
PubMed
8) Rocha V, et al : Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 97 : 2962-2971, 2001.
PubMed
9) Takahashi S, et al : Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 104 : 3813-3820, 2004.
PubMed
10) Ooi J, et al : Unrelated cord blood transplantation after myeloablative conditioning in patients over the age of 45 years. Br J Haematol 126 : 711-714, 2004.
PubMed
11) Barker JN, et al : Creation of a double chimera after the transplantation of umbilicaLcord blood from two partially matched unrelated donors. N Engl J Med 344 : 1870-1871, 2001.
PubMed
12) Barker JN, et al : Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102 : 1915-1919, 2003.
PubMed
13) Wagner JE : International Forum : 5. Vox Sang 89 : 175-176, 2005.
 
14) Chao NJ, et al : Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. Biol Blood Marrow Transplant 10 : 569-575, 2004.
PubMed
15) Miyakoshi S, et al : Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res 10 : 3586-3592, 2004.
PubMed
16) Yuji K, et al : Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma. Biol Blood Marrow Transplant 11 : 314-318, 2005.
PubMed
17) Narimatsu H, et al : Bloodstream infection after umbilical cord blood transplantation using reducedintensity stem cell transplantation for adult patients. Biol Blood Marrow Transplant 11 : 429-436, 2005.
PubMed
18) Yamada T, et al : Unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous transplantation for multiple myeloma. Int J Hematol 80 : 377-380, 2004.
PubMed
19) Gutman JA, et al : Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients : afeasibility study. Bone Marrow Transplant 36 : 443-451, 2005.
 
20) Mao P, et al : Umbilical cord blood transplant for adult patients with severe aplastic anemia using anti-lymphocyte globulin and cyclophosphamide as conditioning therapy. Bone Marrow Transplant 33 : 33-38, 2004.
PubMed
21) Piacibello W, et al : Lentiviral gene transfer and ex vivo expansion of human primitive steln cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Blood 100 : 4391-4400, 2002.
PubMed
22) Ueda T, et al : Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor. J Clin Invest 105 : 1013-1021, 2000.
PubMed
23) Yahata T, et al : A highly sensitive strategy for SCID-repopulating cell assay by direct injection of primitive human hematopoietic cells into NOD/SCID mice bone marrow. Blood 101 : 2905-2913, 2003.
PubMed
24) Wang J, et al : SCID-repopulating cell activity of human cord blood-derived CD34 cells assured by intra-bone marrow injection. Blood 101 : 2924-2931, 2003.
PubMed
25) Mazurier F, et al : Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med 9 : 959-963, 2003.
PubMed
26) Jaroscak J, et al : Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells : results of a phase 1 trial using the AastromReplicell System. Blood 101 : 5061-5067, 2003.
PubMed
27) Sorrentino BP : Clinical strategies for expansion of haematopoietic stem cells. Nat Rev Immunol 4 : 878-888, 2004.
PubMed
28) Castello S, et al : Intra-bone marrow inlection of bone marrow and cord blood cells : an alternative way of transplantation associated with a higher seeding et6ciency. Exp Hematol 32 : 782-787, 2004.
PubMed
29) Nauta AJ, et al : Enhanced engraftment of umbilical cord blood-derived stem cells in NOD/SCID mice by cotransplantation of a second unrelated cord blood unit. Exp Hematol 33 : 1249-1256, 2005.
PubMed
30) Angelopoulou M, et al : Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol 31 : 413-420, 2003.
PubMed
31) Kim DW, et al : Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation. Blood 103 : 1941-1948, 2004.
PubMed
P.449 掲載の参考文献
1) 笹田昌孝 : どんな感染症が多いか. 日常診療と血液 6 : 1421-1426, 1996.
 
2) 笹田昌孝 : 感染症を理解するための基礎的事項. わかり易い内科学 (井村裕夫編), p 375-380, 文光堂, 2002.
 
3) 笹田昌孝 : 血液疾患の易感染性. 血液疾患合併感染症 (正岡徹編), p15-22, 最新医学社, 2002.
 
4) 笹田昌孝 : 好中球の量的・質的異常とその検査. 日本検査血液学会雑誌 3 : 1-6, 2002.
 
5) Masaoka T : Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan : executive summary. Clin Infect Dis 39 : 49-52, 2004.
 
6) 高田徹, 田村和夫 : Febrile Neutropeniaの経験的治療ガイドライン. 血液フロンティア 13 : 37-47, 2003.
 
7) Bodey GP, Rolston KV : Management of fever in neutropenic patients. J Infect Chemother 7 : 1-9, 2001.
PubMed
8) 笹田昌孝 : 血液疾患合併感染症 総論. 血液フロンティア 13 : 9-17, 2003.
 
9) 正岡徹ほか : 重症感染症に対する抗菌薬との併用療法における静注用ヒト免疫グロブリンの効果. 日本化学療法学会雑誌 48 : 199-217, 2000.
 
10) 笹田昌孝 : 抗菌薬・免疫グロブリン併用療法. 日本臨牀 61 (増刊号3) : 261-265, 2003.
Medical*Online
11) Rowe JM : Treatment of acute myeloid leukemia with cytokines : Effect on duration of neutropenia and response to infections. Clin Infect Dis 26 : 1290-1294, 1998.
PubMed
12) Lyman GH : Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy : a review of the evidence. J Natl Compr Canc Netw 3 : 557-571, 2005.
PubMed
13) 笹田昌孝 : 好中球と病態形成-好中球の二面性-. 臨床血液 44 : 351-357, 2003.
 
14) 笹田昌孝 : 感染症に伴う好中球機能亢進による病態形成. 臨床血液 46 : 240-244, 2005.
 
P.453 掲載の参考文献
1) (財) 血液製剤調査機構 (編) : 血小板製剤の使用基準. 血液製剤の使用にあたって, 第2版, p23-31, じほう, 1999.
 
2) Heckman KD, et al : Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia : 10, 000/μl versus 20, 000/μl. J Clin Oncol 15 : 1143-1149, 1997.
 
3) Rebulla P, et al : The threshold for prophylactic platelet transfusion in adults with acute myeloid leukemia. N Engl J Med 337 : 1870-1875, 1997.
PubMed
4) Wandt H, et al : Safety and cost effectiveness of a 10×10 9/l trigger for prophylactic platelet transfusions compared with the traditional 20×10 9/l trigger : a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91 : 3601-3606, 1998.
 
5) Gil-Fernandez JJ, et al : Clinical results of a stringent policy on prophylactic platelet transfusion : non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 18 : 931-935, 1996.
PubMed
6) Wandt H, et al : Safety on the 10/nl trigger for prophylactic platelet transfusion in ASCT. Bone Marrow Transplant 15 (Suppl 2) : 541a, 1995.
 
7) Sacher RA, et al : Management of patients refractory to platelet transfusion. Arch Pathol Lab Med 127 : 409-414, 2003.
PubMed
8) Barbui T, Falanga A : Disseminated intravascular coagulation in acute leukemia. Semin Thromb Haemost 27 : 593-604, 2001.
 
9) (財) 血液製剤調査機構 (編) : 血液製剤の使用基準. 血液製剤の使用にあたって, 第2版, p2-22, じほう, 1999.
 
10) Bernard GR, et al : Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 : 699-709, 2001.
PubMed
P.456 掲載の参考文献
1) 日本静脈経腸栄養学会 (編) : 静脈経腸栄養ガイドライン第2版, 南江堂, 2006.
 
2) CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell trarlsplant recipients. MMWR2000 ; (No. RR-10), 2000.
 
3) Benson AB 3rd, et al : Recommended guidelines fdr the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22 : 2918-2926, 2004.
 
4) Arends J, et al : ESPEN Guidelines on Enteral Nutrition : Non-surgical oncology. Clin Nutr 25 : 245-259, 2006.
PubMed
5) CDC. Guidelines for the prevention of intravascular catheter-related infections. MMWR2002 ; (No. RR-10), 2002.
 
P.466 掲載の参考文献
1) Skipper HE, et al : Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35 : 1-111, 1964.
 
2) Cheson BD, et al : Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21 : 4642-4649, 2003.
 
3) Slovak ML, et al : Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia : a Southwest Oncology Group/Easten Cooperative Oncology Group study. Blood 96 : 4075-4083, 2000.
 
4) Grimwade D, et al : The importance of diagnostic cytogenetics on outcome in AML : analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 : 2322-2333, 1998.
 
5) Matsuo T, et al : The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. Leukemia 17 : 1538-1543, 2003.
 
6) Miyazaki Y, et al : Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia : Japan Adult Leukaemia Study Group-AML 92 study. Br J Haematol 120 : 56-62, 2003.
 
7) Kiyoi H, et al : Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93 : 3074-3080, 1999.
 
8) 栗山一孝ほか : JALSGにおけるAMLの化学療法-スコアリングシステムを用いた予後判定-. 臨血 39 : 98-102, 1998.
 
9) Miyazaki Y, et al : A New Scoring System To Predict the Prognosis of Patients with Acute Myeloid Leukemia.-Study from the Japan Adult Leukemia Study Group. Blood 106 : 667a, 2005.
 
10) Ohno R, et al : Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intenshication therapy between 4 or 12 courses in adult acute myeloid leukemia. Cancer 71 : 3888-3895, 1993.
 
11) Miyawaki S, et al : No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia : the JALSG-AML92 Study. Int J Hematol 70 : 97-104, 1999.
PubMed
12) Bishop JF, et al : Etoposide in acute leukemia. Blood 75 : 27-32, 1990.
PubMed
13) Weick JK, et al : A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia : A Southwest Oncology Group study. Blood 88 : 2841-2851, 1996.
 
14) Bishop JF, et al : A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87 : 1710-1717, 1996.
PubMed
15) Vaughan WP, et al : Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 64 : 975-980, 1984.
PubMed
16) Buchner T, et al : Double induction strategy for acute myeloid leukemia : the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine : A randomized trial by the German AML Cooperative Group. Blood 93 : 4116-4124, 1999.
PubMed
17) Berman E, et al : Results of randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77 : 1666-1674, 1991.
PubMed
18) Wiernick PH, et al : Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79 : 313-319, 1992.
PubMed
19) Vogler WR, et al : A phase III trial comparing idarubicin and daunorubicin with in acute myeloid leukemia : A Southeastern Cancer Study Group study. J Clin Oncol 10 : 1103-1108, 1992.
 
20) The AML collaborative Group : A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction for acute myeloid leukemia. Br J Haematol 103 : 100-109, 1998.
PubMed
21) Ohtake S, et al : Randomized clinical trial of response-oriented individualized versus fixed schedule induction chemotherapy in adult acute myeloid leukemia : the JALSG AML95 study. Blood 94 : 298a, 1999.
 
22) Miyawaki S, et al : A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia. Cancer 104 : 2726-2734, 2005.
PubMed
23) Ohno R, et al : Intensive induction therapy with behenoyl, cytosine arabinoside, daunorubicin, and 6-mercaputopurine followed by intensive consolidation with mitoxantrone, etoposide, vincristine, and intermediate-dose continuous cytarabine (M-85 protocol) for adult acute myelogenous leukemia. Haematol Blood Transfus 33 : 304-308, 1990.
 
24) Kobayashi T, et al : Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. J Clin Oncol 14 : 204-213, 1996.
 
25) Mayer RJ, et al : Intensive post-remission therapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331 : 896-903, 1994.
 
26) Bloomfield CD, et al : Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58 : 4173-4179, 1998.
PubMed
27) Byrd JC, et al : Patients with t (8 ; 21) (q22 ; q22) and acute myeloid leukemia have superior failure-free and over-all survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17 : 3767-3775, 1999.
 
28) Moore JO, et al : Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensh6cation therapy for acute myeloid leukemia in adults under 60 years of age : Cancer and Leukemia Group B Study 9222. Blood 105 : 3420-3427, 2005.
PubMed
29) Zittoun RA, et al : Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332 : 217-223, 1995.
 
30) Harousseau JL, et al : Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 90 : 2978-2986, 1997.
PubMed
31) Cassileth PA, et al : Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339 : 1649-1656, 1998.
 
32) Burnett AK, et al : The value of allogeneic bone marrow transplantation in patietnts with acute myeloid leukemia at differing risk of relapse : results of the UK MRC AML10 trial. Br J Haematol 118 : 385-400, 2002.
 
33) Sakamaki H, et al : Postremission treatment with chemotherapy or allogeneic stem cell transplantation (Allo-SCT) in adults with acute myelogenous leukemia (AML)-JALSG AML-97 trial. Blood 104 : 632a, 2004.
 
34) Buchner T, et al : 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML) : a randomized trial of the German AML Cooperative Group. J Clin Oncol 21 : 4496-4504, 2003.
PubMed
35) Tallman MS : New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology Am Soc Hematol Educ Program, 143-150, 2005.
PubMed
36) Yanada M, et al : High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24 : 460-466, 2006.
 
37) Cortes J, et al : Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101 : 1692-1697, 2003.
PubMed
38) Kell WJ, et al : A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102 : 4277-4283, 2003.
PubMed
39) Lowenberg B, et al : Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy. N Engl J Med 349 : 743-752, 2003.
PubMed
40) Matsunaga T, et al : Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of myelogenous leukemia. Nat Med 9 : 1158-1165, 2003.
PubMed
P.473 掲載の参考文献
1) Rowe JM, Tallman MS : Intensifying induction therapy in acute myeloid leukemia : Has a new standard of care emerged? Blood 90 : 2121-2126, 1997.
 
2) Bradstock KF, et al : A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high.-dose cytarabine. Blood 105 : 481-488, 2005.
PubMed
3) Ohno R : How high can we increase complete remission rate in adult acute myeloid leukemia? Int J Hematol 72 : 272-279, 2000.
PubMed
4) Hann I, et al : Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Councir s 10th AML trial (MRC AML10). Blood 89 : 2311-2318, 1997.
 
5) The AML Collaborative Group : A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 103 : 100-109, 1998.
PubMed
6) Buchner T, et al : Double induction strategy for acute myeloid leukemia : the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine : a randomized trial by the German AML Cooperative Group. Blood 93 : 4116-4124, 1999.
PubMed
7) Lowenberg B. et al : Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 349 : 743-752, 2003.
PubMed
8) Amadori S, et al : Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia : final results of AML-13, a randomized phase-3 study of the European Organization for Research and Treatment of Cancer and Grippo Italiano Malattie Ematologiche dell Advito (EORTC/GIMEMA) Leukemia groups. Blood 106 : 27-34, 2005.
 
9) Kell W, et al : A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102 : 4277-4283, 2003.
PubMed
10) Mayer RJ, et al : Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331 : 896-903, 1994.
 
11) Bloomfield CD, et al : Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58 : 4173-4179, 1998.
PubMed
12) Byrd JC, et al : Patients with t (8 ; 21) (q22 ; q22) and acute myeloid leukemia have superior failure-free and overall stlrvival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17 : 3767-3775, 1999.
 
13) Buchner T, et al : 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML) : a randomized trial of the German AML Cooperative Group. J Clin Oncol 21 : 4496-4504, 2003.
PubMed
14) Miyawaki S, et al : A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia : the Japan Adult Leukemia Study Group AML97 Study. Cancer 104 : 2726-2734, 2005.
 
15) Sakamaki H, et al : Postremission treatment with chemotherapy or allogeneic stem cell transplantation (Allo-SCT) in adults with acute myeloid leukemia (AML)-JALSG AML-97 Trial-. Blood (ASH Annual Meeting Abstracts) 104 : 2298, 2004.
 
P.478 掲載の参考文献
1) Boissel N, et al : Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21 : 774-780, 2003.
 
2) Stock W, et al : Outcome of adolescents and young adults with ALL : a comparison of Children's Cancer Group (CCG) and Cancer and leukemia Group B (CALGB) regimens. Blood 96 : 467a, 2000.
 
3) DeAngelo D : The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 123-130, 2005.
 
P.481 掲載の参考文献
1) Larson RA : Management of acute lymphoblastic leukemia in older patients. Semin Hematol 43 : 126-133, 2006.
PubMed
2) TakeuchiJ, et al : Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia : the JALSG-ALL93 study. Leukemia 16 : 1259-1266, 2002.
PubMed
3) Kantarjian HM, et al : Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18 : 547-561, 2000.
PubMed
4) Schrappe M, et al : Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia : good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92 : 2730-2741, 1998.
PubMed
5) Roy A, et al : Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia : results of the Medical Research Council ALL 97 trial. Br J Haematol 129 : 35-44, 2005.
PubMed
6) Yanada M, et al : Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults : significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 36 : 867-872, 2005.
PubMed
7) Dombret H, et al : Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 100 : 2357-2366, 2002.
PubMed
8) Druker BJ, et al : Activity of a specfic inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 : 1038-1042, 2001.
 
9) Ottmann OG, et al : A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100 : 1965-1971, 2002.
 
10) Towatari M, et al : Combination of intensive chemotherapy and imatinib can rapidly induce highquality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104 : 3507-3512, 2004.
PubMed
11) Yanada M, et al : High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24 : 460-466, 2006.
 
12) Thomas DA, et al : Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103 : 4396-4407, 2004.
PubMed
13) Lee S, et al : The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosomeっositive acute lymphoblastic leukemia. Blood 105 : 3449-3457, 2005.
 
14) Lee KH, et al : Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 19 : 1509-1516, 2005.
 
15) Wassmann B, et al : Alternating versus concurrent schedules of Imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 108 : 1469-1477, 2006.
PubMed
P.486 掲載の参考文献
1) Ohno R, et al : Treatment of acute promyelocytic leukemia : strategy toward further increase of cure rate. Leukemia 17 : 1454-1463, 2003.
PubMed
2) Huang ME, et al : Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 : 567-572, 1988.
PubMed
3) 麻生範雄 : All-trans retinoic acidによる分化誘導療法 : JALSGにおける急性前骨髄球性白血病の臨床研究. 臨床血液 45 : 115-124, 2004.
 
4) Asou N, et al : Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia : the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol 48 (Suppl 1) : S65-S71, 2001.
 
5) Tallman MS, et al : All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337 : 1021-1028, 1997.
PubMed
6) Fenaux P, et al : A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94 : 1192-1200, 1999.
PubMed
7) Mandelli F, et al : Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell' Adulto and Associazione Italiana di Ematologia ed Oncol ogia Pediatrica Cooperative Groups. Blood 90 : 1014-1021, 1997.
 
8) Sanz MA, et al : Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy : a multicenter study by the PETHEMA group. Blood 103 : 1237, 2004.
PubMed
9) De Botton S, et al : Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 92 : 2712-2718, 1998.
PubMed
10) Burnett AK, et al : Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid : result of the Randomized MRC Trial. Blood 93 : 4131-4143, 1999.
PubMed
11) Lengfelder E, et al : Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid : effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 14 : 1362-1370, 2000.
PubMed
12) Asou N : Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia. Intern Med 44 : 775-776, 2005.
PubMed
13) Diverio D, et al : Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood 92 : 784-789, 1998.
PubMed
14) de Botton S, et al : Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid : aretrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 23 : 120, 2005.
 
15) Asou N, et al : Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 16 : 78-85, 1998.
 
P.493 掲載の参考文献
1) 小寺良尚 : 同種末梢血幹細胞移植におけるドナーの安全性. 血液フロンティア 11 : 29-36, 2001.
 
2) Blaise D, et al : Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia : areport from the Societe Francaise de Greffe de Moelle. J Clin Oncol l8 : 537-546, 2000.
 
3) Powles R, et al : Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases : a randomised trial. Lancet 355 : 1231-1237, 2000.
 
4) Bensinger WI, et al : Transplantation of bone marrow as compared with periphera1-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344 : 175-181, 2001.
PubMed
5) Couban S, et al : A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100 : 1525-1531, 2002.
PubMed
6) Cutler C, et al : Acute and chronic graft-versus-host disease after allogeneic periphera1-blood stem-cell and bone marrow transplantation : a meta-analysis. J Clin Oncol 19 : 3685-3691, 2001.
 
7) Kanda Y, et al : Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 102 : 1541-1547, 2003.
 
8) Ichinohe T, et al : Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood 104 : 3821-3828, 2004.
PubMed
9) Sasazuki T, et al : Effect of matching of class I HLA alleles on clinical outcome a丘er transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 339 : 1177-1185, 1998.
 
10) Morishima Y, et al : The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99 : 4200-4206, 2002.
PubMed
11) Takahashi S, et al : Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 104 : 3813-3820, 2004.
PubMed
12) Gluckman E, et al : Factors associated with outcomes of unrelated cord blood transplant : guidelines for donor choice. Exp Hematol 32 : 397-407, 2004.
PubMed
13) 日本造血細胞移植学会全国データ集計事務局 : 日本造血細胞移植学会平成17年度全国調査報告書, 2006.
 
14) de Botton S, et al : Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid : a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 23 : 120-126, 2005.
 
15) Attal M, et al : Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 : 2495-2502, 2003.
PubMed
P.498 掲載の参考文献
1) Tallman MS, et al : Drug therapy for acute myeloid leukemia. Blood 106 : 1154-1163, 2005.
PubMed
2) Freeman SD, et al : Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 85 : 2005, 1995.
PubMed
3) Bernstein ID, et al : Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Invest 79 : 1153, 1987.
PubMed
4) Andrews RG, et al : The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not their precursors. Blood 68 : 1030, 1986.
 
5) Dinndorf PA, et al : Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia : increased concentration of CD33 antigen predicts poor outcome. Med Pediatr Oncol 20 : 192, 1992.
PubMed
6) Smith FO, et al : Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia lacks prognostic significance. Blood 79 : 2415, 1992.
PubMed
7) van Der Velden VH, et al : Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia : in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97 (10) : 3197-3204, 2001.
PubMed
8) Matsui H, et al : Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 16 (5) : 813-819, 2002.
PubMed
9) Sievers EL, et al : Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19 (13) : 3244-3254, 2001.
 
10) Larson RA, et al : Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104 : 1442-1452, 2005.
PubMed
11) 吉場史朗ほか : 急性骨髄性白血病 (AML) に対するCMA-676の有効性と安全性の評価-第II相臨床試験の報告-. 臨床血液 46 : 171 (733), 2005.
 
12) Russo D, et al : Report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia : Phase I. EHA, 2002.
 
13) DeAngelo DJ, et al : Gemtuzumab ozogamicin (Mylotarg) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia : Two age-specific phase 2 trial. Blood 102 : 100a, 2003.
 
14) Kell WJ, et al : A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102 : 4277-4283, 2003.
PubMed
15) Tsimberidou AM, et al : The role of gemtuzumab ozogamicin in acute leukemia therapy. Br J Haematol 132 : 398-409, 2006,
PubMed
P.504 掲載の参考文献
1) Druker BJ, et al : Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP) : The 5-year update from the IRIS study. J Clin Oncol 24 : 338s, 2006.
 
2) Baccarani M, et al : Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 : 1809-1820, 2006.
 
3) Simonsson B : On behalf of the IRIS Study Group hematology beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) : Update from the IRIS Study. Blood 106 : 52a, 2005.
 
4) Deininger M : Management of early stage disease. Hematology Am Soc Hematol Educ Program : 174-182, 2005.
PubMed
5) Peng B, et al : Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22 : 935-942, 2004.
 
6) Aoki E, et al : High-dose imatinib mesylate treatment in patients (Pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML) : 2.5-year follow-up. J Clin Oncol 24 : 345s, 2006.
 
7) Hughes TP, et al : Maintenance of lmatinib dose intensity in the first siX months of therapy for newly diagnosed patients with CML is predictive of molecular response, independent of the ability to increase dose at a later point. Blood 106 : 51a, Abstract 164, 2005.
 
8) Merante S, et al : Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90 : 979-981, 2005.
PubMed
9) Rousselot P, et al : Imatinib mesylate discontinuation in patients with chronic myelogenous leukaemia in complete molecular remission for more than two years. Blood 106 : 321a, 2005.
 
10) 日本造血細胞移植学会全国データ集計事務局 : 日本造血細胞移植学会平成17年度全国調査報告書, 2006.
 
11) Gratwohl A, et al : Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006 : transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91 : 513-521, 2006.
 
12) Deininger M, et al : The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 91 : 452, 2006.
PubMed
13) National Comprehensive Cancer Network : Clinical Practice Guidelines in Oncology-ver 1.2006. Chronic Myelogenous Leukemia. http://www.nccn.org/
 
P.510 掲載の参考文献
1) O'Brien SG, et al : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (11) : 994, 2003.
PubMed
2) Goldman JM, et al : Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first line imatinib in the IRIS study. Blood 163 (ASH annual meeting abstracts ; 106, 2005).
 
3) Kantarjian HM, et al : Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 104 (7) : 1979-1988, 2004.
PubMed
4) Druker BJ, et al : Efficacy and safety of a spechic inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (14) : 1031, 2001.
PubMed
5) Druker BJ, et al : Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosolne. N Engl J Med 344 (14) : 1038, 2001.
PubMed
6) Kantarjian H, et al : High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103 (8) : 2873, 2004.
PubMed
7) Kantarjian HM, et al : Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101 (2) : 473-475, 2003.
PubMed
8) Silver RT, et al : Four years follow up of 1027 patients with late chronic phase, accelerated phase, or blast crisis chronic myeloid leukemia treated with three large phase II trials. Blood 104 (ASH annual meeting abstracts ; 23, 2004).
 
9) O'Dwyer ME, et al : The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100 (5) : 1628, 2002.
PubMed
10) Cortes JE, et al : Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101 (10) : 3794, 2003.
PubMed
11) Mauro MJ, et al : Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28 (Suppl 1) : S71-73, 2004.
 
12) Cortes J, et al : Discontinuation of imatinib therapy after achieving a molecular response. Blood 104 (7) : 2204, 2004.
PubMed
13) Merante S, et al : Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90 (7) : 979-981, 2005.
PubMed
14) Rousselot P, et al : Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years. Blood 1101 (ASH annual meeting abstracts ; 106, 2005).
 
15) Baccarani M, et al : Evolving concepts in the management of chronic myeloid leukemia. Recommendation from an expert panel on behalf of the European Leukemianet. Blood 108 (6) : 1809-1820, 2006.
 
P.515 掲載の参考文献
1) Baker KS, et al : Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation : results from the Bone Marrow Transplant Survivor Study. Blood 104 : 1898-1906, 2004.
PubMed
2) Morishima Y, et al : The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HIA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99 : 4200-4206, 2002.
 
3) Gratwohl A, et al : Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 352 : 1087-1092, 1998.
 
4) Passweg JR, et al : Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukemia (CML) receiving allogeneic haematopoietic stem cell transplantation. Br J Haematol 125 : 613-620, 2004.
PubMed
5) Champlin RE, et al : Blood stem cells compared with bone marrow as a source of hematopoietic cells allogeneic transplantation. Blood 95 : 3702, 2000.
PubMed
6) Or R, et al : Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101 : 441-445, 2003.
PubMed
7) Crawley C, et al : Outcomes of reduced-intensity transplantation for chronic myeloid leukemia : and analysis of prognostic factors from the Chronic Leukemia Wbrking Party of the EBMT. Blood 106 : 2969-2976, 2005.
PubMed
8) Kim DW, et al : Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia. Leukemia 18 : 1907-1909, 2004.
PubMed
9) Kreuzer KA, et al : Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy : safety, feasibility and evidence for an effcient in vivo purging. Br J Haematol 124 : 195-199, 2004.
 
10) Bocchia M, et al : Effect of a p210 multipeptide vaccine associated with imatinib or interferon patients with chronic myeloid leukemia and persistent residual disease : a multicentre observational trial. Lancet 365 : 657-662, 2005.
PubMed
P.520 掲載の参考文献
1) Greenberg PL, et al : International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 : 2079-2088, 1997.
 
2) Malcovati L, et al : Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria : a basis for clinical decision making. J Clin Oncol 23 : 7594-7603, 2005.
PubMed
3) Malcovati L, et al : A WHO-classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes. Blood 106 : 232a, 2005.
 
4) Okamoto T, et al : Combination chemotherapy with risk factor-adjusted dose attenuation for highrisk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG) : results of an interim analysis. Int J Hematol 72 : 200-205, 2000.
 
5) Hofmann WK, et al : Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol 83 : 498-503, 2004.
 
6) 日本造血細胞移植学会 : 造血幹細胞移植の適応ガイドライン, 2002.
 
7) List A, et al : Efficacy of lenalidomide in myelodysplastic syndrome. N Engl J Med 352 : 549-557, 2005.
PubMed
8) Ruter B, et al : DNA methylation as a therapeutic target in hematologic disorders : recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol 80 : 128-135, 2004.
PubMed
9) Bowen D, et al : Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120 : 187-200, 2003.
PubMed
10) Ito Y, et al : Assessment of the international prognostic scoring system for determining chemotherapeutic indications in myelodysplastic syndrome : Japanese retrospective multicenter study. Int J Hematol 82 : 236-242, 2005.
PubMed
P.527 掲載の参考文献
1) Jaffe ES, et al : World health organization classification of tumours. In : Pathology and Genetics : Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001.
 
2) Rosenberg SA : Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas : challenges and opportunities. J Clin Oncol 3 : 299-310, 1985.
PubMed
3) National Comprehensive Cancer Network : non-Hodgkin's lymphoma. Clinical Practice Guidelines in Oncology, 2004.
PubMed
4) Czuczman MS, et al : Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 : 268-276, 1999.
PubMed
5) Hainsworth JD, et al : Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21 : 1746-1751, 2003.
 
6) Solal-Celigny P, et al : Phase II trial of fludarabine monophosphate as first-line treatlnent in patients with advanced follicular lymphoma : a multicenter study by the Groupe d'Etude des Lymphomes de r Adulte. J Clin Oncol 14 : 514-519, 1996.
 
7) Kay AC, et al : 2-Chlorodeoxy adenosine treatment of low-grade lymphomas. J Clin Oncol 10 : 371-377, 1992.
 
8) Archuleta TD, Armitage JO : Advances in follicular lymphoma. Semin Oncol 31 : S66-S71, 2004.
 
9) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329 : 987-994, 1993.
PubMed
10) Armitage JO, Weisenburger DD : New approach to classifying non-Hodgkin's lymphomas : clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16 : 2780-2795, 1998.
PubMed
11) Miller TP, et al : Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 : 21-26, 1998.
PubMed
12) Alizadeh AA, et al : Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 : 503-511, 2000.
PubMed
13) Yamaguchi M, et al : De novo CD5+ diffuse large B-cell lymphoma : a clinicopathologic study of 109 patients. Blood 99 : 815-821, 2002.
PubMed
14) Fisher RI, et al : Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 : 1002-1006, 1993.
PubMed
P.532 掲載の参考文献
1) Lister TA, et al : Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease : Cotswolds meeting. J Clin Oncol 7 : 1630-1636, 1989.
PubMed
2) Hasenclever D, et al : A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339 : 1506-1514, 1998.
PubMed
3) Meyer RM, et al : Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma : National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23 : 4634-4642, 2005.
 
4) Bonadonna G, et al : ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease : long-term results. J Clin Oncol 22 : 2835-2841, 2004.
PubMed
5) Engert A, et al : Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma : results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21 : 3601-3608, 2003.
 
6) Ogura M, et al : Phase II study of ABVd therapy for advanced stage Hodgkin's disease (HD) in Japan : Japan Clinical Oncology Group (JCOG) Study (JCOG9305). J Clin Oncol 20 : 230b, 2001.
 
7) Diehl V, et al : Hodgkin's lymphoma : biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program 225-247, 2003.
PubMed
8) Duggan DB, et al : Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkingsdisease : report of an intergroup trial. J Clin Oncol 21 : 607-614, 2003.
 
9) Aleman BM, et al : Involved-field radiotherapy for advanced Hodgkin' s lymphoma. N Engl J Med 348 : 2396-2406, 2003.
PubMed
10) Diehl V, et al : Standard and increased-dose BEACOPP chemotherapy compared with COPPABVD for advanced Hodgkin's disease. N Engl J Med 348 : 2386-2395, 2003.
PubMed
11) Federico M, et al : High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21 : 2320-2325, 2003.
PubMed
P.539 掲載の参考文献
1) Shipp MA : A predictive model for aggressive non-Hodgkin's lymphomas. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329 : 987-994, 1993.
 
2) Hasenclever D, Diehl V : A prognostic score for advanced Hodgkin's disease. lnternational Prognostic Factors Project on Advanced Hodgkings Disease. N Engl J Med 339 : 1506-1514, 1998.
 
3) Diehl V, et al : German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 : 2386-2395, 2003.
 
4) Horning SJ, et al : Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin'sdisease : Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 18 : 972-980, 2000.
 
5) Solal-Celigny P, et al : Follicular lymphoma international prognostic index. Blood 104 : 1258-1265, 2004.
PubMed
6) Dave SS, et al : Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351 : 2159-2169, 2004.
PubMed
7) Alizadeh AA, et al : Distinct type of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 : 503-511, 2000.
PubMed
8) Hans CP, et al : Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 : 275-282, 2004.
PubMed
9) Mounier N, et al : Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica 91 : 715-716, 2006.
PubMed
10) Winter JN, et al : Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP : a prospective correlative study. Blood 107 : 4207-4213, 2006.
 
11) Gisselbrecht C, et al : Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 92 : 76-82, 1998.
PubMed
12) Gallamini A, et al : Peripheral T-cell lymphoma unspechied (PTCL-U) : a new prognostic model from aretrospective multicentric clinical study. Blood 103 : 2474-2479, 2004.
 
13) Mori M, et al : Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma. Int J Hematol 81 : 246-254, 2005.
PubMed
14) Niitsu N, et al : Multicenter phase II study of the CyclOBEAP (CHOP-like+etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Hematol 85 : 374-380, 2006.
PubMed
P.543 掲載の参考文献
1) Noordijk EM, et al : Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma : long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24 (19) : 3128-3135, 2006.
 
2) Engert A, et al : Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma : results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21 (19) : 3601-3608, 2003.
 
3) Bonadonna G, et al : ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease : long-term results. J Clin Oncol 22 (14) : 2835-2841, 2004.
PubMed
4) Noordijk EM, et al : First results of the EORTC-GELA H9 randomized trials : the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol (Meeting Abstracts) 23 (16 Suppl) : 6505, 2005.
 
5) Diehl V, et al : HD10 : Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). ASCO Meeting Abstracts 23 (16 Suppl) : 6506, 2005.
 
6) Meyer RM, et al : Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma : National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23 (21) : 4634-4642, 2005.
 
7) Aleman BMP, et al : Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348 (24) : 2396-2406, 2003.
PubMed
8) Horning SJ, et al : Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma : Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 22 (15) : 3032-3038, 2004.
 
9) Miller TP : The limits of limited stage lymphoma. J Clin Oncol 22 (15) : 2982-2984, 2004.
PubMed
10) Reyes F, et al : ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352 (12) : 1197-1205, 2005.
PubMed
11) Miller TP, et al : Effect of adding rituximab to three cycles of CHOP plus invoved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014), ASH Annual Meeting Abstracts 104 (11) : 158, 2004.
 
12) Ishikura S, et al : Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach. Cancer Sci 96 (6) : 349-352, 2005.
 
13) Koch P, et al : Treatment results in localized primary gastric lymphoma : data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 23 (28) : 7050-7059, 2005.
PubMed
P.559 掲載の参考文献
1) Ezdinli EZ, et al : Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 3 : 769-775, 1985.
PubMed
2) Dana BW, et al : Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11 : 644-651, 1993.
PubMed
3) Johnson PW, et al : Patterns of survival in patients with recurrent follicular lymphoma : a 20-year study from a single center. J Clin Oncol 13 : 140-147, 1995.
 
4) Advani R, et al : Stage I and II follicular non-Hodgkin's lymphoma : long-term follow-up of no initial therapy. J Clin Oncol 22 : 1454-1459, 2004.
 
5) Maloney DG, et al : IDEC-C2B8 : Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma [see comments]. J Clin Oncol 15 : 3266-3274, 1997.
 
6) Maloney DG, et al : IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 : 2188-2195, 1997.
PubMed
7) McLaughlin P, et al : Rituximab chirneric anti-CD20 inonoclonal antibody therapy for relapsed indolent lymphoma : half of patients respond to a four-dose treatment program. J Clin Oncol 16 : 2825-2833, 1998.
 
8) Igarashi T, et al : Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab : a Japanese phase II study. Ann Oncol 13 (6) : 928-943, 2002.
PubMed
9) Colombat P, et al : Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden : clinical and molecular evaluation. Blood 97 (1) : 101-106, 2001.
PubMed
10) Hainsworth JD, et al : Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21 (9) : 1746-1751, 2003.
 
11) Ghielmini M, et al : Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly×4 schedule. Blood 103 (12) : 4416-4423, 2004.
 
12) Hochster HS, et al : Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL) : Results of the E1496 Phase III Trial from the Eastem Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood (ASH Annual Meeting Abstracts), Nov 106 : 349, 2005.
 
13) van Oers MH, et al : Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction : results of a prospective randomized phase III intergroup trial. Blood 108 : 3295-3301, 2006.
PubMed
14) Czuczman MS, et al : Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 : 268-276, 1999.
PubMed
15) Czuczman MS, et al : Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy : 9-year follow-up. J Clin Oncol 22 : 4711-4716, 2004.
PubMed
16) Czuczman MS, et al : Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23 (4) : 694-704, 2005.
 
17) Marcus R, et al : CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 : 1417-1423, 2005.
PubMed
18) Hiddemann W, et al : Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone-results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood First Edition Paper, prepublished online August 25, 2005.
 
19) Forstpointner R, et al : The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104 : 3064-3071, 2004.
 
20) Ogura M, et al : Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci 97 : 305-312, 2006.
PubMed
21) Fisher RI, et al : Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 : 1002-1006, 1993.
PubMed
22) Coiffier B, et al : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 : 235-242, 2002.
PubMed
23) Habermann TM, et al : Rituximab-CHOPversus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24 : 3121-3127, 2006.
 
24) Pfreundschuh M, et al : CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : arandomised controlled trial by the MabThera lnternational Trial (MInT) Group. Lancet Oncol 7 : 379-391, 2006.
 
25) Witzig TE, et al : Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 : 2453-2463, 2002.
 
26) Kaminski MS, et al : 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 : 441-449, 2005.
PubMed
27) Li JL, et al : The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. Cell Immunol 118 : 85-99, 1989.
PubMed
28) DiJoseph J, et al : CMC-544 : a CD22-targeted immunoconjugate of calicheamicin for the treatment of non-Hodgkin's lymphoma. Eur J Cancer 38 : S150, 2002.
 
29) DiJoseph J, et al : CMC-544, an anti-CD22 antibody-targeted calicheamicin therapeutic for the treatment of B lymphoid malignancies. Blood 100 : 160a, 2002.
 
30) Hemandez-Ilizalituni FJ, et al : Targeting CD20 and CD22 with rituximab in combination with CMC-544 results in improved anti-tumor activity against non-Hodgkin's lymphoma (NHL) pre-clinical models. Session type. Blood 106 : 1473a, 2005.
 
31) Advani A, et al : Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin's lymphoma (NHL). Blood 106 : 230a, 2005.
 
32) Coyle AI, Gutierrez-Ramos JC : The expanding B7 superfamily : Increasing complexity in costimulatory signals regulating T-cell function. Nat Immunol 2 : 203-209, 2001.
 
33) Chambers CA, Allison JP : Costimulatory regulation of T cell function. Curr Opin Cell Biol 11 : 203-210, 1999.
PubMed
34) Suvas S, et al : Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 277 : 7766-7775, 2002.
 
35) Plumas J, et al : Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures : An important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells. Eur J Immunol 25 : 3332-3341, 1995.
PubMed
36) Vyth-Dreese FA, et al : Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology 94 : 580-586, 1998.
 
37) Dorfman DM, et al : In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 90 : 4297-4306, 1997.
PubMed
38) Gordon LI, et al : Phase I results from a multicenter trial of galiximab (anti-CD80 antibody, IDEC-114) in combination with rituximab for the treatment of follicular lymphoma. Blood 102 : 307b, (Abstr 4951), 2003.
 
39) Czuczman MS, et al : Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 23 (19) : 4390-4398, 2005.
PubMed
P.567 掲載の参考文献
1) Pfreundschuh M, et al : Treatment of diffuse large B-cell lymphoma. Hematology (EHA Educational Program) 2 : 154-160, 2006.
 
2) Milpied N, et al : Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350 : 1287-1295, 2004.
PubMed
3) Philip T, et al : Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 : 1540-1545, 1995.
PubMed
4) Vbse JM, et al : Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 23 : 461-467, 2005.
 
5) Bierman PJ, et al : Syngeneic hematopoiedc stem-cell transplantadon for non-Hodgkin's lymphoma : a comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 20 : 3744-3753, 2003.
 
6) Schouten HC, et al : High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma : results from the randomized European CUP trial. J Clin Oncol 21 : 3918-3927, 2003.
 
7) Gopal AK, et al : High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin's lymphomal a multivariable cohort analysis. Blood 102 : 2351-2357, 2003.
 
8) Deconinck E, et al : High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma : a randomized multicenter stUdy by GOELAMS. Blood 105 : 3817-3823, 2005.
PubMed
9) Van Besien K, et al : Comparison of autologous and allogeneic hematopoietic stem cell transplantation follicular lymphoma. Blood 102 : 3521-3529, 2003.
PubMed
10) Peniket AI, et al : An EBMT registry matched study of allogeneic stem cell transplants for lymphoma : allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31 : 667-678, 2003.
 
11) Toze CL, et al : Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol 127 : 311-321, 2004.
PubMed
12) Khouri IF, et al : Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma : low incidence of toxicity, acute graft-versus-host disease, and treatmentrelated mortality. Blood 98 : 3595-3599, 2004.
 
13) Kusumi E, et al : Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma : a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 36 : 205-213, 2005.
PubMed
14) Faulkner RD, et al : Outcome after alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases : GVHD, toxicity, and survival in 65 patients. Blood 103 : 428-434, 2004.
PubMed
P.574 掲載の参考文献
1) Jaffe ES, et al : World Health Organization Classification of Tumors. In : Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001.
 
2) Wiestner A, et al : ZAP-70 expression identifies a chronic lymphocytic leukaemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101 : 4944-4951, 2003.
PubMed
3) Stankovic T, et al : Microarray analysis reveals that TP53-and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood 103 : 291-300, 2004.
 
4) Montserrat E, et al : How I treat refractory CLL. Blood 107 : 1276-1283, 2006.
 
5) Abbott BL : Chronic lymphocytic leukemia : recent advances in diagnosis and treatment. Oncologist 11 : 21-30, 2006.
PubMed
6) Rai KR, et al : Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343 : 1750-1757, 2000.
PubMed
7) Stilgenbauer S, Dohner HC : Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 347 : 452-453, 2002.
 
8) Dreger P, et al : Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia : a population-matched analysis. Leukemia 19 : 1029-1033, 2005.
 
9) Egashira M, et al : P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporine A and its analogue, PSC833. Blood 93 : 599-606, 1999.
PubMed
10) Yamaguchi M, et al : Treatment outcome of nasal NK-cell lymphoma : A report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematopathol 41 : 93, 2001.
 
11) Kim GE, et al : Angiocentric lymphoma of the head and neck : pattems of systemic failure after radiation treatment. J Clin Oncol 18 : 54-63, 2000.
 
12) Japan Clinical Oncology Group : JCOG0211-D1未治療限局期鼻NK/T細胞リンパ腫に対する放射線治療とDeVIC療法との同時併用療法の第I/II相試験実施計画書.
 
13) Ybng W, et al : L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 78 : 163-167, 2003.
 
14) Obama K, et al : L-asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol 78 : 248-250, 2003.
PubMed
15) Nagafuji K, et al : L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 74 : 447-450, 2001.
PubMed
16) Ando M, et al : Selective apoptosis of natural killer-cell tumours by L-asparginase. Br J Haematol 130 : 860-868, 2005.
 
17) NK-cell Tumor Study Group : NKTSG01進行期, 再発・難治NK/T細胞リンパ腫/白血病に対する新規化学療法 (SMILE療法) の第I相試験実施計画書 (案).
 
18) Suzuki R, et al : Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 37 : 425-431, 2006.
PubMed
P.578 掲載の参考文献
1) 木下研一郎 : 成人T細胞白血病・リンパ腫の名称と新分類の提案. 成人T細胞白血病・リンパ腫, p12-17, 新興医学出版社, 2003.
 
2) Yamada Y, et al : A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma : Japan Clinica10ncology Group Study 9303. Br J Haematol 113 : 375-382, 2001.
 
3) 広瀬かおる, 田島和雄 : 第9次成人T細胞白血病/リンパ腫 (ATL) 全国実態調査の報告. 癌の臨床 47 : 341-357, 2001.
Medical*Online
4) Utsunomiya A, et al : Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 27 : 15-20, 2001.
PubMed
5) Fukushima T, et al : Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients With adult T-cell leukemia/lymphoma. Leukemia 19 : 829-834, 2005.
 
6) 宇都宮與ほか : Aggressive ATLLに対するVCAP-AMP-VECP療法とbiweekly CHOP療法のランダム化第III相比較試験 : JCOG9801. 日本臨床血液学会誌 46 : 734, 2005,
 
7) Uozumi K, et al : Granulocyte colony-stimulating factor in the combination chemotherapy for adult T-cell leukemia (ATL). Leuk Lymphoma 29 : 407-414, 1998.
PubMed
8) Matsushita K, et al : Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma. Leuk Lymphoma 36 : 67-75, 1999.
 
9) 徳永雅仁ほか : 治療抵抗性および再発中悪性度非ポジキンリンパ腫に対する新規salvage療法. 日本臨床血液学会誌 46 : 742, 2004.
 
10) 森直樹ほか : ATLに対する分子標的療法の可能性. 血液・腫瘍科 51 : 68-83, 2005.
 
11) Uozumi K, Arima N : Recent advances and future perspectives in the treatment of adult T-cell leukemia/lymphoma (ATL/L). Recent Res Devel Haematol 2 : 1-19, 2005.
 
P.583 掲載の参考文献
1) Attal M, et al : A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 : 91-97, 1996.
PubMed
2) Child JA, et al : High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 : 1875-1883, 2003.
PubMed
3) Attal M, et al : Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 : 2495-2502, 2003.
PubMed
4) Barlogie B, et al : Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93 : 55-65, 1999.
PubMed
5) Lahuerta JJ, et al : Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 109 : 438-446, 2000.
 
6) Mead GP, et al : Serum free light chains for monitoring multiple myeloma. Br J Haematol 126 : 348-354, 2004.
PubMed
7) Oakervee HE, et al : PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129 : 755-762, 2005.
PubMed
8) Wang M, et al : Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood 106 : 231a. 2006.
 
9) Goldschmidt H, et al : HOVON 50/GMMG-HD3-trial : phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years. Blood 106 : 128a, 2006.
 
10) Palumbo A, et al : Oral melphalan, prednisone and thalidomide for multiple myeloma. Blood 106 : 230a, 2006.
 
11) Mateos MV, et al : A phase I/II national, multi-center, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated muldple myeloma (MM) patients. Blood 106 : 232a, 2006.
 
12) Palumbo A, et al : Oral revimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma. Blood 106 : 231a, 2006.
 
13) Harousseau JL, et al : Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : preliminary results of an IFM phase II study. J Clin Oncol 23 : 16s, 2005.
 
14) Facon T, et al : Major superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood 106 : 230a, 2006.
 
15) Miyakoshi S, et al : Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 107 : 3492-3494, 2006.
PubMed
P.589 掲載の参考文献
1) Hahn T, et al : The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma : an evidence-based review. Biol Blood Marrow Transplant 9 : 4-37, 2003.
PubMed
2) Hari P, et al : Cure of multiple myeloma-more hype, less reality. Bone Marrow Transplant 37 : 1-18, 2006.
PubMed
3) Attal M, et al : A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335 : 91-97, 1996.
PubMed
4) Child JA, et al : High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 : 1875-1883, 2003.
PubMed
5) Greipp PR, et al : Development of an international prognostic index (IPI) for myeloma : Report of the International Working Group. Hematol J 4 (Suppl) : S42-S44, 2003.
 
6) Attal M, et al : Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 : 2495-2502, 2003.
PubMed
7) Barlogie B, et al : Total therapy for newly diagnosed myeloma : the Arkansas experience with 1000 patients treated with total therapy 1, 2 and 3. Xth lnternational Myeloma Workshop, Sydney, 2005.
 
8) Morris C, et al : Benefit and timing of second transplantations in multiple myeloma : clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 22 : 1674-1681, 2004.
 
9) Tricot G, et al : Graft-versus-myeloma effect : proof of principle. Blood 87 : 1196-1198, 1996.
PubMed
10) Maloney DG, et al : Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 : 3447-3454, 2003.
PubMed
11) Garban F, et al : Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 : 3474-3480, 2006.
PubMed
P.594 掲載の参考文献
1) Adams GP, Weiner LM : Monoclonal antibody therapy of cancer. Nat Biotechnol 23 : 1147-1157, 2005.
PubMed
2) Schrama D, et al : Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5 : 147-159, 2006.
PubMed
3) Klein B, et al : Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78 : 1198-1204, 1991.
PubMed
4) Moreau P, et al : Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma : final results of the prospective and randomized IFM 99-04 protocol. Blood 107 : 397-403, 2006.
PubMed
5) Nishimoto N, et al : Clinical application of interleukin-6 receptor antibody. Nihon Rinsho Meneki Gakkai Kaishi 20 : 87-94, 1997.
PubMed
6) Cohen BD, et al : Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751, 871. Clin Cancer Res 11 : 2063-2073, 2005.
PubMed
7) Trudel S, et al : The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t (4 ; 14) multiple myeloma cells. Blood 107 : 4039-4046, 2006.
 
8) Body JJ, et al : A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12 : 1221-1228, 2006.
 
9) Treon SP, et al : CD20-directed serotherapy in patients with multiple myeloma : biologic considerations and therapeutic applications. J Immunother 25 : 72-81, 2002.
PubMed
10) Maloney DG, et al : Antibody therapy for treatment of multiple myeloma. Semin Hematol 36 : 30-33, 1999.
PubMed
11) Tai YT, et al : Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells : clinical implications. Cancer Res 64 : 2846-2852, 2004.
PubMed
12) Hussein M, et al : A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma [Abstract]. Blood 106 : 723a, 2005.
 
13) Tai Yr, et al : Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma : clinical implications. Cancer Res 65 : 11712-11720, 2005.
 
14) Tai YT, et al : Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 65 : 5898-5906, 2005.
PubMed
15) Kikuchi Y, et al : Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma. Leuk Res 29 : 445-450, 2005.
PubMed
16) Tassone P, et al : In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 64 : 4629-4636, 2004.
PubMed
17) Sapra P, et al : Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 11 : 5257-5264, 2005.
 
18) Tassone P, et al : Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DMI against CD138+ multiple myeloma cells. Blood 104 : 3688-3696, 2004.
 
19) von Strandmann EP, et al : A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107 : 1955-1962, 2006.
PubMed
20) Goto T, et al : A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84 : 1922-1930, 1994.
 
21) Ishikawa J, et al : Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 26 : 527-534, 1995.
PubMed
22) Ozaki S, et al : Humanized anti-HMI.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood 93 : 3922-3930, 1999.
 
23) Powles R, et al : A phase I study of the safety, tolerance, pharmacokinetics, antigenicity and efficacy of a single intravenous dose of AHM followed by multiple doses of intravenous AHM in patients with multiple myeloma [Abstract]. Blood 98 : 165a, 2001.
 
24) Ozaki S, et al : Anti-myeloma activity of the maytansinoid immunoconjugate of internalizing human monoclonal antibody spechic for HMI.24/BST2 (CD317) [Abstract]. Blood 106 : 947a, 2005.
 
25) Menoret E, et al : Mcl-1L cleavage is involved TRAIL-R1-and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 108 : 1346-1352, 2006.
PubMed
P.599 掲載の参考文献
1) 服部豊 : Thalidomideを用いた多発性骨髄腫の治療. 臨床血液 44 : 302-312, 2003.
 
2) Glasmacher A, et al : A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132 : 584-593, 2005.
 
3) Cavo M, et al : Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 : 35-39, 2005.
PubMed
4) Rajkumar SV, et al : Eastem Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma : a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 20 : 431-436, 2006.
 
5) Wang M, et al : Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood 106 : 231a, 2005.
 
6) Palumbo A, et al : Italian Multiple Myeloma Network, GIMEMA : Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma : randomised controlled trial. Lancet 367 : 825-831, 2006.
PubMed
7) Facon T, et al : Major superiority of melphalan-prednisone (MP) + thalidomide over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood 106 : 230a, 2005.
 
8) Attal M, et al : Maintenance treatment with thalidomide after autologous transplantation for myeloma : final analysis of a prospective randomized study of the Intergroupe Francophone du Myeloma. Blood 106 : 335a, 2005.
 
9) Barlogie B, et al : Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354 : 1021-1030, 2006.
PubMed
10) Kakimoto T, et al : Thalidomide for the treatment of refractory multiple myeloma : association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. Jpn J Cancer Res 93 : 1029-1036, 2002.
PubMed
11) 村上博和ほか : 日本骨髄腫研究会参加施設におけるサリドマイド治療の現状と成績. 臨床血液 45 : 468-472, 2004.
 
12) Hattori Y, et al : Thalidomide-induced severe neutropenia during treatment of multiple myeloma. Int J Hematol 79 : 283-288, 2004.
PubMed
13) Weber DM, et al : A multicenter, randomized, parallel-group double blinded, placebo-controlled study of lenalidomide plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma. Haematologica 90 : 155a, 2005.
 
14) Dimopoulos MA, et al : Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma : result of a phase 3 study (MM-010). Blood 106 : 6a, 2005.
 
15) Uhl K, et al : Thalidomide use in the US : experience with pregnancy testing in the S.T.E.P.S. program. Drug Saf 29 : 321-329, 2006.
 
P.604 掲載の参考文献
1) Adams J : The proteasome : structure, function, and role in the cell. Cancer Treat Rev 29 (Suppl 1) 3-9, 2003.
 
2) Adams J : The proteasonle : a suitable antineoplastic target. Nat Rev Cancer 4 : 349-360, 2004.
PubMed
3) Adams J : The development of the protease inhibitors as anticancer drugs. Cancer Cell 5 : 417-421, 2004.
PubMed
4) Hideshima T, et al : Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101 : 1530-1534, 2003.
PubMed
5) LeBlanc R, et al : Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine modeL Cancer Res 62 : 4996-5000, 2002.
 
6) Orlowski RZ, et al : Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20 : 4420-4427, 2002.
PubMed
7) Aghajanian C, et al : A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8 : 2505-2511, 2002.
 
8) Jagannath S, et al : A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127 : 165-172, 2004.
PubMed
9) Richardson PG, et al : A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 : 2609-2617, 2003.
PubMed
10) Richardson PG, et al : Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 106 : 2977-2981, 2005.
PubMed
11) Richardson PG, et al : Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 : 2487-2498, 2005.
 
12) Jagannath S, et al : Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129 : 776-783, 2005.
PubMed
13) Oakervee HE, et al : PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129 : 755-762, 2005.
PubMed
14) Chauhan D, et al : A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8 : 407-419, 2005.
 
15) Miyakoshi S, et al : Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 107 : 3492-3494, 2006.
PubMed
P.609 掲載の参考文献
1) Miyawaki S, et al : A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia : the Japan Adult Leukemia Study Group AML 97 Study. Cancer 104 : 2726-2734, 2005.
 
2) Moore JO, et al : Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age : Cancer and Leukemia Group B study 9222. Blood 10513420-3427, 2005.
PubMed
3) Estey E, et al : Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107 : 3469-3473, 2006.
PubMed
4) Attar EC, et al : Addition of bortezomib (Velcade) to AML induction chemotherapy is well tolerated and results in a high complete remission rate (abst). Blood 106 : 780a, 2005.
 
5) Bug G, et al : Clinical trial of valporic acid and all-trans retinoic acid in patients with poor-risk myeloid leukemia. Cancer 104 : 2717-2725, 2005.
 
6) Kuendgen A, et al : The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106 : 112-116, 2006.
 
7) Tallman MS, et al : Drug therapy for acute myeloid leukemia. Blood 106 : 1154-1163, 2005.
PubMed
8) Wang Y, et al : AML1-ETO and C-KIT mutation/overexpression in t (8 ; 21) leukemia : implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acd Sci USA 102 : 1104-1109, 2005.
 
9) Schnittger S, et al : KIT-D816 mutations in AML-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107 : 1791-1799, 2006.
PubMed
10) Fiedler W, et al : A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102 : 2763-2767, 2003.
PubMed
11) Karp JE, et al : Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemia : therapy with sequential 1-β-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 10 : 3577-3585, 2004.
 
12) Marcucci G, et al : Phase 1 and pharmacokinetic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101 : 425-432, 2003.
PubMed
13) Marcucci G, et al : Phase I study of oblimersen sodium, an antisense to BcL2, in untreated older patients with acute myeloid leukemia : pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 23 : 3404-3411, 2005.
PubMed
14) Lancet JE, et al : Tipifarnib (ZARNESTRA) in previously untreated poor-risk AMLand MDS : interim results of a phase 2 trial (abst). Blood, 176a, 2003.
 
15) List AF, et al : Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia : a Southwest Oncology Group study. Blood 98 : 3212-3220, 2001.
 
16) Matsunaga T, et al : Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9 : 1158-1165, 2003.
PubMed
17) Laughlin MJ, et al : Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 : 2265-2275, 2004.
 
18) Rocha V, et al : Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351 : 2276-2285, 2004.
 
19) Vermeris MR, et al : Risk of relapse after umbilical cord blood transplantation in patients with acute leukemia : marked reduction in recipients of two units (abst). Blood, 93a, 2005.
 
P.616 掲載の参考文献
1) Kelly LM, et al : CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 1 : 421-432, 2002.
PubMed
2) DeAngelo DJ, et al : Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation. Blood 104 : Abstract 1792, 2004.
 
3) Weisberg E, et al : Inhibition of mutant FLT3 receptors ill leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1 : 433-443, 2002.
 
4) Propper DJ, et al : Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19 : 1485-1492, 2001.
 
5) Stone RM, et al : Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 : 54-60, 2005.
 
6) Giles F, et al : Phase 1 study of PKC412, an oral FLT3 kinase inhibitor, in sequential and concomitant combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine (HDAra-C) consolidation in newly diagnosed patients with AML. Blood 104 : Abstract 262, 2004.
 
7) Levis M, et al : A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99 : 3885-3891, 2002.
PubMed
8) Levis M, et al : In vitro studies of a FLT3 inhibitor combined with chemotherapy : sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104 : 1145-1150, 2004.
PubMed
9) Smith BD, et al : Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 : 3669-3676, 2004.
PubMed
10) Fiedler W, et al : A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 : 986-993, 2005.
 
11) Karp JE, et al : Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias : a phase 1 clinical-laboratory correlative trial. Blood 97 : 3361-3369, 2001.
PubMed
12) Cortes J, et al : Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101 : 1692-1697, 2003.
PubMed
13) Cortes J, et al : Phase I study of BMS-214662, a famesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 23 : 2805-2812.2005.
 
P.620 掲載の参考文献
1) Weisberg E, et al : Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 7 : 129, 2005.
PubMed
2) Manley PW, et al : Advances in the structural biology, design and clinical development of BCR-ABL kinase inhibitors for the treatment of chronic myeloid leukemia. Biochim Biophys Acta 1754 : 3, 2005.
PubMed
3) Giles F, et al : A phase I/II study of AMN107, novel aminopyrimidine inhibitor of BCR-ABL, on a continuous daily dosing schedule in adult patients with imatinib-resistant advanced phase of chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph+) acute lymphocytic leukemia (ALL). Blood 104 : 10a, 2004.
 
4) Kantarjian H, et al : AMN107, a novel aminopyrimidine inhibitor of BCR-ABL, has significant activity in imatinib-resistant BCR-ABL positive chronic myeloid leukemia (CML). J Clin Oncol 23 : 195s, 2005.
 
5) Ottmann O, et al : Activity of AMN107, a novel aminopyrimidine inhibitor of BCR-ABL, in imatinib-resistant BCR-ABL positive lymphoid malignancies. J Clin Oncol 23 : 195s, 2005.
 
6) Shah NP, et al : Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 : 399, 2004.
PubMed
7) Tokarski J, et al : The crystal structure of ABL kinase with BMS-354825, a dual SRC/ABL kinase inhibitor. Blood 104 : 160a, 2004.
 
8) Gambacorti-Passerini C, et al : ABL inhibitor BMS-354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia 19 : 1267, 2005.
 
9) Lee FY, et al : BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum antitumor activities in vitro and in vivo. Proc Am Assoc Cancer Res 46 : 159, 2005.
 
10) Sawyers CL, et al : Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825 : results from a Phase I dose escalating study. Blood 104 : 4a, 2004.
 
11) Tarpaz M, et al : Hematologic and cytogenetic responses in imatinib-resistant accelerated and blast phase chronic myeloid leukemia (CML) patients treated with the dual SRC/ABL kinase inhibitor BMS-354825 : results from a Phase I dose escalation study. Blood 104 : 10a, 2004.
 
12) Talpaz M, et al : A Phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML) : results from CA180002. J Clin Oncol 23 : 564s, 2005.
 
13) Sawyers CL, et al : A Phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia (CML) : results from CA180002. J Clin Oncol 23 : 565s, 2005.
 
14) Shah N, et al : Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome associated acute lymphoblastic leukemia (Ph+ ALL). J Clin Oncol 23 : 565s, 2005.
 
15) Gao H, et al : BMS-354825 induced complete hematologic remission in chronic phase CML patients without affecting T-cell cytokine production. J Clin Oncol 23 : 589s, 2005.
 
P.627 掲載の参考文献
1) Molldrem J, et al : Targeted T cell therapy for human leukemia : cytotoxic T lymphocytes spechic for apeptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88 : 2450-2457, 1996.
 
2) Ohminami H, et al : HLA class I restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95 : 286-293, 2000.
 
3) Makita M, et al : Anti-lung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 8 : 2626-2631, 2002.
 
4) Yotnda P, et al : Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101 : 2290-2296, 1998.
PubMed
5) Rezvani K, et al : Functional leukemia-associated antigen-specific memory CD8+ Tcells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102 : 2892-2900, 2003.
 
6) Molldrem JJ, et al : Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6 : 1018-1023, 2000.
PubMed
7) Burchert A, et al : Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101 : 259-264, 2003.
 
8) Pellat-Deceunynck C : Tumor-associated antigens in multiple myeloma. Br J Haematol 120 : 3-9, 2003.
PubMed
9) Jalili A, et al : Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheralblood stem-cell harvests in patients with multiple myeloma. Blood 106 : 3538-3545, 2005.
PubMed
10) Harashima N, et al : Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res 64 : 391-399, 2004.
PubMed
11) Claxton DF, et al : Therapeutic potential of leukemia-derived dendritic cells : preclinical and clinical progress. Crit Rev Immunol 21 : 147-155, 2001.
PubMed
12) Kugler A, et al : Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6 : 332-336, 2000.
PubMed
13) Rooney CM, et al : Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol 258 : 221-229, 2001.
PubMed
14) Tsuji T, et al : Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 106 : 470-476, 2005.
 
15) van der Veken LT, et al : αβT-cell receptor engineered γδT cells mediate effective antileukemic reactivity. Cancer Res 66 : 3331-3337, 2006.
 
P.635 掲載の参考文献
1) Demidem A, et al : Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12 : 177-186, 1997.
 
2) Czuczman MS, et al : Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 : 268-276, 1999.
PubMed
3) Czuczman MS, et al : Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy : 9-year follow-up. J Clin Oncol 22 : 4711-4716, 2004.
PubMed
4) Forstpointner R, et al : The addition of ritu) dmab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104 : 3064-3071, 2004.
 
5) Czuczman MS, et al : Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23 : 694-704, 2005.
 
6) Marcus R, et al : CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 : 1417-1423, 2005.
PubMed
7) Hiddemann W, et al : Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone-results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood First Edition Paper, prepublished online August 25, 2005.
 
8) Coiffier B, et al : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 : 235-242, 2002.
PubMed
9) Witzig TE, et al : Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 21 : 1263-1270, 2003.
 
10) Witzig TE, et al : Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 : 2453-2463, 2002.
 
11) Kaminski MS, et al : 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 : 441-449, 2005.
PubMed
12) Fisher RI, et al : Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 23 : 7565-7573, 2005.
 
13) Vose JM, et al : Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 23 (3) : 461-467, 2005.
PubMed
14) Leonard JP, et al : Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 23 : 5696-5704, 2005.
PubMed
15) Lee MD, et al : Calicheamicin, a novel family of antitumor antibiotics 4. J Am Chem Soc 114 : 985-997, 1992.
 
16) Hinman LM, et al : Preparation and characterization of monoclonal antibody conjugates of the calicheamicins : a novel and potent family of antitumor antibiotics. Cancer Res 53 : 3336-3342, 1993.
PubMed
17) Lee MD, et al : Calicheamicin, a novel family of antitumor antibiotics 1. J Am Chem Soc 109 : 3464-3466, 1987.
 
18) Lee MD, et al : Calicheamicin, a novel family of antitumor antibiotics 2. J Am Chem Soc 109 : 3466-3468, 1987.
 
19) Sievers EL, et al : Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy : a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93 : 3678-3684, 1999.
PubMed
20) Advani A, et al : Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin's lymphoma (NHL). Blood 106 : 230a, 2005.
 
21) Swords R, et al : Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT. Eur J Haematol 73 : 450-451, 2004.
PubMed
P.641 掲載の参考文献
1) Appelbaum FR : Haematopoietic cell transplantation as immunotherapy. Nature 411 : 385-389, 2001.
PubMed
2) Giralt S, et al : Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy : harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 : 4531-4536, 1997.
PubMed
3) Kolb HJ, et al : Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 : 2462-2465, 1990.
PubMed
4) Dazzi F, et al : Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95 : 67-71, 2000.
PubMed
5) Falkenburg JH, et al : Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 94 : 1201-1208, 1999.
PubMed
6) Bonini C, et al : HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 : 1719-1724, 1997.
PubMed
7) Ciceri F, et al : Modulation of GvHD by suicide-gene transduced donor T lymphocytes : clinical applications in mismatched transplantation. Cytotherapy 7 : 144-149, 2005.
PubMed
8) Berger C, et al : Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107 : 2294-2302, 2006.
PubMed
9) Thomis DC, et al : A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97 : 1249-1257, 2001.
 
10) Li Z, et al : Murine leukemia induced by retroViral gene marking. Science 296 : 497, 2002.
PubMed
11) Bonini C, et al : Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 9 : 367-369, 2003.
PubMed
12) Hacein-Bey-Abina S, et al : A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 : 255-256, 2003.
PubMed
13) Recchia A, et al : Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 103 : 1457-1462, 2006.
PubMed
P.645 掲載の参考文献
1) Attal M, et al : A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 : 91-97, 1996.
PubMed
2) Child JA, et al : High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 : 1875-1883, 2003.
PubMed
3) Moreau P, et al : Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma : final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99 : 731-735, 2002.
PubMed
4) Attal M, et al : Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 : 2495-2502, 2003.
PubMed
5) Barlogie B, et al : Total therapy 2 without thalidomide in comparison with total therapy 1 : role of intensified induction and posttransplantation consolidation therapies. Blood 107 : 2633-2638, 2006.
PubMed
6) Moreau P, et al : Tandem autologous stem cell transplantation in high-risk de llovo rnultiple myeloma : final results of the prospective and randomized IFM99-04 protocol. Blood 107 : 397-403, 2006.
 
7) Palumbo A, et al : Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70 : results of a randomized controlled trial. Blood 104 : 3052-3057, 2004.
PubMed
8) Facon T, et al : Major superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood 106 : 230a (abst 780), 2005.
 
9) Attal M, et al : Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood prepublished online July 27, 2006.
 
10) Stewart A, Fonseca R : Prognostic and therapeutic signhicance of myeloma genetics and gene expression profiling. J Clin Oncol 23 : 6339-6344, 2005.
PubMed
11) Garban F, et al : Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 : 3474-3480, 2006.
PubMed
12) Bruno B, et al : Double auto transplantation versus tandem auto-non myeloablative allo transplantation for newly diagnosed multiple myeloma. Blood 106 : 18a (abst 46), 2005.
 
13) Rosinol L, et al : Feasibility and efficacy of a planed second transplant (auto or mini-allo) intensification in patients with multiple myeloma (MM) not achieving complete remission (CR) or near-CR with a first autologous transplant. Results from a Spanish PETHEMA/GEM study. Blood 106 : 128a (abst 425), 2005.
 
14) Cavo M, et al : Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 : 35-39, 2005.
PubMed
15) Barlogie B, et al : Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354 : 1021-1030, 2006.
PubMed
P.652 掲載の参考文献
1) The International Non-Hodgkin's Lymphoma Prognostic Factors Project : Apredictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 : 987-994, 1993.
 
2) Perea G, et al : Prognostic indexes in follicular lymphoma : a comparison of different prognostic systems. Ann Oncol 16 : 1508-1513, 2005.
PubMed
3) Miller KB, Daoust PR : Clinical manifestations of acute myeloid leukemia. In : Hematology. Basic Principles and Practice (ed by Hoffman R, et al), p 1071-1097, Elsevier. Philadelphia, 2005.
 
4) Rosenberg S, Canellos GP : Hodgkin's disease. In : The Lymphomas (ed by Cannelos GP, et al), p305-331, Saunders, Philadelphia, 1998.
 
5) Carroll WL, et al : Pediatric lymphoblastic leukemia. Hematology 2003 : 102-108, 2003.
PubMed
6) Willman CL : Biologic and genetic risk assessment of AML in the genomic era. Hematology 2002 : 90-97, 2002.
 
7) Alizadeh M, et al : Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 : 503-511, 2000.
 
8) Hans CP, et al : Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 : 275-282, 2004.
PubMed
9) Cave H et al : Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 399 : 591-598, 1998.
 
10) Marcucci G, et al : Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 12 : 1482-1489, 1998.
PubMed
11) Haioun C, et al : [18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma : an early prognostic tool for predicting patient outcome. Blood 106 : 1376-1381, 2005.
PubMed
12) Pui C-H, et al : Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukemia. Best Practice Res Clin Haematol 15 : 741-756, 2002,
 
13) Evans W, Relling MV : Moving towards individualized medicine with pharmacogenomics. Nature 429 : 464-468, 2004.
PubMed
P.656 掲載の参考文献
1) Smith M, et al : Adult acute myeloid luekaemia. Crit Rev Oncol Hematol 50 : 197-222, 2004.
PubMed
2) Lowenberg M : Prognostic factors in acute myeloid leukaemia. Best Prac Res Clin Haematol 14 : 65-75, 2001.
 
3) Ferrant A, et al : Karyotype in acute myeloblastic leukemia : prognostic significance for bone marrow transplantation in first remission : A European Group for Blood and Marrow Transplantation Study. Blood 90 : 2931-2938, 1997.
 
4) Matsuo T, et al : The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. Leukemia 17 : 1538-1543, 2003.
 
5) Kiyoi H, et al : Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93 : 3074-3080, 1999.
 
6) Stirewalt DL, Radich JP : The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3 : 650-665, 2003.
PubMed
7) Falini B, et al : Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352 : 254-266, 2005.
PubMed
8) Miyawaki S, et al : A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia. Cancer 104 : 2726-2734, 2005.
PubMed
9) Kebriaei P, et al : Acute lymphoblastic leukaemia : diagnosis and classification. Best Prac Res Clin Haematol 4 : 597-621, 2003.
 
10) DeAngelo DJ : The treatment of adolescents and young adults With acute lymphoblastic leukemia. In : Hematology 2005 (ed by Berliner N, et al), American Society of Hematology, 2005.
 
11) Takeuchi J, et al : Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia : the JALSG-ALL93 study. Luekemia 16 : 1259-1266, 2002.
 
12) Yanada M, et al : High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24 : 460-466, 2006.
 
13) Thomas DA, et al : Chemoimmunotherapy with Hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106 : 1569-1580, 2006.
PubMed
P.661 掲載の参考文献
1) Sokal JE, et al : Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63 : 789-799, 1984.
PubMed
2) Cortes JE, et al : Staging of chronic myeloid leukemia in the imatinib era : an evaluation of the World Health Organization proposal. Cancer 106 : 1306-1315, 2006.
PubMed
3) Simonsson B : Beneficial Effects of Cytogenetic and Molecular Response on Long-Teml Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (IM) : Update from the IRIS Study. Blood (ASH Annual Meeting Abstracts 166) 106 : 166, 2005.
 
4) Hughes TP, et al : Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 : 1423-1432, 2003.
 
5) Goldman JM, et al : Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line imatinib in the IRIS stUdy. Blood (ASH Annual Meeting Abstracts 163), 2005.
 
6) Cortes J, et al : Molecular responses in patients with chronic nlyelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11 : 3425-3432, 2005.
PubMed
7) White D, et al : In vitro sensitivity to imatinib-induced inhibition of ABL Idnase activity is predictive of molecular response in patients with de novo CML. Blood 106 : 2520-2526, 2005.
 
8) Kantarjian HM, et al : The degree of bone marrow fibrosis in chronic myelogenous leukemia is not aprognostic factor with imatinib mesylate therapy. Leuk Lymphoma 46 : 993-997, 2005.
 
9) Kantarjian HM, et al : Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 104 : 777-780, 2005.
PubMed
10) Quintas-Cardama A, et al : Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105 : 2281-2286, 2005.
PubMed
11) Bosch F, Montserrat E : Refining prognostic factors in chronic lymphocytic leukemia. Rev Clin Exp Hematol 6 : 335-349 ; discussion 449-350, 2002.
 
12) Caballero D, et al : Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 11 : 7757-7763, 2005.
PubMed
13) Boonstra JG, et al : CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL) : comparison of three approaches to analyze its expression. Cytometry B Clin Cytom 70 : 136-141, 2006.
 
14) Crespo M, et al : ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 : 1764-1775, 2003.
PubMed
15) Oppezzo P, et al : The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 106 : 650-657, 2005.
PubMed
P.664 掲載の参考文献
1) Bonadonna G, et al : ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease : long-term results. J Clin Oncol 22 : 2835-2841, 2004.
PubMed
2) Meyer RM, et al : Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma : National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23 : 4634-4642, 2005.
 
3) Hasenclever D, et al : A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339 : 1506-1514, 1998.
PubMed
4) Solal-C61igny P, et al : Follicular lymphoma international prognostic index. Blood 104 : 1258-1265, 2004.
PubMed
5) Buske C, et al : The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediate-or low-risk patients With advanced-stage follicular lymphoma treated front-linewith rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108 : 1504-1508, 2006.
PubMed
6) The International Non-Hodgkin's Lymphoma Prognostic Factors Project : A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 : 987-994, 1993.
 
7) Rosenwald A, et al : The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 : 1937-1947, 2002.
PubMed
8) Hans CP, et al : Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 : 275-282, 2004.
PubMed
9) Yamaguchi M, et al : De novo CD5+ diffuse large B-cell lymphoma : a clinicopathologic study of 109 patients. Blood 99 : 815-821, 2002.
PubMed
10) Lossos IS, et al : Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 98 : 945-951, 2001.
PubMed
11) Hutchings M, et al : FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 : 52-59, 2006.
PubMed
12) Kostakoglu L, et al : PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43 : 1018-1027, 2002.
PubMed
P.670 掲載の参考文献
1) Durie BGM, et al : Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55 : 364-372, 1980.
 
2) Durie BGM, et al : Prognostic value of pretreatment serum, β-2 microglobulin in myeloma : A Southwest Oncology Group Study. Blood 75 : 823-830, 1990.
 
3) Meletios A, et al : High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 115 : 931-935, 1991.
 
4) Bataille R, et al : C-reactive protein and β2-microglobulin produce a simple and powerful myeloma staging system. Blood 80 : 733-737, 1992.
 
5) Zojer N, et al : Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95 : 1925-1930, 2000.
PubMed
6) Fonseca R, et al : Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (del 13) in multiple myeloma : an eastern cooperationve oncology group study. Cancer Res 62 : 715-720, 2002.
 
7) Fonseca R, et al : Myeloma and the t (11 ; 14) (q13 ; 32) ; evidence for a biologically defined unique subset of patients. Blood 99 : 3735-3741, 2002.
 
8) Fonseca R, et al : Clinical and biologic implication of recurrent genomic aberrations in myeloma. Blood 101 : 4569-4575, 2003.
PubMed
9) Fonseca R, et al : Genetics and cytogenetics of multiple myeloma : A workshop report. Cancer Res 64 : 1546-1558, 2004.
PubMed
10) Chang H, et al : p53 gene deletion detected by fiuorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105 : 358-360, 2005.
 
11) Filipits M, et al : Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma. Clin Cancer Res 9 : 820-826, 2003.
PubMed
12) Durie BGM, Salmon SE : A clinical staging system for multiple myeloma. Cancer 36 : 842.-854, 1975.
 
13) Murakami H, et al : A staging system for multiple myeloma based on the morphology of myeloma cells. Eur J Haematol 62 : 63-67, 1999.
 
14) Facon T, et al : Chromosome 13 abnormalities identified by FISH analysis and serum β-2 microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97 : 1566-1571, 2001.
 
15) Jacobson JL, et al : A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 122 : 441-450, 2003.
 
16) Greipp PR, et al : International staging system for multiple myeloma. J Clin Oncol 23 : 3412-3420, 2005.
PubMed
P.675 掲載の参考文献
1) Brunning RD, et al : Myelodysplastic syndromes : Introduction. In : Tumors of Hematopoietic and Lymphoid Tissues (ed by Jaffe E, et al), p 63-67, IARC Press, Lyon, 2001.
 
2) Greenberg P, et al : International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 : 2079-2088, 1997.
PubMed
3) Ito Y, et al : Assessment of the international prognostic scoring system for determining chemotherapeutic indications in myelodysplastic syndrome : Japanese retrospective multicenter study. Int J Hematol 82 : 236-242, 2005.
PubMed
4) 不応性貧血 (骨髄異形成症候群) の診断基準と診療参照ガイド作成のためのワーキンググループ : 不応性貧血 (骨髄異形成症候群) 診療の参照ガイドライン.臨床血液 47 : 47-68, 2006.
 
P.685 掲載の参考文献
1) Knudson AG : Hereditary predisposition to cancer. Ann N Y Acad Sci 833 : 58-67, 1997.
PubMed
2) Merks JH, et al : High incidence of malformation syndromes in a series of 1,073 children with cancer. Am J Med Genet 134A : 132-143, 2005.
 
3) Segel GB, Lichtman MA : Familial (inherited) leukemia, lymphoma, and myeloma : an overview. Blood Cells Mol Dis 32 (1) : 246-261, 2004.
PubMed
4) 水谷修紀 : Ataxia telangiectasia. 日本臨牀 63 (Suppl 5) : 570-574, 2005.
 
5) Nakada S, et al : Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations. J Clin Invest 116 (1) : 80-89, 2006.
PubMed
6) Kennedy RD, D'Andrea AD : The Fanconi anemia/BRCA pathway : new faces in the crowd. Genes Dev 19 (24) : 2925-2940, 2005.
 
7) Malkin D, et al : Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 (4985) : 1233-1238, 1990.
 
8) De Luca A, et al : NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet 77 (6) : 1092-1101, 2005.
PubMed
9) Tartaglia M, Gelb BD : Noonan syndrome and related disorders : genetics and pathogenesis. Annu Rev Genomics Hum Genet 6 : 45-68, 2005.
PubMed
10) Aoki Y, et al : Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37 (10) : 1038-1040, 2005.
PubMed
11) Hitzler JK, Zipursky A : Origins of leukemia in children with Down syndrome. Nat Rev Cancer 5 (1) : 11-20, 2005.
PubMed
P.693 掲載の参考文献
1) Isoyama K, et al : Risk-directed treatment of infant acute lymphoblastic leukemia based on early assessment of MLL gene status : results of the Japan Infant Leukemia Study (MLL96). Br J Haematol 118 : 999-1010, 2002.
PubMed
2) Kawasaki H, et al : A superior outcome of infant acute myeloid leukemia with intensive chemotherapy. Blood 98 : 3589-3594, 2001.
PubMed
3) Dordelmann M, et al : Prednisone response is the strongest predictor of treatmenht outcome in infant acute lymphoblastic leukemia. Blood 94 : 1209-1217, 1999.
PubMed
4) Camitta BM : Pathogenesis and treatment of acute lymphocytic leukemia in infants. Jpn J pediatr Hematol 18 : 593-600, 2004.
 
5) Hilden JM, et al : Analysis of acute lymphoblastic leukemia in infants : report on CCG1953 from the Children's Oncology Group. Blood 108 : 441-456, 2006.
 
6) Kosaka K, et al : Infant acute lymphoblastic leukemia with MLL gene rearrangements : outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 104 : 3527-3534, 2004.
 
7) Sanders JE, et al : Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 105 : 3749-3756, 2005.
PubMed
8) Nagayama J, et al : Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone : results from the Japan Infant Leukemia Study Group. Blood 107 : 4663-4665, 2006.
 
9) Woods WG, et al : A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission : a report from the Children's Cancer Group. Blood 97 : 56-62, 2001.
 
10) Ford AM, et al : In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363 : 358-360, 1993.
PubMed
11) Alexander FE, et al : Transplacental chemical exposure and risk of infant leukaemia with MLL gene fusion. Cancer Res 61 : 2542-2546, 2001.
PubMed
12) Strissel PL, et al : An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood 92 : 3793-3803, 1998.
 
13) Nakada S, et al : Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations. J Clin Invest 116 : 80-89, 2006.
PubMed
14) Eguchi-Ishimae M, et al : The association of a distinctive allele of NAD (P) H : quinone oxidoreductase with pediatric acute lymphoblastic leukemia with MLL fusion genes in Japan. Haematologica 90 : 1511-1515, 2005.
 
15) Pui CH, et al : Mechanism of disease : a cute lymphoblastic leukemia. N Engl J Med 350 : 1535-1548, 2004.
 
16) Taketani K, et al : FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant acute lymphoblastic leukemia (ALL) with MLL rearrangement and pediatric ALL with hyperdiploidy. Blood 103 : 1085-1088, 2004.
 
17) Brown P, et al : Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia 20 : 1368-1376, 2006.
 
18) Jumaa H, et al : Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia. Nature 423 : 452-456, 2003.
PubMed
19) Sadakane Y, et al : Expression and production of aberrant Pax5 with deletion of exon 8 in B-lineage acute lymphoblastic leukemia of children. (submited).
 
P.699 掲載の参考文献
1) 加藤忠明ほか : 平成10-13年度小児慢性特定疾患治療研究事業の全国登録状況.平成14年度厚生労働科学研究 (子ども家庭総合研究事業) 分担研究報告書, 2003.
 
2) Pui C-H, Evans WE : Treatment of acute lymphoblastic leukemia. N Engl J Med 354 : 166-178, 2006.
PubMed
3) 堀部敬三 : 厚生労働科学研究費補助金 (がん臨床研究事業) 「小児造血器腫瘍の標準的治療法の確立に関する研究」平成14年度-16年度総合研究報告書, 2005.
 
4) Pui C-H, et al : Ponte di Legno Working Group : statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop. Leukemia 18 : 1043-1053, 2004.
 
5) Arico M, et al : The seventh international childhood acute lymphoblastic leukemia workshop report : Palermo, Italy, January 29-30, 2005. Leukemia 19 : 1145-1152, 2005.
 
6) Patte C : B-acute lymphoblastic leukemia. Int J Pediatr Hematol Oncol 5 : 81-88, 1998.
 
7) Gaynon PS, et al : Early response to therapy and outcome in childhood acute lymphoblastic leukemia. Cancer 80 : 1717-1726, 1997.
PubMed
8) Carroll WL, et al : Childhood acute lymphoblastic leukemia in the age of genomics. Pediatr Blood Cancer 46 : 570-589, 2006.
PubMed
9) Jeda S : Who should be treating adolescents and young adults with acute lymphoblastic leukemia? Eur J Cancer 39 : 2579-2583, 2003.
 
10) Kudo K, et al : Results of the Japanese Childhood Acute Myeloid Leukemia 99 Protocol for Down Syndrome and Acute Myeloid Leukemia. Blood 106 (11) : 84a #276, 2005.
 
11) Shimada A, et al : KIT mutations, and not FLT3 intemal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t (8 ; 21) : a study of the Japanese Childhood AML Cooperative Study Group. Blood 107 : 1806-1809, 2006.
 
12) Johnston DL, et al : Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol 23 : 9172-9178, 2005.
PubMed
13) Kaspers GJL, Creutzig U : Pediatric acute myeloid leukemia : international progress and future directions. Leukemia 19 : 2025-2029, 2005.
 
14) Tsukimoto I, et al : Excellent Outcome of Risk Stratified Treatment for Childhood Acute Myeloid Leukemia-AML99 Trial. For the Japanese Childhood AML Cooperative Study Group. Blood 106 (11) : 261a #889, 2005.
 
P.706 掲載の参考文献
1) Sekeres MA, et al : Decision-maldng and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 18 : 809-816, 2004.
PubMed
2) Estey EH : How I treat older patients with AML Blood 96 : 1670-1673, 2000.
 
3) Wojtacki J, et al : Anthracycline-induced cardiotoxicity : clinical course, risk factors, pathogenesis, detection and prevention-review of the literatrre. Med Sci Monit 6 : 411-420, 2000.
PubMed
4) Iwakiri R, et al : Prognosis of elderly patients with acute myelogenous leukemia : analysis of 126 AML cases. Int J Hematol 75 : 45-50, 2002.
PubMed
5) Yoshida S, et al : De novo acute myeloid leukemia in the elderly ; a consistent fraction of long-term survivors by standard-dose chemotherapy. Leuk Res 25 : 33-38, 2001.
PubMed
6) Tallman BS : Treatment of the older patient with acute myeloid leukemia. American Society of Clinical Oncology, 2005 Educational Book, p 540-546, 2005.
 
7) Mori M, et al : Treatment of acute myeloid leukemia patients older than 75 years : Results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). Leuk Lymphoma 47 : 2062-2069, 2006.
 
8) Miyawaki S, et al : A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia, The Japan Adult Leukemia Study Group AML 97 Study. Cancer 104 : 2726-2734, 2005.
 
9) Amadori S, et al : Gemutuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia : final results of AML-15B, a phase 2 study of the European Organization for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell' Adulto Leukemia Groups. Leukemia 19 : 1768-1773, 2005.
 
10) Lataqliata R, et al : The role of all-trans retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. Ann Oncol 8 (12) : 1273-1275, 1997.
 
11) Asou N, et al : Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia : the APL92 study of Japan Adult Leukemia Study GroupσALSG). Cancer Chemother Pharmacol 48 (Suppl 1) : S65-S71, 2001.
 
12) Ohnishi K, et al : Arsenic nioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia : need for careful electrocardiogram monitoring. Leukemia 16 : 617-622, 2002.
PubMed
13) Lo-Coco F, et al : Gemutuzumab ozogamicin as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104 : 1995-1999, 2004.
 
14) Tomas X, et al : Acute lymphocytic leukemia in elderly : the Edouard Herriot hospital experience. Am J Hematol 67 : 73-83, 2001.
 
15) O'Brien SG, et al : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 : 994-1004, 2003.
PubMed
16) Kantarjian H, et al : Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 : 2542-2551, 2006.
 
17) Talpaz M, et al : Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 : 2531-2541, 2006.
PubMed
P.717 掲載の参考文献
1) Hasegawa H, et al : Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med 12 : 466-472, 2006.
PubMed
2) Waldmann TA, et al : The interleukin-2 receptor : a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82 : 1701-1712, 1993.
 
3) Waldmann TA, et al : Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 86 : 4063-4075, 1995.
 
4) Azimi N, et al : Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis : implications for therapy with a monoclonal antibody directed to the IL-2/15R9 receptor. J Immunol 163 : 4064-4072, 1999.
 
5) Zhang Z, et al : Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood 102 : 284-288, 2003.
PubMed
6) Zhang Z, et al : Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 63 : 6453-6457, 2003.
PubMed
7) Zhang Z, et al : Effective treatment of a murine model of adult T cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizmab) directed towards CD25. Blood 108 : 1007-1012, 2006.
 
8) Moura IC, et al : A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 103 : 1838-1845, 2004.
PubMed
9) Ishida T, et al : The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res 10 : 7529-7539, 2004.
 
10) Mori N, et al : Bay 11-7082 inhibits transcription factor NF-κB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100 : 1828-1834, 2002.
 
11) Watanabe M, et al : Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 106 : 2462-2471, 2005.
 
12) Dewan MZ, et al : Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/γcnull mice : suppression by an inhibitor against NF-κB. J Virol 77 : 5286-5294, 2003.
 
13) Sanda T, et al : Induction of cell death in adult T-cell leukemia cells by a novel IκB kinase inhibitor. Leukemia 20 : 590-598, 2006.
 
14) Mohapatra S, et al : Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line. Cancer Res 63 : 8523-8530, 2003.
PubMed
15) Tomita M, et al : Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Retrovirology 3 : 22, 2006.
PubMed
16) Peloponese JM Jr, Jeang KT : Role for Akt/protein kinase B and activator protein-1 in cellular proliferation induced by the human T-cell leukemia virus type 1 Tax oncoprotein. J Biol Chem 281 : 8927-8938, 2006.
PubMed
17) Jeong SJ, et al : Activated AKT regulates NF-κB activation, p53 inhibition and cell surVival in HTLV-1-transformed cells. Oncogene 24 : 6719-6728, 2005.
 
18) Tomita M, et al : Curcumin targets Akt cell survival signaling pathway in HTLV-I-infected T-cell lines. Cancer Sci 97 : 322-327, 2006.
PubMed
19) Fukuda RI, et al : Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL). Proc Natl Acad Sci USA 102 : 15213-15218, 2005.
 
20) 川上博哉ほか : Hsp90阻害薬によるATL治療の可能性. Cancer Sci 95 (Suppl) : 114, 2004.
 
21) Mori N, et al : Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. J Virol 78 : 4582-4590, 2004.
 
22) Dewan MZ, et al : Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonaVir. Blood 107 : 716-724, 2006.
PubMed
23) Okudaira T, et al : NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-κB signal pathway. Mol Cancer Ther 5 : 704-712, 2006.
 
24) Ishikawa C, et al : The bisphosphonate, incadronate, inhibits cell growth of HTLV-1-infected T cell lines and primary ATL cells by inhibiting mevalonate pathway. Blood 106 : 282b-283b, 2005.
 
25) Gao L, et al : HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 106 : 4294-4302, 2005.
PubMed
26) Okudaira T, et al : Suppression of cell growth and induction of apoptosis of HTLV-I-infected T-cell lines and primary ATL cells by galectin-9. Blood 106 : 283b, 2005.
 
27) Haneji K, et al : Fucoidan extracted from Cladosiphon oleamuranus Tokida induces apoptosis of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Nutr Cancer 52 : 189-201, 2005.
PubMed
28) Tomita M, et al : Curcumin (diferuloylmethane) inhibits constitutive active NF-κB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int J Cancer 118 : 765-772, 2006.
 
29) Tomita M, et al : Curcumin suppresses constitutive activation of AP-1 by downregulation of JunD protein in HTLV-1-infected T-cell lines, Leuk Res 30 : 313-321, 2006.
PubMed
30) Rajasingh J, et al : Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia. Biochem Biophys Res Commun 340 : 359-368, 2006.
 
P.723 掲載の参考文献
1) Marth C, et al : Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. J Natl Cancer Inst 77 : 1197-1202, 1986.
 
2) Lotan R : Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition. Cancer Res 39 : 1014-1019, 1979.
PubMed
3) Jetten A, et al : Modulation of growth, differentiation, and glycoprotein synthesis by β-all-trans retinoic acid. Int J Cancer 45 : 195-202, 1990.
 
4) Maeda Y, et al : 13-cis retinoic acid inhibits growth of adult T cell leukemia cells and causes apoptosis ; possible new indication for retinoid therapy. Intern Med 35 : 180-184, 1996.
PubMed
5) Maeda Y, et al : New therapeutic effects of retinoid for adult T-cell leukemia. Blood 88 : 4726-4727, 1996.
PubMed
6) Mori N, et al : Constitutive activation of NF-κB in primary adult T-cell leukemia cells. Blood 93 : 2360-2368, 1999.
 
7) Nawata H, et al : A mechanism of apoptosis induced by a11-trans retinoic acid on adult T-cell leuke-mia cells : a possible involvement of the Tax/NF-κB signaling pathway. Leukemia Res 25 : 323-331, 2001.
 
8) Yamaguchi T, et al : Dichotomy of all-trans retinoic acid inducing signals for adult T-cell leukemia. Leukemia 19 : 1010-1017, 2005.
 
9) Maeda Y, et al : All-trans retinoic acid reduced skin involvement of adult T-cell leukemia. Leukemia 18 : 1159-1160, 2004.
PubMed
10) Maeda Y, et al : Clinical application of all-trans retinoic acid (tretinoin) for adult T-cell leukemia. Br J Haematol 109 : 677-678, 2000.
PubMed
11) Fujimura S, et al : Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. Leuk Res 22 : 611-618, 1998.
PubMed
12) Tsukasaki K, et al : Concomitant complete remission of APL and smoldering ATL following ATRA therapy in a patient with the two diseases simultaneously. Leukemia 9 : 1797-1798, 1995.
 
13) Maeda Y, et al : All-trans retinoic acid attacks reverse transcriptase resulting in inhibition of HIV-1 replication. (manuscript in submission).
 
P.728 掲載の参考文献
1) Soignet SL, et al : Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339 : 1341-1348, 1998.
PubMed
2) Forkner CE, Scott TFM : Arsenic as a therapeutic agent in chronic myelogenous leukaemia. JAMA 97 : 3-5, 1931.
 
3) Waxman S, Anderson KC : History of the development of arsenic derivatives in cancer therapy. Oncologist 6 (Suppl 2) : 3-10, 2001.
 
4) Niu C, et al : Studies on treatment of acute promyelocytic leukemia with arsenic trioxide : remission induction, follow-up, and molecular monitoring in ll newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94 : 3315-3324, 1999.
 
5) Soignet SL, et al : United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19 : 3852-3860, 2001.
 
6) Diverio D, et al : Early detection of relapse by prospective RT-PCR analysis of the PML/RARα fusion gene in patients with APL. Blood 92 : 784-789, 1998.
 
7) Chen GQ, et al : Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) : I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89 : 3345-3353, 1997.
PubMed
8) Dai J, et al : Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93 : 268-277, 1999.
PubMed
9) Kajiguchi T, et al : Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in acute myeloid leukemia (M2) derived cell line, NKM-1. Leukemia 17 (11) : 2189-2195, 2003.
PubMed

書評

最近チェックした商品履歴

Loading...